(lp1
(dp2
S'qwordcount'
p3
I10
sS'mcwordcount'
p4
I11
sS'mc'
p5
(lp6
Vneedle diameter
p7
aVrate of administration
p8
aVinjection site blood flow
p9
aVinjection volume
p10
asS'qtext'
p11
S'Most important factor influencing drug absorption rate following intramuscular injection:'
p12
sS'url'
p13
S'http://www.pharmacology2000.com/General/Introduction/questions2/intro2.htm'
p14
sS'QID'
p15
S'Q0#7'
p16
sS'qno'
p17
S'7'
sS'correct'
p18
I2
sS'qset'
p19
S'0'
sa(dp20
g3
I21
sg4
I30
sg5
(lp21
Vweak acid (pKa 7.4)
p22
aVweak base (pKa 8.4)
p23
aVweak acid (pKa 8.4)
p24
aVweak base (pKa 6.4)
p25
aVweak acid (pKa 6.4)
p26
asg11
S'Drug with this ionization property most likely to diffuse from intestine (pH 8.4) to blood (pH 7.4)'
p27
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions2/intro2.htm'
p28
sg15
S'Q0#11'
p29
sg17
S'11'
p30
sg18
I3
sg19
S'0'
sa(dp31
g3
I11
sg4
I10
sg5
(lp32
V1%
p33
aV10%
p34
aV50%
p35
aV90%
p36
aV99%
p37
asg11
S'Weak organic acid, pKa 6.5. Percent ionization at pH 7.5'
p38
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions2/intro2.htm'
p39
sg15
S'Q0#13'
p40
sg17
S'13'
p41
sg18
I3
sg19
S'0'
sa(dp42
g3
I16
sg4
I22
sg5
(lp43
Vextreme drug instability at stomach pH
p44
aVhepatic "first-pass" effect
p45
aVdrug metabolized by gut flora
p46
aVtablet does not dissolve
p47
aVpatient non-complance
p48
asg11
S'Dramatic decrease in systemic availability of a drug following oral administration is most likely due to:'
p49
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions2/intro2.htm'
p50
sg15
S'Q0#15'
p51
sg17
S'15'
p52
sg18
I1
sg19
S'0'
sa(dp53
g3
I9
sg4
I16
sg5
(lp54
Vless than 1%
p55
aV5%-15%
p56
aV30%
p57
aV> 50%
p58
aV> 90%
p59
asg11
S'Percentage of all drugs that exist as enantiomeric pairs:'
p60
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions3/questionset3.htm'
p61
sg15
S'Q1#0'
p62
sg17
S'0'
sg18
I3
sg19
S'1'
sa(dp63
g3
I7
sg4
I36
sg5
(lp64
Vcardiotoxicity is probably associated with both enantiomers of bupivacaine
p65
aVRopivacaine is less cardiotoxic compared to bupivacaine because it is metabolized faster
p66
aVcisatracurium is an atracurium isomer that doesn\u005c
p67
aVboth l- and d- morphine occur in nature
p68
asg11
S'Examples of enantiomeric differences important in anesthesia:'
p69
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions3/questionset3.htm'
p70
sg15
S'Q1#3'
p71
sg17
S'3'
sg18
I2
sg19
S'1'
sa(dp72
g3
I25
sg4
I4
sg5
(lp73
Velectrostatic
p74
aVcovalent
p75
aVhydrophobic interactions
p76
asg11
S'The binding of the activated form of phenoxybenzamine (alpha-receptor antagonist) with the alpha receptor is an example of this type of chemical force/bond:'
p77
sg13
S'http://www.pharmacology2000.com/General/Introduction/questions3/questionset3.htm'
p78
sg15
S'Q1#6'
p79
sg17
S'6'
sg18
I1
sg19
S'1'
sa(dp80
g3
I4
sg4
I5
sg5
(lp81
VED50/LD50
p82
aVpotency/selectivity
p83
aVEC50/LD50
p84
aVTD50/ED50
p85
aVED50
p86
asg11
S'Definition: Therapeutic Index'
p87
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p88
sg15
S'Q3#0'
p89
sg17
S'0'
sg18
I3
sg19
S'3'
sa(dp90
g3
I9
sg4
I10
sg5
(lp91
Vpropranolol
p92
aViron-complex with its binding protein
p93
aVerythromycin-macrolide antibiotic
p94
aVphenylalanine
p95
aVpeptide
p96
asg11
S'Most likely to be transportred into cells by endocytosis:'
p97
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p98
sg15
S'Q3#2'
p99
sg17
S'2'
sg18
I1
sg19
S'3'
sa(dp100
g3
I11
sg4
I11
sg5
(lp101
Varea/thickness
p102
aVdifference in concentration
p103
aVpermeability coefficient
p104
aVarea x permeability coefficient/thickness
p105
aVthickness
p106
asg11
S'Driving force for passive flux of molecules down a concentration gradient:'
p107
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p108
sg15
S'Q3#3'
p109
sg17
S'3'
sg18
I1
sg19
S'3'
sa(dp110
g3
I15
sg4
I8
sg5
(lp111
Vcarrier transport
p112
aVpassive diffusion
p113
aVendocytosis
p114
aVexocytosis
p115
aVlipid diffusion
p116
asg11
S'Elaboration of vesicular content (neurotransmitter) into the synaptic cleft is an example of:'
p117
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p118
sg15
S'Q3#5'
p119
sg17
S'5'
sg18
I3
sg19
S'3'
sa(dp120
g3
I3
sg4
I8
sg5
(lp121
Vprimary amine
p122
aVsecondary amine
p123
aVtertiary amine
p124
aVquaternary amine
p125
asg11
S'Permanently charged amine:'
p126
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p127
sg15
S'Q3#8'
p128
sg17
S'8'
sg18
I3
sg19
S'3'
sa(dp129
g3
I2
sg4
I11
sg5
(lp130
Vurine
p131
aVbreast milk
p132
aVjejunum,ileum contents
p133
aVstomach contents
p134
aVvaginal secretions
p135
asg11
S'Most acidic'
p136
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions1/dyn1.htm'
p137
sg15
S'Q3#9'
p138
sg17
S'9'
sg18
I3
sg19
S'3'
sa(dp139
g3
I5
sg4
I6
sg5
(lp140
Vstomach
p141
aVsmall intestine
p142
aVkidney
p143
aVmuscle
p144
aVliver
p145
asg11
S'Primary site for drug metabolism:'
p146
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions2/kin2.htm'
p147
sg15
S'Q4#0'
p148
sg17
S'0'
sg18
I4
sg19
S'4'
sa(dp149
g3
I8
sg4
I9
sg5
(lp150
Vmitochondrial fraction
p151
aVcell membranes
p152
aVgolgi bodies
p153
aVmicrosomal fraction
p154
aVnucleolus
p155
asg11
S'Drug mixed-function oxidase (p450) mainly localized:'
p156
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions2/kin2.htm'
p157
sg15
S'Q4#1'
p158
sg17
S'1'
sg18
I3
sg19
S'4'
sa(dp159
g3
I3
sg4
I6
sg5
(lp160
Vamine oxidase
p161
aVepoxidation
p162
aVN-oxidation
p163
aVS-oxidation
p164
aVdeamination
p165
asg11
S'Cytochrome-P450 INDEPENDENT oxidation'
p166
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions2/kin2.htm'
p167
sg15
S'Q4#4'
p168
sg17
S'4'
sg18
I0
sg19
S'4'
sa(dp169
g3
I5
sg4
I22
sg5
(lp170
Vrelated to phencyclidine structurally
p171
aVsignificant cardiac depression
p172
aVsignificant respiratory depression
p173
aVflumazenil (Romazicon) is a specific ketamine (Ketalar) antagonist
p174
asg11
S'Ketamine (Ketalar):'
p175
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p176
sg15
S'Q8#0'
p177
sg17
S'0'
sg18
I0
sg19
S'8'
sa(dp178
g3
I5
sg4
I19
sg5
(lp179
Vdissociative anesthesia
p180
aVswallow and corneal reflexes present
p181
aVamnestic effects
p182
aVreduced muscle limb tone
p183
aV80% likelihood of emergence syndrome
p184
asg11
S'Ketamine (Ketalar) pharmacology:'
p185
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p186
sg15
S'Q8#3'
p187
sg17
S'3'
sg18
I2
sg19
S'8'
sa(dp188
g3
I5
sg4
I14
sg5
(lp189
Vrapid onset
p190
aVrapid initial redistribution phase
p191
aVlow clearance compared to thiopental (Pentothal)
p192
asg11
S'Etomidate (Amidate) pharmacokinetics:'
p193
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p194
sg15
S'Q8#7'
p195
sg17
S'7'
sg18
I1
sg19
S'8'
sa(dp196
g3
I8
sg4
I26
sg5
(lp197
Vexcellent analgesic
p198
aVprobably acts by interacting with GABA-ergic receptor systems
p199
aVreduction in cerebral metabolism
p200
aVreduce cerebral blood flow
p201
aVEEG activation, consistent with possible epileptogenic activity
p202
asg11
S'Etomidate (Amidate) pharmacology: CNS actions'
p203
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p204
sg15
S'Q8#8'
p205
sg17
S'8'
sg18
I4
sg19
S'8'
sa(dp206
g3
I10
sg4
I14
sg5
(lp207
Vreduced cerebral metabolic rate
p208
aVincreased cerebral blood flow
p209
aVincreased intracranial pressure
p210
aVEEG changes observed
p211
asg11
S'Propofol (Diprivan): organ system effects -- CNS'
p212
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p213
sg15
S'Q8#12'
p214
sg17
S'12'
p215
sg18
I3
sg19
S'8'
sa(dp216
g3
I10
sg4
I12
sg5
(lp217
Vthiopental (Pentothal)
p218
aVpropofol (Diprivan)
p219
aVetomidate (Amidate)
p220
asg11
S'More likely to be associated with a painful IV administration:'
p221
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p222
sg15
S'Q8#16'
p223
sg17
S'16'
p224
sg18
I1
sg19
S'8'
sa(dp225
g3
I11
sg4
I3
sg5
(lp226
Vkappa
p227
aVmu
p228
aVsigma
p229
asg11
S'Opioid receptor subtype most likely associated with analgesia and respiratory depression'
p230
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p231
sg15
S'Q8#18'
p232
sg17
S'18'
p233
sg18
I1
sg19
S'8'
sa(dp234
g3
I11
sg4
I12
sg5
(lp235
Vsufentanil (Sufenta)
p236
aValfentanil (Alfenta)
p237
aVfentanyl (Sublimaze)
p238
asg11
S'Most likely to be un-ionized (uncharged) at physiological pH:'
p239
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p240
sg15
S'Q8#23'
p241
sg17
S'23'
p242
sg18
I1
sg19
S'8'
sa(dp243
g3
I26
sg4
I12
sg5
(lp244
Vfentanyl (Sublimaze)
p245
aVsufentanil (Sufenta)
p246
aValfentanil (Alfenta)
p247
asg11
S'Extremely short duration of action may make this agent preferable to block physiological responses to a single, brief intervention such as performing a retrobulbar block'
p248
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p249
sg15
S'Q8#24'
p250
sg17
S'24'
p251
sg18
I2
sg19
S'8'
sa(dp252
g3
I16
sg4
I16
sg5
(lp253
Valfentanil (Alfenta)
p254
aVremifentanil (Ultiva)
p255
aVfentanyl (Sublimaze)
p256
aVsufentanil (Sufenta)
p257
asg11
S'Unique among the various opioids use in IV anesthesia because of its susceptibility to ester hydrolysis:'
p258
sg13
S'http://www.pharmacology2000.com/General/Pharmacokinetics/questions6/kin6.htm'
p259
sg15
S'Q8#25'
p260
sg17
S'25'
p261
sg18
I1
sg19
S'8'
sa(dp262
g3
I8
sg4
I7
sg5
(lp263
Vbeta-adrenergic receptor
p264
aVmuscarinic cholinergic receptor
p265
aVsteroid receptor
p266
asg11
S'Example(s) of an intracellular receptor:'
p267
sg13
S'http://www.pharmacology2000.com/General/Pharmacodynamics/questions1/questionset1.htm'
p268
sg15
S'Q9#5'
p269
sg17
S'5'
sg18
I2
sg19
S'9'
sa(dp270
g3
I8
sg4
I7
sg5
(lp271
Visoproterenol
p272
aVnorepinephrine
p273
aVgrowth hormone
p274
aVcorticosteroids
p275
aVvitamin D
p276
asg11
S'Example of an agent that activates cytokine receptor:'
p277
sg13
S'http://www.pharmacology2000.com/General/Pharmacodynamics/questions1/questionset1.htm'
p278
sg15
S'Q9#6'
p279
sg17
S'6'
sg18
I2
sg19
S'9'
sa(dp280
g3
I2
sg4
I46
sg5
(lp281
Vat high concentrations of agonist, a maximal physiological responds is not possible even in the presence of the antagonist
p282
aVwith competitive inhibition, the dose effect curve is shifted to the right
p283
aVis irreversible
p284
aVis produced by antagonists that have the ability to activate receptors
p285
asg11
S'Competitive inhibition:'
p286
sg13
S'http://www.pharmacology2000.com/General/Pharmacodynamics/questions1/questionset1.htm'
p287
sg15
S'Q9#10'
p288
sg17
S'10'
p289
sg18
I1
sg19
S'9'
sa(dp290
g3
I9
sg4
I5
sg5
(lp291
Vaspartate
p292
aVGABA
p293
aVacetylcholine
p294
aVglutamate
p295
aV serotonin
p296
asg11
S'Valium (diazepam) acts through this receptor system:'
p297
sg13
S'http://www.pharmacology2000.com/General/Pharmacodynamics/questions2/questionset2.htm'
p298
sg15
S'Q10#0'
p299
sg17
S'0'
sg18
I1
sg19
S'10'
p300
sa(dp301
g3
I13
sg4
I4
sg5
(lp302
VLD50
p303
aVKd
p304
aVEC50
p305
aVTI
p306
asg11
S"Refers to drug concentration producing 50% of that drug's maximal effect:"
p307
sg13
S'http://www.pharmacology2000.com/General/Pharmacodynamics/questions2/questionset2.htm'
p308
sg15
S'Q10#8'
p309
sg17
S'8'
sg18
I2
sg19
S'10'
p310
sa(dp311
g3
I5
sg4
I30
sg5
(lp312
Vsomatic nerves, like autonomic nerves contain ganglia.
p313
aVMost of the fibers in the vagus nerve ar sensory
p314
aVdenervated smooth muscle show spontaneous activity
p315
aVmotor nerves are typically unmyelinated.
p316
asg11
S'Comparing autonomic and somatic nerves:'
p317
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p318
sg15
S'Q11#1'
p319
sg17
S'1'
sg18
I1
sg19
S'11'
p320
sa(dp321
g3
I8
sg4
I9
sg5
(lp322
Vcerebellum
p323
aVsensory cortex
p324
aVhypothalamus
p325
aVspinal cord--dorsal horn
p326
asg11
S'Major anatomical site for integration of autonomic information:'
p327
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p328
sg15
S'Q11#2'
p329
sg17
S'2'
sg18
I2
sg19
S'11'
p330
sa(dp331
g3
I19
sg4
I12
sg5
(lp332
Vvasoconstriction, vasoconstriction
p333
aVvasodilatation, vasodilatation
p334
aVvasodilatation, vasoconstriction
p335
aVvasoconstriction, vasodilation
p336
asg11
S'Activation of the sympathetic nervous system will caus which change in the skeletal muscle versus cutaneous vascular beds.'
p337
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p338
sg15
S'Q11#4'
p339
sg17
S'4'
sg18
I2
sg19
S'11'
p340
sa(dp341
g3
I9
sg4
I4
sg5
(lp342
Vbeta-2
p343
aValpha-1
p344
aVmuscarinic
p345
aVserotonergic
p346
asg11
S'Adrenergic receptor type(s) mediating pupillary dilation'
p347
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p348
sg15
S'Q11#5'
p349
sg17
S'5'
sg18
I1
sg19
S'11'
p350
sa(dp351
g3
I11
sg4
I8
sg5
(lp352
Vnicotinic
p353
aVmuscarinic
p354
aVnitric oxide receptor
p355
aVsubstance P receptor
p356
asg11
S'Cholinergic receptor type that mediates vasodilation following low-dose i.v. acetylcholine administration:'
p357
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p358
sg15
S'Q11#6'
p359
sg17
S'6'
sg18
I1
sg19
S'11'
p360
sa(dp361
g3
I7
sg4
I4
sg5
(lp362
Vglia
p363
aVliver
p364
aVerythrocytes
p365
aVplasma
p366
asg11
S'"True" acetylcholinesterase is found in:'
p367
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p368
sg15
S'Q11#7'
p369
sg17
S'7'
sg18
I2
sg19
S'11'
p370
sa(dp371
g3
I6
sg4
I8
sg5
(lp372
VDOPA decarboxylase
p373
aVphenylethanolamine N-methyl transferase
p374
aVtyrosine hydroxylase
p375
aVdopamine-beta-hydroxylase
p376
asg11
S'Catalyzes rate-limiting step in catecholamine biosynthesis:'
p377
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p378
sg15
S'Q11#8'
p379
sg17
S'8'
sg18
I2
sg19
S'11'
p380
sa(dp381
g3
I9
sg4
I14
sg5
(lp382
VCOMT (catechol-O-methyl transferase)
p383
aVMAO (monoamine oxidase)
p384
aVcholine acetyltransferase
p385
aVreuptake-I inhibitor
p386
asg11
S'Inhibited by drugs such as phenelzine or tranylcypromine;'
p387
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p388
sg15
S'Q11#9'
p389
sg17
S'9'
sg18
I1
sg19
S'11'
p390
sa(dp391
g3
I14
sg4
I10
sg5
(lp392
Vepinephrine
p393
aVterbutaline (Brethine)
p394
aVphenylephrine
p395
aVphentolamine (Regitine)
p396
asg11
S'Due to receptor specificity, catecholamine LEAST likely to produce bronchiolar smooth muscle relaxation:'
p397
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p398
sg15
S'Q11#11'
p399
sg17
S'11'
p400
sg18
I2
sg19
S'11'
p401
sa(dp402
g3
I4
sg4
I10
sg5
(lp403
Vedrophonium (Tensilon)
p404
aVdiisopropylphosphate (DFP)
p405
aVatropine
p406
aVmuscarine
p407
asg11
S'Covalent inhibitor of acetylcholinesterse:'
p408
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p409
sg15
S'Q11#13'
p410
sg17
S'13'
p411
sg18
I1
sg19
S'11'
p412
sa(dp413
g3
I3
sg4
I13
sg5
(lp414
Vterbutaline (Brethine)
p415
aVatropine
p416
aVmethoxamine (Vasoxyl)
p417
aVisoproterenol (Isuprel)
p418
asg11
S'Alpha-adenergic receptor agonist:'
p419
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p420
sg15
S'Q11#14'
p421
sg17
S'14'
p422
sg18
I2
sg19
S'11'
p423
sa(dp424
g3
I4
sg4
I23
sg5
(lp425
Vdecrease heart rate; increase contractility
p426
aVincrease heart rate; decrease contractility
p427
aVdecrease heart rate; decrease contractility
p428
aVincrease AV nodal conduction velocity
p429
asg11
S'Parasympathetic direct cardiac effects:'
p430
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p431
sg15
S'Q11#15'
p432
sg17
S'15'
p433
sg18
I2
sg19
S'11'
p434
sa(dp435
g3
I8
sg4
I13
sg5
(lp436
VDFP
p437
aVpilocarpine (Pilocar)
p438
aVphysostigmine (Antilirium)
p439
aVipratropium (Atrovent)
p440
asg11
S'Alkaloid agonist acting at muscarinic, cholinergic receptors:'
p441
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p442
sg15
S'Q11#17'
p443
sg17
S'17'
p444
sg18
I1
sg19
S'11'
p445
sa(dp446
g3
I8
sg4
I10
sg5
(lp447
Vnicotine
p448
aVechothiophate (Phospholine)
p449
aVatropine
p450
aVpilocarpine (Pilocar)
p451
asg11
S'Effective in treating both organophosphate and muscarine intoxication:'
p452
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p453
sg15
S'Q11#18'
p454
sg17
S'18'
p455
sg18
I2
sg19
S'11'
p456
sa(dp457
g3
I6
sg4
I10
sg5
(lp458
Vincreased
p459
aVdecreased
p460
aVno changed
p461
aVone of the others is right
p462
asg11
S'Cholinergic activity on stomach acid secretion'
p463
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions3/intro1.htm'
p464
sg15
S'Q11#19'
p465
sg17
S'19'
p466
sg18
I0
sg19
S'11'
p467
sa(dp468
g3
I11
sg4
I17
sg5
(lp469
Vphentolamine (Regitine)
p470
aVpropranolol (Inderal)
p471
aVnitroprusside sodium (Nipride)
p472
aVphenylephrine (Neo-Synephrine)
p473
asg11
S'Most likely to reduce blood pressure by directly decreasing heart rate:'
p474
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p475
sg15
S'Q12#0'
p476
sg17
S'0'
sg18
I1
sg19
S'12'
p477
sa(dp478
g3
I19
sg4
I17
sg5
(lp479
Vmethoxamine (Vasoxyl)
p480
aVnitroprusside sodium (Nipride)
p481
aVpropranolol (Inderal)
p482
aVmetoprolol (Lopressor)
p483
asg11
S"From the point of view of Starling's law which antihypertensive would be most likely to reduce contractility."
p484
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p485
sg15
S'Q12#1'
p486
sg17
S'1'
sg18
I1
sg19
S'12'
p487
sa(dp488
g3
I2
sg4
I10
sg5
(lp489
Visoproterenol (Isuprel)
p490
aVepinephrine
p491
aVdiltiazem (Cardiazem)
p492
aVnorepinephrine
p493
asg11
S'Negative inotropism'
p494
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p495
sg15
S'Q12#2'
p496
sg17
S'2'
sg18
I2
sg19
S'12'
p497
sa(dp498
g3
I10
sg4
I19
sg5
(lp499
Vdopamine (Intropin)
p500
aVmetoprolol (Lopressor)
p501
aVnitroprusside sodium (Nipride)
p502
aVdigoxin (Lanoxin, Lanoxicaps)
p503
asg11
S'Increases pulmonary congestion in congestive heart failure (CHF)'
p504
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p505
sg15
S'Q12#3'
p506
sg17
S'3'
sg18
I1
sg19
S'12'
p507
sa(dp508
g3
I16
sg4
I7
sg5
(lp509
Vdopamine (Intropin)
p510
aVepinephrine
p511
aVnorepinephrine
p512
aVacetylcholine
p513
asg11
S'Major neurotransmitter released at end organ effectors of the thoracolumbar division of the autonomic nervous system:'
p514
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p515
sg15
S'Q12#4'
p516
sg17
S'4'
sg18
I2
sg19
S'12'
p517
sa(dp518
g3
I4
sg4
I5
sg5
(lp519
Vnorepinephrine
p520
aVsubstance P
p521
aVepinephrine
p522
aVacetylcholine
p523
asg11
S'Neurotransmitter of preganglionic fibers:'
p524
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p525
sg15
S'Q12#5'
p526
sg17
S'5'
sg18
I3
sg19
S'12'
p527
sa(dp528
g3
I9
sg4
I16
sg5
(lp529
Vpupillary constriction
p530
aVblood flow shifted from cutaneous beds to skeletal muscle
p531
aVblood glucose falls
p532
aVbronchiolar constriction
p533
asg11
S'"Fight or flight" activation of the ANS:'
p534
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p535
sg15
S'Q12#6'
p536
sg17
S'6'
sg18
I1
sg19
S'12'
p537
sa(dp538
g3
I4
sg4
I12
sg5
(lp539
Vtyrosine to DOPA
p540
aVDOPA to dopamine
p541
aVdopamine to norepinephrine
p542
aVnorepinephrine to epinephrine
p543
asg11
S'Dopamine beta hydroxylase catalyzes:'
p544
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p545
sg15
S'Q12#8'
p546
sg17
S'8'
sg18
I2
sg19
S'12'
p547
sa(dp548
g3
I9
sg4
I25
sg5
(lp549
Vmetabolic transformation catalyzed by MAO
p550
aVmetabolic transformation catalyzed by COMT
p551
aVdiffusion away from the synaptic cleft and uptake at extraneuronal sites
p552
aVreuptake into nerve terminals
p553
asg11
S'Primary mechaism for termination of norepinephrine and epinephrine action:'
p554
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p555
sg15
S'Q12#9'
p556
sg17
S'9'
sg18
I3
sg19
S'12'
p557
sa(dp558
g3
I6
sg4
I7
sg5
(lp559
Vepinephrine
p560
aVisoproterenol (Isuprel)
p561
aVnorepinephrine
p562
aVdopamine
p563
asg11
S'Most potent at beta adrenergic receptors'
p564
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p565
sg15
S'Q12#10'
p566
sg17
S'10'
p567
sg18
I1
sg19
S'12'
p568
sa(dp569
g3
I4
sg4
I30
sg5
(lp570
Valpha-methyltyrosine by preventing synthesis of a protein that promotes fusion of the vesicle and the presynaptic membrane
p571
aVbretylium (Bretylol) following a transient stimulation of release by displacement
p572
aVreserpine
p573
asg11
S'Interferes with norepinephrine release:'
p574
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p575
sg15
S'Q12#11'
p576
sg17
S'11'
p577
sg18
I1
sg19
S'12'
p578
sa(dp579
g3
I6
sg4
I13
sg5
(lp580
Vyohimbine (Yocon)
p581
aVdobutamine (Dobutrex)
p582
aVclonidine (Catapres)
p583
aVphenylephrine
p584
asg11
S'alpha-2 receptor agonist; peripheral sympathomimetic'
p585
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p586
sg15
S'Q12#12'
p587
sg17
S'12'
p588
sg18
I2
sg19
S'12'
p589
sa(dp590
g3
I13
sg4
I14
sg5
(lp591
Vatropine
p592
aVnitroprusside sodium (Nipride)
p593
aVmecamylamine (Inversine)
p594
aVcaptopril (Capoten)
p595
asg11
S'Primary antihypertensive effect due to nitric oxide mediation of smooth muscle relaxation.'
p596
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p597
sg15
S'Q12#13'
p598
sg17
S'13'
p599
sg18
I1
sg19
S'12'
p600
sa(dp601
g3
I4
sg4
I13
sg5
(lp602
Vtubocurarine
p603
aVphenoxybenzamine (Dibenzyline)
p604
aVphysostigmine (Antilirium)
p605
aVbretylium (Bretylol)
p606
asg11
S'Inhibits neurotransmitter enzymic degradation:'
p607
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p608
sg15
S'Q12#14'
p609
sg17
S'14'
p610
sg18
I2
sg19
S'12'
p611
sa(dp612
g3
I14
sg4
I11
sg5
(lp613
Vacetylcholine
p614
aVmethacholine (Provocholine)
p615
aVvagal stimulation
p616
aVcarbamylcholine (carbachol)
p617
asg11
S'Cardiac effects not like to be directly affected by the presence of an anticholinesterase:'
p618
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p619
sg15
S'Q12#15'
p620
sg17
S'15'
p621
sg18
I3
sg19
S'12'
p622
sa(dp623
g3
I5
sg4
I9
sg5
(lp624
Vdry mouth
p625
aVpupillary dilation
p626
aVincreased gastrointestinal tone
p627
aVbronchiolar relaxation
p628
asg11
S'Pilocarpine (Pilocar):'
p629
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions2/matching1.htm'
p630
sg15
S'Q12#16'
p631
sg17
S'16'
p632
sg18
I2
sg19
S'12'
p633
sa(dp634
g3
I8
sg4
I7
sg5
(lp635
Vatropine
p636
aVscopolamine
p637
aVipratropium (Atrovent)
p638
aVDFP
p639
asg11
S'Cholinergic agent least likely to enter the brain:'
p640
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p641
sg15
S'Q13#1'
p642
sg17
S'1'
sg18
I2
sg19
S'13'
p643
sa(dp644
g3
I6
sg4
I10
sg5
(lp645
Vphysostigmine (Antilirium)
p646
aVDFP
p647
aVedrophonium (Tensilon)
p648
aVsoman
p649
asg11
S'Reversible, noncovalent inhibitor of acetylcholinesterase'
p650
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p651
sg15
S'Q13#2'
p652
sg17
S'2'
sg18
I2
sg19
S'13'
p653
sa(dp654
g3
I2
sg4
I9
sg5
(lp655
Vscopolamine
p656
aVdopamine (Intropin)
p657
aVmecamylamine (Inversine)
p658
asg11
S'Ganglionic blocker:'
p659
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p660
sg15
S'Q13#3'
p661
sg17
S'3'
sg18
I2
sg19
S'13'
p662
sa(dp663
g3
I3
sg4
I14
sg5
(lp664
Vveins:parasympathetic
p665
aVheart:sympathetic
p666
aVciliary muscle: sympathetic
p667
aVsalivary glands: parasympathetic
p668
asg11
S'Predominant autonomic tone:'
p669
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p670
sg15
S'Q13#4'
p671
sg17
S'4'
sg18
I3
sg19
S'13'
p672
sa(dp673
g3
I9
sg4
I13
sg5
(lp674
Visoproterenol (Isuprel)
p675
aVdopamine (Intropin)
p676
aVclonidine (Catapres)
p677
aVepinephrine
p678
asg11
S'Powerful agonist at both alpha and beta adrenergic receptors'
p679
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p680
sg15
S'Q13#5'
p681
sg17
S'5'
sg18
I3
sg19
S'13'
p682
sa(dp683
g3
I15
sg4
I16
sg5
(lp684
Vdobutamine (Dobutrex)
p685
aVdopamine (Intropin)
p686
aVterbutaline (Brethine)
p687
aVlodoxamine (Alomide)
p688
asg11
S'Positive inotropic drug that at low doses specifically promotes an increase in renal blood flow:'
p689
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p690
sg15
S'Q13#6'
p691
sg17
S'6'
sg18
I1
sg19
S'13'
p692
sa(dp693
g3
I9
sg4
I16
sg5
(lp694
Vguanfacine (Tenex)
p695
aVcaptopril (Capoten)
p696
aVesmolol (Brevibloc)
p697
aVphenoxybenzamine (Dibenzyline)
p698
asg11
S'Antihypertensive effect due to activation of CNS alpha-2 receptors'
p699
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p700
sg15
S'Q13#8'
p701
sg17
S'8'
sg18
I0
sg19
S'13'
p702
sa(dp703
g3
I10
sg4
I13
sg5
(lp704
Vscopolamine
p705
aVmethylphenidate (Ritalin)
p706
aVmecamylamine (Inversine)
p707
aVclonidine (Catapres)
p708
asg11
S'CNS stimulant used in management of narcolepsy or attention-deficit disorder'
p709
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p710
sg15
S'Q13#9'
p711
sg17
S'9'
sg18
I1
sg19
S'13'
p712
sa(dp713
g3
I8
sg4
I15
sg5
(lp714
Vlabetalol (Trandate, Normodyne)
p715
aVhydralazine (Apresoline)
p716
aVmethoxamine (Vasoxyl)
p717
aVreserpine
p718
asg11
S'Antihypertensive agent that acts by direct arteriolar dilation:'
p719
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p720
sg15
S'Q13#10'
p721
sg17
S'10'
p722
sg18
I1
sg19
S'13'
p723
sa(dp724
g3
I5
sg4
I16
sg5
(lp725
Vnicardipine (Cardene)
p726
aVcaptopril (Capoten)
p727
aVphentolamine (Regitine)
p728
aVesmolol (Brevibloc)
p729
asg11
S'Inhibitor of angiotensin converting enzyme'
p730
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p731
sg15
S'Q13#11'
p732
sg17
S'11'
p733
sg18
I1
sg19
S'13'
p734
sa(dp735
g3
I6
sg4
I17
sg5
(lp736
Vcaptopril (Capoten)
p737
aVnitroprusside sodium (Nipride)
p738
aVphenoxybenzamine (Dibenzyline)
p739
aVminoxidil (Loniten)
p740
asg11
S'Vasodilator used to manage hypertensive emergencies:'
p741
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p742
sg15
S'Q13#12'
p743
sg17
S'12'
p744
sg18
I1
sg19
S'13'
p745
sa(dp746
g3
I4
sg4
I16
sg5
(lp747
Vcaptopril (Capoten)
p748
aVlosartin (Cozaar)
p749
aVmethyldopa (Aldomet)
p750
aVphenoxybenzamine (Dibenzyline)
p751
asg11
S'Angiotensin II receptor antagonist:'
p752
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p753
sg15
S'Q13#13'
p754
sg17
S'13'
p755
sg18
I1
sg19
S'13'
p756
sa(dp757
g3
I9
sg4
I4
sg5
(lp758
Vbrochodilation
p759
aVtremor
p760
aVvasodilation
p761
aVtachycardia
p762
asg11
S'Most common side effect of oral beta-2 receptor agonists'
p763
sg13
S'http://www.pharmacology2000.com/Autonomics/Introduction/questions4/intro3.htm'
p764
sg15
S'Q13#14'
p765
sg17
S'14'
p766
sg18
I1
sg19
S'13'
p767
sa(dp768
g3
I9
sg4
I8
sg5
(lp769
Vbeta1 adrenergic
p770
aVmuscarinic cholinergic
p771
aVbeta2 adrenergic
p772
aVnicotinic cholinergic
p773
asg11
S'Drugs activating this receptor are used in treating asthma:'
p774
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p775
sg15
S'Q14#0'
p776
sg17
S'0'
sg18
I2
sg19
S'14'
p777
sa(dp778
g3
I7
sg4
I6
sg5
(lp779
Valpha1
p780
aVbeta1
p781
aVdopamine D1
p782
aVmuscarinic cholinergic
p783
asg11
S'Receptor activation mainly responsible for positive inotropism:'
p784
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p785
sg15
S'Q14#2'
p786
sg17
S'2'
sg18
I1
sg19
S'14'
p787
sa(dp788
g3
I3
sg4
I16
sg5
(lp789
Visoproterenol (Isuprel)
p790
aVpropranolol (Inderal)
p791
aVphenylephrine (Neo-Synephrine)
p792
aVterbutaline (Brethine)
p793
asg11
S'Activates alpha receptors'
p794
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p795
sg15
S'Q14#4'
p796
sg17
S'4'
sg18
I2
sg19
S'14'
p797
sa(dp798
g3
I4
sg4
I13
sg5
(lp799
Vterbutaline (Brethine)
p800
aVesmolol (Brevibloc)
p801
aVatropine
p802
aVmecamylamine (Inversine)
p803
asg11
S'Blocks cardiac isoproterenol effects'
p804
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p805
sg15
S'Q14#5'
p806
sg17
S'5'
sg18
I1
sg19
S'14'
p807
sa(dp808
g3
I8
sg4
I16
sg5
(lp809
Vmetoprolol (Lopressor)
p810
aVmethoxamine (Vasoxyl)
p811
aVterbutaline (Brethine)
p812
aVipratropium (Atrovent)
p813
asg11
S'Alpha agonist: vasoconstriction and elevates blood pressure:'
p814
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p815
sg15
S'Q14#6'
p816
sg17
S'6'
sg18
I1
sg19
S'14'
p817
sa(dp818
g3
I4
sg4
I10
sg5
(lp819
Vmethoxamine (Vasoxyl)
p820
aVcocaine
p821
aVreserpine
p822
aVtimolol (Blocadren)
p823
asg11
S'Nerve terminal reuptake inhibitor'
p824
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p825
sg15
S'Q14#7'
p826
sg17
S'7'
sg18
I1
sg19
S'14'
p827
sa(dp828
g3
I4
sg4
I16
sg5
(lp829
Vpropranolol (Inderal)
p830
aVphenoxybenzamine (Dibenzyline)
p831
aVphentolamine (Regitine)
p832
aVpilocarpine (Pilocar)
p833
asg11
S'Alpha adrenoceptor COVALENT blocker:'
p834
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p835
sg15
S'Q14#8'
p836
sg17
S'8'
sg18
I1
sg19
S'14'
p837
sa(dp838
g3
I5
sg4
I12
sg5
(lp839
Vbeta receptor activation
p840
aValpha receptor activation
p841
aValpha receptor blocker
p842
aVdopamine receptor blockade
p843
asg11
S'Orthostatic (postural) hypotension'
p844
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p845
sg15
S'Q14#9'
p846
sg17
S'9'
sg18
I2
sg19
S'14'
p847
sa(dp848
g3
I5
sg4
I13
sg5
(lp849
Vmecamylamine (Inversine)
p850
aVprazosin (Minipress)
p851
aVatropine
p852
aVpropranolol (Inderal)
p853
asg11
S'Norepinephrine pressor response blocked by:'
p854
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p855
sg15
S'Q14#10'
p856
sg17
S'10'
p857
sg18
I1
sg19
S'14'
p858
sa(dp859
g3
I11
sg4
I8
sg5
(lp860
Vphase 0
p861
aVphase 4
p862
aVphase 2
p863
aVphase 3
p864
asg11
S'Phase of the cardiac action potential that principally determine heart rate'
p865
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p866
sg15
S'Q14#14'
p867
sg17
S'14'
p868
sg18
I1
sg19
S'14'
p869
sa(dp870
g3
I6
sg4
I20
sg5
(lp871
Vangiotensin converting enzyme inhibitor (decreases angiotensin II concentration)
p872
aVpropranolol (Inderal)
p873
aVphenylephrine (Neo-Synephrine)
p874
aVlow-dose epinephrine
p875
asg11
S'Most likely to increase myocardial afterload'
p876
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p877
sg15
S'Q14#15'
p878
sg17
S'15'
p879
sg18
I2
sg19
S'14'
p880
sa(dp881
g3
I15
sg4
I16
sg5
(lp882
Vpropranolol (Inderal)
p883
aVphentolamine (Regitine)
p884
aVphenylephrine (Neo-Synephrine)
p885
aVmetoprolol (Lopressor)
p886
asg11
S'Pressor effects of epinephrine are blocked by this drug ("epinephrine reversal")'
p887
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p888
sg15
S'Q14#16'
p889
sg17
S'16'
p890
sg18
I1
sg19
S'14'
p891
sa(dp892
g3
I4
sg4
I16
sg5
(lp893
Vphenoxybenzamine (Dibenzyline)
p894
aVpropranolol (Inderal)
p895
aVguanfacine (Tenex)
p896
aVmethoxamine (Vasoxyl)
p897
asg11
S'Specific alpha2 receptor agonist'
p898
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p899
sg15
S'Q14#18'
p900
sg17
S'18'
p901
sg18
I2
sg19
S'14'
p902
sa(dp903
g3
I3
sg4
I17
sg5
(lp904
Vnitroprusside sodium (Nipride)
p905
aVclonidine (Catapres)
p906
aVmethoxamine (Vasoxyl)
p907
aVcaptopril (Capoten)
p908
asg11
S'Centrally-acting antihypertensive drug'
p909
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/question5/auto1.htm'
p910
sg15
S'Q14#19'
p911
sg17
S'19'
p912
sg18
I1
sg19
S'14'
p913
sa(dp914
g3
I7
sg4
I30
sg5
(lp915
Vlimited effect
p916
aVbeta1 adrenergic receptor  activation decreases renin release
p917
aVsignificant reduction in renal blood flow
p918
aVsignificant increase in renal blood flow; mechanism similar to that exhibited by low-dose dopamine
p919
asg11
S'Renal effects relatively low epinephrine dose.'
p920
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p921
sg15
S'Q16#4'
p922
sg17
S'4'
sg18
I2
sg19
S'16'
p923
sa(dp924
g3
I15
sg4
I24
sg5
(lp925
Vprevious administration of the alpha-receptor antagonist will not influence the blood-pressure response to epinephrine
p926
aVincreased blood-pressure response to epinephrine
p927
aVdecreased blood-pressure response to epinephrine
p928
asg11
S'Most probable BP effect of epinephrine, if epinephrine is administered after an alpha-receptor antagonist:'
p929
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p930
sg15
S'Q16#5'
p931
sg17
S'5'
sg18
I2
sg19
S'16'
p932
sa(dp933
g3
I5
sg4
I3
sg5
(lp934
Vbeta-1
p935
aVbeta-2
p936
aVbeta-3
p937
asg11
S'Prominent cardiac beta-adrenergic receptor type:'
p938
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p939
sg15
S'Q16#6'
p940
sg17
S'6'
sg18
I0
sg19
S'16'
p941
sa(dp942
g3
I6
sg4
I13
sg5
(lp943
Vbeta-2 receptor mediated bronchoconstriction
p944
aValpha-1 receptor-mediated bronchodilation
p945
aVbeta-1 receptor-mediated bronchodilation
p946
aVbeta-2 receptor-mediated bronchodilation
p947
asg11
S'Significant respiratory tract effects of epinephrine:'
p948
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p949
sg15
S'Q16#8'
p950
sg17
S'8'
sg18
I3
sg19
S'16'
p951
sa(dp952
g3
I5
sg4
I27
sg5
(lp953
Vinsulin secretion reduced by beta2 adrenergic receptor activation
p954
aVglucagon secretion: diminished by beta adrenergic receptor activation
p955
aVfree fatty acids: increased
p956
aVminimal calorigenic effect
p957
aVglycolysis inhibition
p958
asg11
S'Examples of epinephrine metabolic effects'
p959
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p960
sg15
S'Q16#9'
p961
sg17
S'9'
sg18
I2
sg19
S'16'
p962
sa(dp963
g3
I5
sg4
I17
sg5
(lp964
Vphentolamine (Regitine)
p965
aVterbutaline (Brethine)
p966
aVdopamine (Intropin)
p967
aVdobutamine (Dobutrex)
p968
aVatropine
p969
asg11
S'Drugs antagonize epinephrine pressor effects:'
p970
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p971
sg15
S'Q16#11'
p972
sg17
S'11'
p973
sg18
I0
sg19
S'16'
p974
sa(dp975
g3
I6
sg4
I9
sg5
(lp976
Vincreased conduction velocity
p977
aVdecreased conduction velocity
p978
aVpromotes AV block
p979
asg11
S'Epinephrine effects on AV nodall conduction:'
p980
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions6/questionset6.htm'
p981
sg15
S'Q16#12'
p982
sg17
S'12'
p983
sg18
I0
sg19
S'16'
p984
sa(dp985
g3
I9
sg4
I12
sg5
(lp986
Vbeta-1 adrenergic receptor effect
p987
aValpha adrenergic receptor effect
p988
aVcholinergic muscarinic receptor effect
p989
asg11
S'Enhanced antidiuretic hormone secretion (ADH secretion):'
p990
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions7/questionset7.htm'
p991
sg15
S'Q17#8'
p992
sg17
S'8'
sg18
I0
sg19
S'17'
p993
sa(dp994
g3
I4
sg4
I6
sg5
(lp995
Valpha-1 adrenergic
p996
aVbeta-2 adrenergic
p997
aVcholinergic muscarinic
p998
asg11
S'Decreases bronchial gland secretion'
p999
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions7/questionset7.htm'
p1000
sg15
S'Q17#9'
p1001
sg17
S'9'
sg18
I0
sg19
S'17'
p1002
sa(dp1003
g3
I11
sg4
I5
sg5
(lp1004
Vepinephrine
p1005
aVdopamine
p1006
aVdobutamine
p1007
aVnorepinephrine
p1008
aVphenylephrine
p1009
asg11
S'Primary neurotransmitter released by postganglionic neurons of the autonomic sympathetic system:'
p1010
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1011
sg15
S'Q18#0'
p1012
sg17
S'0'
sg18
I3
sg19
S'18'
p1013
sa(dp1014
g3
I8
sg4
I31
sg5
(lp1015
Vsignificantly decreases  glomerularl filtration rates
p1016
aVeffective in treating variant (Prinzmetal\u005c
p1017
aVnorepinephrine pressor effects blocked by prazosin (Minipress)
p1018
aVincreased blood flow to liver, kidney, and skeletal muscle
p1019
asg11
S'Vascular effects of norepinephrine (Levophed):'
p1020
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1021
sg15
S'Q18#2'
p1022
sg17
S'2'
sg18
I2
sg19
S'18'
p1023
sa(dp1024
g3
I5
sg4
I6
sg5
(lp1025
Vepinephrine
p1026
aVtyrosine
p1027
aVtyrosine hydroxylase
p1028
aVdopamine
p1029
aVdopa
p1030
asg11
S'Immediate synthetic precursor of norepinephrine:'
p1031
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1032
sg15
S'Q18#3'
p1033
sg17
S'3'
sg18
I3
sg19
S'18'
p1034
sa(dp1035
g3
I10
sg4
I15
sg5
(lp1036
Vepinephrine
p1037
aVdopa
p1038
aVdopamine (Intropin)
p1039
aVdobutamine (Dobutrex)
p1040
aVnitroprusside sodium (Nipride)
p1041
asg11
S'Low doses, this precursor of norepinephrine causes renovascular dilation:'
p1042
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1043
sg15
S'Q18#5'
p1044
sg17
S'5'
sg18
I2
sg19
S'18'
p1045
sa(dp1046
g3
I5
sg4
I14
sg5
(lp1047
Vmanagement of sleep cycles
p1048
aVtreatment of Raynaud\u005c
p1049
aVtreatment of cardiogenic/hypovolemic shock
p1050
aVmanagement of tachyarrhythmias
p1051
asg11
S'Significant therapeutic use for dopamine:'
p1052
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1053
sg15
S'Q18#7'
p1054
sg17
S'7'
sg18
I2
sg19
S'18'
p1055
sa(dp1056
g3
I6
sg4
I20
sg5
(lp1057
Vphenylephrine (Neo-Synephrine)
p1058
aVmethoxamine (Vasoxyl)
p1059
aVnorepinephrine (Levophed)
p1060
aVisoproterenol (Isuprel)
p1061
aVprazosin (Minipress)
p1062
asg11
S'Has limited action at alpha-adrenergic receptors'
p1063
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1064
sg15
S'Q18#8'
p1065
sg17
S'8'
sg18
I3
sg19
S'18'
p1066
sa(dp1067
g3
I11
sg4
I29
sg5
(lp1068
Vsignificant vasopressor effect
p1069
aVsignificant hypotensive effect
p1070
aVslight decrease in mean pressure with a significant decrease in diastolic pressure
p1071
aVsignificant increase in systolic pressure with minimal effect on diastolic pressure
p1072
asg11
S'Effect of IV isoproterenol (Isuprel) infusions on blood pressure:'
p1073
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions8/questionset8.htm'
p1074
sg15
S'Q18#9'
p1075
sg17
S'9'
sg18
I2
sg19
S'18'
p1076
sa(dp1077
g3
I14
sg4
I11
sg5
(lp1078
Vlow systemic blood pressure
p1079
aVdecreased atrial filling pressures
p1080
aVhigh urinary output
p1081
asg11
S'Cardiovascular characteristics of patients who might benefit from IV dopamine (Intropin) administration:'
p1082
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions9/questionset9.htm'
p1083
sg15
S'Q19#0'
p1084
sg17
S'0'
sg18
I2
sg19
S'19'
p1085
sa(dp1086
g3
I25
sg4
I17
sg5
(lp1087
Vepinephrine
p1088
aVisoproterenol (Isuprel)
p1089
aVphenylephrine (Neo-Synephrine)
p1090
aVdopamine (Intropin)
p1091
aVnorepinephrine (Levophed)
p1092
asg11
S'Simultaneous increases in myocardial contractility, glomerular filtration rate, sodium excretion, urine output, and renal blood flow are associated most likely with:'
p1093
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions9/questionset9.htm'
p1094
sg15
S'Q19#1'
p1095
sg17
S'1'
sg18
I3
sg19
S'19'
p1096
sa(dp1097
g3
I6
sg4
I23
sg5
(lp1098
Vpromotes renal tubule or solid reabsorption
p1099
aVreduces sodium excretion
p1100
aVcauses reduced ventilatory response to arterial hypoxemia
p1101
aVdecreases myocardial contractility
p1102
aVincreases atrial filling pressures
p1103
asg11
S'IV dopamine (Intropin) properties:'
p1104
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions9/questionset9.htm'
p1105
sg15
S'Q19#2'
p1106
sg17
S'2'
sg18
I2
sg19
S'19'
p1107
sa(dp1108
g3
I7
sg4
I36
sg5
(lp1109
Vpositive inotropic agent; causes significant increase in heart rate
p1110
aVpromotes catecholamine release
p1111
aVmainly acts through dopamine receptors
p1112
aVpositive inotropic effect is mediated through beta-adrenergic receptor activation
p1113
aVappropriate for long-term management of myocardial pump-failure following surgery
p1114
asg11
S'Properties of dobutamine (Dobutrex):'
p1115
sg13
S'http://www.pharmacology2000.com/Autonomics/Adrenergics1/questions9/questionset9.htm'
p1116
sg15
S'Q19#4'
p1117
sg17
S'4'
sg18
I3
sg19
S'19'
p1118
sa(dp1119
g3
I3
sg4
I20
sg5
(lp1120
VGanglionic neurotransmitter: acetylcholine
p1121
aVgeneralized response upon sympathetic activation
p1122
aVthoraco-lumbar origin for preganglionic cell bodies
p1123
aVA, B and C
p1124
asg11
S'Sympathetic Nervous System'
p1125
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1126
sg15
S'Q20#0'
p1127
sg17
S'0'
sg18
I3
sg19
S'20'
p1128
sa(dp1129
g3
I8
sg4
I10
sg5
(lp1130
Vcarbachol
p1131
aVacetylcholine
p1132
aVmethacholine (Provocholine)
p1133
aVpilocarpine (Pilocar)
p1134
asg11
S'Choline ester most susceptible to hydrolysis by acetylcholinesterase:'
p1135
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1136
sg15
S'Q20#1'
p1137
sg17
S'1'
sg18
I1
sg19
S'20'
p1138
sa(dp1139
g3
I7
sg4
I7
sg5
(lp1140
Vacetylcholine
p1141
aVatropine
p1142
aVmethacholine (Provocholine)
p1143
aVcarbachol
p1144
asg11
S'Highest nicotinic receptor activity among choline esters:'
p1145
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1146
sg15
S'Q20#3'
p1147
sg17
S'3'
sg18
I3
sg19
S'20'
p1148
sa(dp1149
g3
I9
sg4
I11
sg5
(lp1150
Vincrease heart rate
p1151
aVdecreased GI motility
p1152
aVdecrease cardiac contractility
p1153
aVurinary retention
p1154
asg11
S'Associated with parasympathetic activation (direct effects):'
p1155
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1156
sg15
S'Q20#4'
p1157
sg17
S'4'
sg18
I2
sg19
S'20'
p1158
sa(dp1159
g3
I4
sg4
I15
sg5
(lp1160
Vmetoprolol (Lopressor)
p1161
aVatropine
p1162
aValbuterol (Ventolin,Proventil)
p1163
aV ipratropium (Atrovent)
p1164
asg11
S'Bronchoconstriction in an asthmatic:'
p1165
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1166
sg15
S'Q20#5'
p1167
sg17
S'5'
sg18
I0
sg19
S'20'
p1168
sa(dp1169
g3
I6
sg4
I4
sg5
(lp1170
Vatropine
p1171
aVscopolamine
p1172
aVhomatropine
p1173
aVmuscarine
p1174
asg11
S'Antimuscarinic drug with highest CNS activity'
p1175
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1176
sg15
S'Q20#7'
p1177
sg17
S'7'
sg18
I1
sg19
S'20'
p1178
sa(dp1179
g3
I9
sg4
I13
sg5
(lp1180
Visoproterenol (Isuprel)
p1181
aVatropine
p1182
aVpropranolol (Inderal)
p1183
aVmethacholine (Provocholine)
p1184
asg11
S'Muscarinic agent: enhances transmission through the A-V node:'
p1185
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1186
sg15
S'Q20#8'
p1187
sg17
S'8'
sg18
I1
sg19
S'20'
p1188
sa(dp1189
g3
I13
sg4
I14
sg5
(lp1190
Vhomatropine (Isopto Homatropine)
p1191
aVatropine
p1192
aVcyclopentolate (Cyclogyl)
p1193
aVbenztropine (Cogentin)
p1194
asg11
S'Least likely to be used as a mydriatic because of long-duration of action:'
p1195
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1196
sg15
S'Q20#9'
p1197
sg17
S'9'
sg18
I1
sg19
S'20'
p1198
sa(dp1199
g3
I10
sg4
I14
sg5
(lp1200
Vhomatropine (Isopto Homatropine)
p1201
aVatropine
p1202
aVbenztropine (Cogentin)
p1203
aVtropicamide (Mydriacyl)
p1204
asg11
S'Clinically-used to treat sinus bradycardia secondary to acute myocardial infarction:'
p1205
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions2/cho1.htm'
p1206
sg15
S'Q20#10'
p1207
sg17
S'10'
p1208
sg18
I1
sg19
S'20'
p1209
sa(dp1210
g3
I8
sg4
I4
sg5
(lp1211
VM1
p1212
aVM2
p1213
aVM3
p1214
aVM4
p1215
asg11
S'Muscarinic receptor subtype primarily associated with the heart:'
p1216
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions3/questionset3.htm'
p1217
sg15
S'Q21#5'
p1218
sg17
S'5'
sg18
I1
sg19
S'21'
p1219
sa(dp1220
g3
I2
sg4
I8
sg5
(lp1221
Vatropine
p1222
aVedrophonium (Tensilon)
p1223
aVcarbachol
p1224
aVacetylcholine
p1225
aVephedrine
p1226
asg11
S'Indirect-acting cholinomimetic:'
p1227
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions3/questionset3.htm'
p1228
sg15
S'Q21#12'
p1229
sg17
S'12'
p1230
sg18
I1
sg19
S'21'
p1231
sa(dp1232
g3
I13
sg4
I5
sg5
(lp1233
Vsodium
p1234
aVpotassium
p1235
aVchloride
p1236
aVcalcium
p1237
aVmagnesium
p1238
asg11
S'Cholinergic-receptor-mediated vasodilation -- changes in intracellular concentration of this ion is principally responsible:'
p1239
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions4/questionset4.htm'
p1240
sg15
S'Q22#0'
p1241
sg17
S'0'
sg18
I3
sg19
S'22'
p1242
sa(dp1243
g3
I14
sg4
I5
sg5
(lp1244
Vprostaglandins
p1245
aVleukotrienes
p1246
aVnitric oxide
p1247
aVcalcium
p1248
asg11
S'Cholinergic-mediated vasodilation involves liberation of this substance, a gas, from endothelial cells:'
p1249
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions4/questionset4.htm'
p1250
sg15
S'Q22#1'
p1251
sg17
S'1'
sg18
I2
sg19
S'22'
p1252
sa(dp1253
g3
I11
sg4
I17
sg5
(lp1254
Vphysostigmine (Antilirium)
p1255
aVneostigmine (Prostigmin)
p1256
aVedrophonium (Tensilon)
p1257
aVtacrine (Cognex)
p1258
aVatropine
p1259
asg11
S'anticholinesterase agent; quaternary ammonium compound; intermediate-duration, carbamylating agent:'
p1260
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions5/questionset5.htm'
p1261
sg15
S'Q23#1'
p1262
sg17
S'1'
sg18
I1
sg19
S'23'
p1263
sa(dp1264
g3
I9
sg4
I3
sg5
(lp1265
Vprimary
p1266
aVsecondary
p1267
aVcongenital
p1268
asg11
S'Which type of glaucoma response to anticholinesterase treatment?'
p1269
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions5/questionset5.htm'
p1270
sg15
S'Q23#7'
p1271
sg17
S'7'
sg18
I0
sg19
S'23'
p1272
sa(dp1273
g3
I5
sg4
I36
sg5
(lp1274
Vexcessive synthesis of cholinergic receptors
p1275
aVinadequate synthesis of acetylcholine
p1276
aVfailure of acetylcholine reuptake system
p1277
aVbinding of anti--muscarinic receptor antibodies to the muscarinic cholinergic receptor
p1278
aVbinding of anti-nicotinic receptor antibodies to the nicotinic cholinergic receptor
p1279
asg11
S'Probable cause of myasthenia gravis:'
p1280
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions5/questionset5.htm'
p1281
sg15
S'Q23#9'
p1282
sg17
S'9'
sg18
I4
sg19
S'23'
p1283
sa(dp1284
g3
I12
sg4
I29
sg5
(lp1285
Vspontaneous recovery rate from the blocking drug
p1286
aVactivity of the pharmacologic antagonist (anticholinesterase drug)
p1287
aVboth (sum of A plus B)
p1288
aVdifference (A- B)
p1289
asg11
S'Determination of the recovery rates from neuromuscular-blockade when antagonist-assisted reversal is used:'
p1290
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1291
sg15
S'Q24#2'
p1292
sg17
S'2'
sg18
I2
sg19
S'24'
p1293
sa(dp1294
g3
I12
sg4
I24
sg5
(lp1295
Vbefore the neuromuscular-blocking drug is given
p1296
aVwhile the neuromuscular-blocking drug is being infused
p1297
aVduring the spontaneous neuromuscular-blockade recovery, following cessation of neuromuscular-blocking administration
p1298
asg11
S'When our anticholinesterase agents usually administered to enhance neuromuscular blockade reversal?'
p1299
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1300
sg15
S'Q24#3'
p1301
sg17
S'3'
sg18
I2
sg19
S'24'
p1302
sa(dp1303
g3
I19
sg4
I9
sg5
(lp1304
Vshort-or intermediate-acting neuromuscular-blocking drugs
p1305
aVlong-acting nondepolarizing neuromuscular-blockade
p1306
aVequally effective
p1307
asg11
S'Pharmacologic antagonism (anticholinesterase drugs) would likely be more effective for which type of neuromuscular blocking drug?'
p1308
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1309
sg15
S'Q24#4'
p1310
sg17
S'4'
sg18
I0
sg19
S'24'
p1311
sa(dp1312
g3
I13
sg4
I15
sg5
(lp1313
Vincreases acetylcholine concentration that neuromuscular junctions
p1314
aVinhibits acetylcholinesterase
p1315
aVminimizes muscarinic receptor-mediated effects of anticholinesterase drugs
p1316
asg11
S'Rationale for using muscarinic antagonists in pharmacologic (anticholinesterase-mediated) reversal of neuromuscular-blockade:'
p1317
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1318
sg15
S'Q24#5'
p1319
sg17
S'5'
sg18
I2
sg19
S'24'
p1320
sa(dp1321
g3
I23
sg4
I14
sg5
(lp1322
Vedrophonium (Tensilon)
p1323
aVhigh-dose atropine (10-15 ug/kg)
p1324
aVneostigmine (Prostigmin)
p1325
asg11
S'which antimuscarinic agent might be used in combination with an anticholinesterase when desiring reversal of neuromuscular-blockade and opioid-based maintenance anesthesia has been used:'
p1326
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1327
sg15
S'Q24#6'
p1328
sg17
S'6'
sg18
I1
sg19
S'24'
p1329
sa(dp1330
g3
I25
sg4
I12
sg5
(lp1331
Vedrophonium (Tensilon)
p1332
aVneostigmine (Prostigmin)
p1333
aVboth are equally effective
p1334
asg11
S'More effective in reversing deep neuromuscular-blockade produced by continuous atracurium (Tracrium), vecuronium (Norcuron), or pancuronium (Pavulon) infusions'
p1335
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions6/questionset6.htm'
p1336
sg15
S'Q24#7'
p1337
sg17
S'7'
sg18
I1
sg19
S'24'
p1338
sa(dp1339
g3
I23
sg4
I6
sg5
(lp1340
Vscopolamine
p1341
aVatropine
p1342
aVglycopyrrolate (Robinul)
p1343
asg11
S'In using anticholinergic drugs as preoperative medication in a patient with glaucoma: drug least likely to have an effect on pupil size'
p1344
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions7/questionset7.htm'
p1345
sg15
S'Q25#2'
p1346
sg17
S'2'
sg18
I2
sg19
S'25'
p1347
sa(dp1348
g3
I11
sg4
I6
sg5
(lp1349
Vatropine
p1350
aVglycopyrrolate (Robinul)
p1351
aVscopolamine
p1352
asg11
S'Preferred anticholinergic drug when sedation is the principal objective, preoperatively:'
p1353
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions7/questionset7.htm'
p1354
sg15
S'Q25#3'
p1355
sg17
S'3'
sg18
I2
sg19
S'25'
p1356
sa(dp1357
g3
I12
sg4
I4
sg5
(lp1358
Vyoung adult
p1359
aVinfants
p1360
aVelderly
p1361
asg11
S'Atropine: most likely to increase heart rate in this patient population:'
p1362
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions7/questionset7.htm'
p1363
sg15
S'Q25#4'
p1364
sg17
S'4'
sg18
I0
sg19
S'25'
p1365
sa(dp1366
g3
I12
sg4
I20
sg5
(lp1367
Valbuterol (Ventolin,Proventil) (beta-adrenergic agonist)
p1368
aVipratropium (Atrovent) (antimuscarinic agent)
p1369
aVequally effective
p1370
asg11
S'More effective in producing bronchodilation in patients with chronic bronchitis or emphysema:'
p1371
sg13
S'http://www.pharmacology2000.com/Autonomics/Cholinergics/questions7/questionset7.htm'
p1372
sg15
S'Q25#6'
p1373
sg17
S'6'
sg18
I1
sg19
S'25'
p1374
sa(dp1375
g3
I47
sg4
I28
sg5
(lp1376
Vminoxidil (Loniten): TPR increases
p1377
aVfosinopril (Monopril): TPR increases
p1378
aVnorepinephrine (Levophed): TPR increases
p1379
aVphenoxybenzamine (Dibenzyline): TPR increases
p1380
asg11
S'Total peripheral resistance (TPR) is a determining factor for mean arterial pressure, i.e. Mean arterial pressure (MAP) = cardiac output x total peripheral resistance (TPR). What are correct relationships between norepinephrine, minoxidil, and lisinopril and TPR?'
p1381
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1382
sg15
S'Q26#0'
p1383
sg17
S'0'
sg18
I2
sg19
S'26'
p1384
sa(dp1385
g3
I2
sg4
I16
sg5
(lp1386
Vprazosin (Minipress)
p1387
aVhydralazine (Apresoline)
p1388
aVmecamylamine (Inversine)
p1389
aVnicardipine (Cardene)
p1390
asg11
S'Ganglionic blocker'
p1391
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1392
sg15
S'Q26#2'
p1393
sg17
S'2'
sg18
I2
sg19
S'26'
p1394
sa(dp1395
g3
I2
sg4
I18
sg5
(lp1396
Vnifedipine (Procardia, Adalat)
p1397
aVcaptopril (Capoten)
p1398
aVtimolol (Blocadren)
p1399
aVmethyldopa (Aldomet)
p1400
asg11
S'ACE inhibitor'
p1401
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1402
sg15
S'Q26#4'
p1403
sg17
S'4'
sg18
I1
sg19
S'26'
p1404
sa(dp1405
g3
I6
sg4
I18
sg5
(lp1406
Vtimolol (Blocadren)
p1407
aVlabetalol (Trandate, Normodyne)
p1408
aVpropranolol (Inderal)
p1409
aVdiazoxide (Hyperstat)
p1410
asg11
S'Blocks both alpha and beta receptors:'
p1411
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1412
sg15
S'Q26#5'
p1413
sg17
S'5'
sg18
I1
sg19
S'26'
p1414
sa(dp1415
g3
I2
sg4
I14
sg5
(lp1416
Vdiltiazem (Cardiazem)
p1417
aVnitroprusside sodium (Nipride)
p1418
aVreserpine
p1419
aVphenylephrine (Neo-Synephrine)
p1420
asg11
S'Hypertensive emergencies:'
p1421
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1422
sg15
S'Q26#6'
p1423
sg17
S'6'
sg18
I1
sg19
S'26'
p1424
sa(dp1425
g3
I14
sg4
I16
sg5
(lp1426
Vpropranolol (Inderal)
p1427
aVmecamylamine (Inversine)
p1428
aVhydralazine (Apresoline)
p1429
aVdiazoxide (Hyperstat)
p1430
asg11
S'Side effects of this antihypertensive agent includes tachycardia, angina, reversible lupus-like syndrome'
p1431
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1432
sg15
S'Q26#7'
p1433
sg17
S'7'
sg18
I2
sg19
S'26'
p1434
sa(dp1435
g3
I8
sg4
I12
sg5
(lp1436
Vphosphodiesterase inhibitor
p1437
aVblockade of calcium channels
p1438
aValpha-1 receptor antagonists
p1439
aVbeta-1 receptor antagonist
p1440
asg11
S'Mechanism of action:diltiazem (Cardiazem)'
p1441
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1442
sg15
S'Q26#8'
p1443
sg17
S'8'
sg18
I1
sg19
S'26'
p1444
sa(dp1445
g3
I8
sg4
I11
sg5
(lp1446
Valpha-1 receptor blocker
p1447
aVbeta receptor blocker
p1448
aVphosphodiesterase inhibitor
p1449
aVcalcium channel blocker
p1450
asg11
S'Mechanism of action: prazosin (Minipress)'
p1451
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1452
sg15
S'Q26#9'
p1453
sg17
S'9'
sg18
I0
sg19
S'26'
p1454
sa(dp1455
g3
I8
sg4
I16
sg5
(lp1456
Vpropranolol (Inderal)
p1457
aVmetoprolol (Lopressor)
p1458
aVchlorothiazide (Diuril)
p1459
aVdiltiazem (Cardiazem)
p1460
asg11
S'Antihypertensive drug LEAST likely to elevate serum lipids:'
p1461
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1462
sg15
S'Q26#10'
p1463
sg17
S'10'
p1464
sg18
I3
sg19
S'26'
p1465
sa(dp1466
g3
I43
sg4
I16
sg5
(lp1467
Vchlorothiazide (Diuril)
p1468
aVcaptopril (Capoten)
p1469
aVpropranolol (Inderal)
p1470
aVmetoprolol (Lopressor)
p1471
asg11
S'An elderly male patient has essential hypertension, congestive heart failure, and type I insulin-dependent diabetes. His congestive failure developed secondary to coronary vascular disease associated with hyperlipidemia. What antihypertensive drug(s) may be most appropriate for this patient?'
p1472
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1473
sg15
S'Q26#11'
p1474
sg17
S'11'
p1475
sg18
I1
sg19
S'26'
p1476
sa(dp1477
g3
I14
sg4
I15
sg5
(lp1478
Vnifedipine (Procardia, Adalat)
p1479
aVnitroprusside sodium (Nipride)
p1480
aVnicardipine (Cardene)
p1481
asg11
S'i.v. route of administration; few side effects; effective in treating hypertensive crisis:'
p1482
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1483
sg15
S'Q26#12'
p1484
sg17
S'12'
p1485
sg18
I1
sg19
S'26'
p1486
sa(dp1487
g3
I67
sg4
I104
sg5
(lp1488
VPropranolol (Inderal) is appropriate because it will reduce heart rate and cardiac output. Negative inotropism will help reduce the incidence of angina. It is an effective antihypertensive agent
p1489
aVPropranolol (Inderal) is inappropriate because it is only useful in mild hypertension; a better drug would be minoxidil or hydralazine because they are more effective in lowering blood pressure
p1490
aVPropranolol (Inderal) is appropriate because it is an effective, low-cost antihypertensive. It will augment the effects of terbutaline, an additional benefit
p1491
aVPropranolol (Inderal) is inappropriate because its use is contraindicated in a patient with asthma.
p1492
asg11
S'A patient presents with a blood pressure of 160/110 mm Hg. The patient has a history of coronary vascular disease, resulting in angina, but has no evidence of congestive heart failure. The patient also has asthma and has been treated mainly using terbutaline (Brethine), by aerosol inhalation Propranolol (Inderal) was prescribed to manage essential hypertension. Was this action appropriate?'
p1493
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1494
sg15
S'Q26#13'
p1495
sg17
S'13'
p1496
sg18
I3
sg19
S'26'
p1497
sa(dp1498
g3
I26
sg4
I12
sg5
(lp1499
Vblocks all three
p1500
aVblocks only vasoconstriction
p1501
aVblocks all except vasoconstriction
p1502
aVno effect
p1503
asg11
S'Vasoconstriction, aldosterone secretion, and renin release suppression occur upon activation of the renin-angiotensin-aldosterone system. How would captopril (Capoten) affect these responses?'
p1504
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1505
sg15
S'Q26#14'
p1506
sg17
S'14'
p1507
sg18
I0
sg19
S'26'
p1508
sa(dp1509
g3
I13
sg4
I16
sg5
(lp1510
Vpropranolol (Inderal)
p1511
aVguanadrel (Hylorel)
p1512
aVmecamylamine (Inversine)
p1513
aVphentolamine (Regitine)
p1514
asg11
S'Antihypertensive: action based on inhibition of norepinephrine release from adrenergic nerve endings:'
p1515
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1516
sg15
S'Q26#16'
p1517
sg17
S'16'
p1518
sg18
I1
sg19
S'26'
p1519
sa(dp1520
g3
I7
sg4
I62
sg5
(lp1521
Vdoxazosin (Cardura), prazosin (Minipress), metoprolol (Lopressor)
p1522
aVnifedipine (Procardia, Adalat), verapamil (Isoptin, Calan), diltiazem (Cardiazem)
p1523
aVclonidine (Catapres), guanabenz (Wytensin),terazosin (Hytrin)
p1524
aVlisinopril (Prinvivil, Zestril), fosinopril (Monopril), guanadrel (Hylorel)
p1525
asg11
S'Antihypertensive drugs belonging to the same class:'
p1526
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions2/ah1.htm'
p1527
sg15
S'Q26#18'
p1528
sg17
S'18'
p1529
sg18
I1
sg19
S'26'
p1530
sa(dp1531
g3
I2
sg4
I7
sg5
(lp1532
Vpheochromocytoma
p1533
aVaortic coarctation
p1534
aVfamilial dysautonomia
p1535
aVchronic pyelonephritis
p1536
asg11
S'Neurogenic hypertension:'
p1537
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions3/questionset3.htm'
p1538
sg15
S'Q27#2'
p1539
sg17
S'2'
sg18
I2
sg19
S'27'
p1540
sa(dp1541
g3
I10
sg4
I12
sg5
(lp1542
Vincreased preload
p1543
aVincreased afterload
p1544
aVdecreased heart rate
p1545
aVincrease contractility
p1546
aV increased peripheral resistance
p1547
asg11
S'Hemodynamic change(s) that may reduce arterial blood-pressure:'
p1548
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions3/questionset3.htm'
p1549
sg15
S'Q27#5'
p1550
sg17
S'5'
sg18
I2
sg19
S'27'
p1551
sa(dp1552
g3
I6
sg4
I25
sg5
(lp1553
Vsodium channel blockade in late distal  tubule and collecting duct
p1554
aVmineralocorticoid receptors
p1555
aVsodium, chloride synport transporter at the distal convoluted tubule
p1556
aVloop of Henle
p1557
asg11
S'Site of action of thiazide diuretics:'
p1558
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1559
sg15
S'Q28#6'
p1560
sg17
S'6'
sg18
I2
sg19
S'28'
p1561
sa(dp1562
g3
I3
sg4
I20
sg5
(lp1563
Vbumetanide (Bumex)
p1564
aVchlorothiazide (Diuril)
p1565
aVamiloride (Midamor)
p1566
aVmannitol (Osmitrol)
p1567
aVacetazolamide (Diamox)
p1568
asg11
S'Potassium sparing diuretic:'
p1569
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1570
sg15
S'Q28#7'
p1571
sg17
S'7'
sg18
I2
sg19
S'28'
p1572
sa(dp1573
g3
I7
sg4
I21
sg5
(lp1574
Vhydralazine (Apresoline)
p1575
aVdiltiazem (Cardiazem)
p1576
aVguanabenz (Wytensin)
p1577
aVnitroprusside sodium (Nipride)
p1578
aVmecamylamine (Inversine)
p1579
asg11
S'Example(s) of centrally-acting sympatholytics:'
p1580
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1581
sg15
S'Q28#8'
p1582
sg17
S'8'
sg18
I2
sg19
S'28'
p1583
sa(dp1584
g3
I7
sg4
I20
sg5
(lp1585
Vmanagement of moderate hypertension
p1586
aVtreatment of paralytic ileus
p1587
aVto reduce heart rate
p1588
aVhypertension associated with dissecting aortic aneurysm
p1589
aVrenovascular stenosis
p1590
asg11
S'Relatively common use for ganglionic blocking drugs'
p1591
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1592
sg15
S'Q28#10'
p1593
sg17
S'10'
p1594
sg18
I3
sg19
S'28'
p1595
sa(dp1596
g3
I11
sg4
I16
sg5
(lp1597
Vpropranolol (Inderal)
p1598
aVtimolol (Blocadren)
p1599
aVatenolol (Tenormin)
p1600
aVpindolol (Visken)
p1601
asg11
S'Beta-blocker that might be preferable in a patient with insulin-dependent diabetes:'
p1602
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1603
sg15
S'Q28#16'
p1604
sg17
S'16'
p1605
sg18
I2
sg19
S'28'
p1606
sa(dp1607
g3
I10
sg4
I22
sg5
(lp1608
Vvasodilation-- arteriolar
p1609
aVvasodilation -- venular
p1610
aVreduced heart rate and reduced myocardial contractility
p1611
aVblockade of angiotensin  II receptors
p1612
aVdecreased central sympathetic outflow
p1613
asg11
S'Principal mechanisms by which beta adrenergic receptor blockade decreases BP:'
p1614
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1615
sg15
S'Q28#18'
p1616
sg17
S'18'
p1617
sg18
I2
sg19
S'28'
p1618
sa(dp1619
g3
I8
sg4
I4
sg5
(lp1620
Vincrease
p1621
aVdecrease
p1622
aVno effect
p1623
asg11
S'Effect of beta adrenergic blockers on renin levels:'
p1624
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1625
sg15
S'Q28#19'
p1626
sg17
S'19'
p1627
sg18
I1
sg19
S'28'
p1628
sa(dp1629
g3
I9
sg4
I4
sg5
(lp1630
Vincrease
p1631
aVdecrease
p1632
aVno effect
p1633
asg11
S'Effect of beta adrenergic blockers on angiotensin II levels:'
p1634
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions4/questionset4.htm'
p1635
sg15
S'Q28#20'
p1636
sg17
S'20'
p1637
sg18
I1
sg19
S'28'
p1638
sa(dp1639
g3
I27
sg4
I20
sg5
(lp1640
Vfirst-degree heart block
p1641
aVsecond-degree heart block, Mobitz Type I
p1642
aVsecondary heart block, Mobitz Type II
p1643
aVthird-degree heart block
p1644
asg11
S'Heart block in which the P wave appears before each QRS in a regular manner; P-R interval > 0.2 seconds; QRS interval < 0.12 seconds'
p1645
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions5/questionset5.htm'
p1646
sg15
S'Q29#0'
p1647
sg17
S'0'
sg18
I0
sg19
S'29'
p1648
sa(dp1649
g3
I13
sg4
I21
sg5
(lp1650
Vhydralazine (Apresoline)
p1651
aVisoproterenol (Isuprel)
p1652
aVmetoprolol (Lopressor)
p1653
aVpindolol (Visken)
p1654
aVnitroprusside sodium (Nipride)
p1655
asg11
S'Agent which would attenuate reflex-mediated cardiac stimulation following minoxidil (Loniten) administration:'
p1656
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions5/questionset5.htm'
p1657
sg15
S'Q29#4'
p1658
sg17
S'4'
sg18
I2
sg19
S'29'
p1659
sa(dp1660
g3
I7
sg4
I24
sg5
(lp1661
Vmore arteriolar dilation compared to venular dilation
p1662
aVmore venular dilation compared to arteriolar dilation
p1663
aVarteriolar and venular dilation similar with hydralazine (Apresoline)
p1664
asg11
S'Hydralazine (Apresoline)--vascular effects:'
p1665
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions5/questionset5.htm'
p1666
sg15
S'Q29#5'
p1667
sg17
S'5'
sg18
I0
sg19
S'29'
p1668
sa(dp1669
g3
I34
sg4
I20
sg5
(lp1670
Vpropranolol (Inderal)
p1671
aVprazosin (Minipress)
p1672
aVminoxidil (Loniten)
p1673
aVphenylephrine (Neo-Synephrine)
p1674
aVisoproterenol (Isuprel)
p1675
asg11
S'Direct relaxation of arteriolar smooth muscle; when combined with the diuretic and sympatholytic, can be very effective for management of severe hypertension associated with renovascular disease, transplant rejection, renal failure:'
p1676
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions5/questionset5.htm'
p1677
sg15
S'Q29#8'
p1678
sg17
S'8'
sg18
I2
sg19
S'29'
p1679
sa(dp1680
g3
I24
sg4
I19
sg5
(lp1681
Vlabetalol (Trandate, Normodyne)
p1682
aVhydralazine (Apresoline)
p1683
aVminoxidil (Loniten)
p1684
aVnitroprusside sodium (Nipride)
p1685
asg11
S'Antihypertensive: direct acting, nonselective peripheral vasodilator -- acts on arteriole and venous vascular smooth muscle: 44% cyanide by weight --'
p1686
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions5/questionset5.htm'
p1687
sg15
S'Q29#10'
p1688
sg17
S'10'
p1689
sg18
I3
sg19
S'29'
p1690
sa(dp1691
g3
I12
sg4
I21
sg5
(lp1692
Vnitroprusside sodium (Nipride)
p1693
aVhydralazine (Apresoline)
p1694
aVminoxidil (Loniten)
p1695
aVmethyldopa (Aldomet)
p1696
aVguanfacine (Tenex)
p1697
asg11
S'Antihypertensive drug associated with hypertrichosis (particularly around phase, arms)'
p1698
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions6/questionset6.htm'
p1699
sg15
S'Q30#4'
p1700
sg17
S'4'
sg18
I2
sg19
S'30'
p1701
sa(dp1702
g3
I18
sg4
I21
sg5
(lp1703
Vminoxidil (Loniten)
p1704
aVnitroprusside sodium (Nipride)
p1705
aVhydralazine (Apresoline)
p1706
aVcaptopril (Capoten)
p1707
aVdiltiazem (Cardiazem)
p1708
asg11
S'Antihypertensive drug associated with a lupus-like syndrome: frequency 10%-20%; reversible upon drug discontinuation:'
p1709
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions6/questionset6.htm'
p1710
sg15
S'Q30#5'
p1711
sg17
S'5'
sg18
I2
sg19
S'30'
p1712
sa(dp1713
g3
I21
sg4
I9
sg5
(lp1714
Vcalcium channel blockers
p1715
aVbeta-blockers
p1716
aValpha-adrenergic blockers
p1717
aVACE inhibitors
p1718
aVvasodilators
p1719
asg11
S'Antihypertensive drug group considered advantageous and management of diabetic patients because these drugs reduce/delay development of diabetic neuropathy and glomerulosclerosis--'
p1720
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions6/questionset6.htm'
p1721
sg15
S'Q30#9'
p1722
sg17
S'9'
sg18
I3
sg19
S'30'
p1723
sa(dp1724
g3
I17
sg4
I20
sg5
(lp1725
Vmannitol (Osmitrol)
p1726
aVfurosemide (Lasix)
p1727
aVchlorothiazide (Diuril)
p1728
aVtriamterene (Dyrenium)
p1729
aVacetazolamide (Diamox)
p1730
asg11
S'Promotes hyperosmolar diuresis; acts in the distal tubule to decrease sodium absorption; promotes calcium reabsorption'
p1731
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions7/questionset7.htm'
p1732
sg15
S'Q31#0'
p1733
sg17
S'0'
sg18
I2
sg19
S'31'
p1734
sa(dp1735
g3
I13
sg4
I20
sg5
(lp1736
Vtriamterene (Dyrenium)
p1737
aVspironolactone (Aldactone)
p1738
aVbumetanide (Bumex)
p1739
aVamiloride (Midamor)
p1740
aVchlorothiazide (Diuril)
p1741
asg11
S'Example(s) of "high-ceiling" diuretic(s):'
p1742
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions7/questionset7.htm'
p1743
sg15
S'Q31#2'
p1744
sg17
S'2'
sg18
I2
sg19
S'31'
p1745
sa(dp1746
g3
I11
sg4
I22
sg5
(lp1747
Vmetoprolol (Lopressor)
p1748
aVpropranolol (Inderal)
p1749
aVguanethidine (Ismelin)
p1750
aVverapamil (Isoptin, Calan)
p1751
aVtriamterene (Dyrenium)
p1752
asg11
S'Antihypertensive drug effect inhibited by imipramine (Tofranil) or cocaine:'
p1753
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions7/questionset7.htm'
p1754
sg15
S'Q31#8'
p1755
sg17
S'8'
sg18
I2
sg19
S'31'
p1756
sa(dp1757
g3
I11
sg4
I22
sg5
(lp1758
Vmetoprolol (Lopressor)
p1759
aVesmolol (Brevibloc)
p1760
aVtimolol (Blocadren)
p1761
aVlabetalol (Trandate, Normodyne)
p1762
aVphysostigmine (Antilirium)
p1763
asg11
S'Adrenergic antagonist but with intrinsic sympathomimetic effect at beta2 adrenergic receptors:'
p1764
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions7/questionset7.htm'
p1765
sg15
S'Q31#9'
p1766
sg17
S'9'
sg18
I3
sg19
S'31'
p1767
sa(dp1768
g3
I6
sg4
I30
sg5
(lp1769
Vcauses reflex mediated tachycardia
p1770
aVcauses an increase in plasma renin
p1771
aVhigher affinity for venular alpha receptors compared to arteriolar alpha receptors
p1772
aVimpairs renal blood flow
p1773
aVno effect on plasma lipids
p1774
asg11
S'Cardiovascular effects of chronic prazosin administration:'
p1775
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions7/questionset7.htm'
p1776
sg15
S'Q31#11'
p1777
sg17
S'11'
p1778
sg18
I2
sg19
S'31'
p1779
sa(dp1780
g3
I4
sg4
I16
sg5
(lp1781
Vcaused by Cushing\u005c
p1782
aVmay be due to pheochromocytoma
p1783
aVcaused by hyperaldosteronism
p1784
aV> 90% of cases
p1785
asg11
S'Primary or idiopathic hypertension:'
p1786
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1787
sg15
S'Q32#0'
p1788
sg17
S'0'
sg18
I3
sg19
S'32'
p1789
sa(dp1790
g3
I3
sg4
I6
sg5
(lp1791
Vhypothyroidism
p1792
aVperipheral vasodilators
p1793
aVaortic regurgitation
p1794
aVtachycardia
p1795
asg11
S'Increases stroke volume:'
p1796
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1797
sg15
S'Q32#1'
p1798
sg17
S'1'
sg18
I2
sg19
S'32'
p1799
sa(dp1800
g3
I2
sg4
I10
sg5
(lp1801
Vacromegaly
p1802
aVhypocalcemia
p1803
aValpha1 adrenergic receptor antagonists
p1804
aVbeta2 adrenergic receptor activation
p1805
asg11
S'Systolic/diastolic hypertension:'
p1806
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1807
sg15
S'Q32#2'
p1808
sg17
S'2'
sg18
I0
sg19
S'32'
p1809
sa(dp1810
g3
I2
sg4
I20
sg5
(lp1811
Vheart rate x peripheral resistance
p1812
aVstroke volume x  peripheral resistance
p1813
aVheart rate x arterial pressure
p1814
aVstroke volume x heart rate
p1815
asg11
S'Cardiac output:'
p1816
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1817
sg15
S'Q32#4'
p1818
sg17
S'4'
sg18
I3
sg19
S'32'
p1819
sa(dp1820
g3
I3
sg4
I50
sg5
(lp1821
Vincreased ventricular stretch may reduce ventricular function (reduced output)
p1822
aVmost antihypertensive drugs promote calcium release from sarcoplasmic reticulum stores
p1823
aVreduced preload coupled with increased contractility will lead to increased stroke volume and usually an increase in arterial pressure
p1824
aVmetoprolol (Lopressor) administration would tend to increase contractility
p1825
asg11
S'Preload and contractility:'
p1826
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1827
sg15
S'Q32#5'
p1828
sg17
S'5'
sg18
I0
sg19
S'32'
p1829
sa(dp1830
g3
I6
sg4
I14
sg5
(lp1831
Vtypically increase afterload
p1832
aVmay increase heart rate
p1833
aVusually increase contractility
p1834
aVusually increased peripheral resistance
p1835
asg11
S'Antihypertensive agents, directly or indirectly:'
p1836
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1837
sg15
S'Q32#6'
p1838
sg17
S'6'
sg18
I1
sg19
S'32'
p1839
sa(dp1840
g3
I8
sg4
I28
sg5
(lp1841
Vreduced likelihood of orthostatic hypotension
p1842
aVincreased hypotensive response to acute blood loss
p1843
aVsupersensitivity (significantly increase sensitivity) to actions of indirect-acting sympathomimetic drugs
p1844
aVhyperactivity would be expected
p1845
asg11
S'Patients receiving antihypertensive medications prior to undergoing anesthesia:'
p1846
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1847
sg15
S'Q32#7'
p1848
sg17
S'7'
sg18
I1
sg19
S'32'
p1849
sa(dp1850
g3
I9
sg4
I68
sg5
(lp1851
Vassociated with increased systemic blood-pressure and heart rate fluctuations during anesthesia
p1852
aVdecrease likelihood of arrhythmias
p1853
aVsince previously effective antihypertensive drug therapy typically should be continued during the perioperative time frame, the pharmacology of the particular antihypertensive agent need not be considered in the development of the anesthesia plan.
p1854
aVusually, is appropriate to maintaina patient on preoperative diuretics when those drugs are used to reduce blood pressure
p1855
asg11
S'Maintenance of antihypertensive drug treatment during perioperative time frame:'
p1856
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1857
sg15
S'Q32#8'
p1858
sg17
S'8'
sg18
I1
sg19
S'32'
p1859
sa(dp1860
g3
I2
sg4
I19
sg5
(lp1861
Vbeta adrenergic receptor up regulation
p1862
aVincreased endothelium-mediated vascular relaxation
p1863
aVincreased vasoconstrictive tone (chronic vasoconstriction)
p1864
aVreduced sympathetic activation
p1865
asg11
S'Essential hypertension:'
p1866
sg13
S'http://www.pharmacology2000.com/Cardio/antihyper/questions8/questionset8.htm'
p1867
sg15
S'Q32#10'
p1868
sg17
S'10'
p1869
sg18
I2
sg19
S'32'
p1870
sa(dp1871
g3
I6
sg4
I21
sg5
(lp1872
Vquinidine gluconate (Quinaglute, Quinalan)
p1873
aVlidocaine (Xylocaine)
p1874
aVencainide (Enkaid)
p1875
aVverapamil (Isoptin, Calan)
p1876
asg11
S'Not a class I antiarrhythmic Drug:'
p1877
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1878
sg15
S'Q34#0'
p1879
sg17
S'0'
sg18
I3
sg19
S'34'
p1880
sa(dp1881
g3
I7
sg4
I19
sg5
(lp1882
Vlidocaine (Xylocaine)
p1883
aVquinidine gluconate (Quinaglute, Quinalan)
p1884
aVadenosine (Adenocard)
p1885
aVencainide (Enkaid)
p1886
asg11
S'Not classified as a Type I antiarrhythmic'
p1887
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1888
sg15
S'Q34#1'
p1889
sg17
S'1'
sg18
I2
sg19
S'34'
p1890
sa(dp1891
g3
I8
sg4
I16
sg5
(lp1892
Vadenosine (Adenocard)
p1893
aVencainide (Enkaid)
p1894
aVamiodarone (Cordarone)
p1895
aVdiltiazem (Cardiazem)
p1896
asg11
S'Corneal microdeposits, blurred vision, and photophobia:'
p1897
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1898
sg15
S'Q34#3'
p1899
sg17
S'3'
sg18
I2
sg19
S'34'
p1900
sa(dp1901
g3
I9
sg4
I19
sg5
(lp1902
Vquinidine gluconate (Quinaglute, Quinalan)
p1903
aVsotalol (Betapace)
p1904
aVbretylium (Bretylol)
p1905
aVpropafenone (Rythmol)
p1906
asg11
S'Class III anti-arrhythmic drug which also blocks potassium channels:'
p1907
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1908
sg15
S'Q34#4'
p1909
sg17
S'4'
sg18
I1
sg19
S'34'
p1910
sa(dp1911
g3
I59
sg4
I61
sg5
(lp1912
VQuinidine activated beta-1 cardiac receptors which cause the increase in heart rate.
p1913
aVQuinidine converted the atrial fibrillation to atrial flutter which resulted in an increase in heart rate.
p1914
aVQuinidine produced an anti-vagal effect and converted atrial fibrillation to atrial flutter. Both effects caused the heart rate to increase.
p1915
aVQuinidine has an anti-vagal effect which facilitated transmission through the A-V  node.
p1916
asg11
S'A patient is diagnosed with atrial fibrillation and exhibits a ventricular following rate of 150 beats / min. Quinidine gluconate (Quinaglute, Quinalan) was administered and although atrial fibrillation was converted to atrial flutter, the ventricular rate increased to 190 beats / min. What is the most likely explanation for the effect on heart rate?'
p1917
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1918
sg15
S'Q34#5'
p1919
sg17
S'5'
sg18
I2
sg19
S'34'
p1920
sa(dp1921
g3
I27
sg4
I21
sg5
(lp1922
Vlidocaine (Xylocaine)
p1923
aVquinidine gluconate (Quinaglute, Quinalan)
p1924
aVdigoxin (Lanoxin, Lanoxicaps)
p1925
aVpropranolol (Inderal)
p1926
asg11
S'Torsades de Pointes, a polymorphic ventricular arrhythmia, is associated with prolongation of Q-T intervals. Which antiarrhythmic agent is most likely to cause this arrhythmia?'
p1927
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1928
sg15
S'Q34#9'
p1929
sg17
S'9'
sg18
I1
sg19
S'34'
p1930
sa(dp1931
g3
I14
sg4
I11
sg5
(lp1932
Vshortened P-R interval
p1933
aVdecreased ventricular rate
p1934
aVweight loss
p1935
aVaccelerated ventricular repolarization
p1936
asg11
S'Best indicator of digoxin (Lanoxin, Lanoxicaps) efficacy in treating atrial fibrillation:'
p1937
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1938
sg15
S'Q34#10'
p1939
sg17
S'10'
p1940
sg18
I1
sg19
S'34'
p1941
sa(dp1942
g3
I13
sg4
I21
sg5
(lp1943
Vdigoxin (Lanoxin, Lanoxicaps)
p1944
aVprocainamide (Procan SR, Pronestyl-SR)
p1945
aVlidocaine (Xylocaine)
p1946
aVadenosine (Adenocard)
p1947
asg11
S'cardiac effects resemble those of quinidine gluconate (Quinaglute, Quinalan):'
p1948
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1949
sg15
S'Q34#11'
p1950
sg17
S'11'
p1951
sg18
I1
sg19
S'34'
p1952
sa(dp1953
g3
I6
sg4
I8
sg5
(lp1954
Vsupraventricular tachycardia
p1955
aVangina
p1956
aVcongestive heart failure
p1957
aVventricular arrhythmias
p1958
asg11
S'Intravenous lidocaine (Xylocaine):'
p1959
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1960
sg15
S'Q34#12'
p1961
sg17
S'12'
p1962
sg18
I3
sg19
S'34'
p1963
sa(dp1964
g3
I12
sg4
I16
sg5
(lp1965
Vnausea and vomiting 
p1966
aVirregular P waves
p1967
aVventricular tachycardia with alterations in the QRS complex
p1968
aVatrial fibrillation
p1969
asg11
S'Most ominous sign of digoxin (Lanoxin, Lanoxicaps) intoxication: '
p1970
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1971
sg15
S'Q34#13'
p1972
sg17
S'13'
p1973
sg18
I2
sg19
S'34'
p1974
sa(dp1975
g3
I102
sg4
I23
sg5
(lp1976
Vsotalol (Betapace)
p1977
aVprocainamide (Procan SR, Pronestyl-SR)
p1978
aVquinidine gluconate (Quinaglute, Quinalan) than
p1979
aVlidocaine (Xylocaine)
p1980
asg11
S'A patient is admitted for treatment of myocardial infarction. During a prolonged recovery period, the patient experienced episodes of vetnricular tachycardia. Following discharge from hospital, the patient was instructed to take a drug to prevent recurrence of ventricular tachycardia. After a few days, the patient complained of dizziness and then lost consciousness. Upon admission to the hospital, the patient was found to be somewhat hypokalemic. A diagnosis of Torsades de Pointes was made. A test to determine the blood level of the antiarrhythmic reveal the drug was present in a slightly subtherapeutic level. What was the drug?'
p1981
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1982
sg15
S'Q34#15'
p1983
sg17
S'15'
p1984
sg18
I2
sg19
S'34'
p1985
sa(dp1986
g3
I115
sg4
I16
sg5
(lp1987
Vamiodarone (Cordarone)
p1988
aVlidocaine (Xylocaine)
p1989
aVadenosine (Adenocard)
p1990
aVpropranolol (Inderal)
p1991
asg11
S'A patient is being treated with digoxin for congestive heart failure. To enhance inotropic effects, the dosage was increased. Soon afterwards, the patient complained of dizziness, fatigue, and disturbances in color vision. An ECG was taken. What ECG finding(s) would be consistent with digitalis intoxication?A patient is being treated with digoxin for congestive heart failure. To enhance inotropic effects, the dosage was increased. Soon afterwards, the patient complained of dizziness, fatigue, and disturbances in color vision. An ECG was taken and exhibit arrhythmias consistent with digitialis intoxication. What antiarrhythmic drugs might be used to treat worsening ventricular arrhythmias with hemodynamic compromise?'
p1992
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p1993
sg15
S'Q34#18'
p1994
sg17
S'18'
p1995
sg18
I1
sg19
S'34'
p1996
sa(dp1997
g3
I23
sg4
I8
sg5
(lp1998
VPhase 0
p1999
aVPhase 1
p2000
aVPhase 2
p2001
aVPhase 3
p2002
asg11
S'Phase of ventricular muscle action potential is associated with an inward,depolarizing Ca2+ current and an outward, repolarizing K+ current.'
p2003
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions2/arrset1.htm'
p2004
sg15
S'Q34#19'
p2005
sg17
S'19'
p2006
sg18
I2
sg19
S'34'
p2007
sa(dp2008
g3
I6
sg4
I13
sg5
(lp2009
Vsodium channel blocker
p2010
aVcalcium channel blocker
p2011
aVbeta adrenergic receptor blocker
p2012
aVpotassium channel blocker
p2013
asg11
S'Antiarrhythmic drug classification: class II'
p2014
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2015
sg15
S'Q35#1'
p2016
sg17
S'1'
sg18
I2
sg19
S'35'
p2017
sa(dp2018
g3
I9
sg4
I29
sg5
(lp2019
Vchloride, sodium, potassium
p2020
aVpotassium, calcium, chloride
p2021
aVsodium, calcium, large organic anions
p2022
aVsodium, calcium, potassium
p2023
aVsodium, potassium, large organic anions
p2024
asg11
S'Principal ions involved in determining the cardiac transmembrane potential:'
p2025
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2026
sg15
S'Q35#6'
p2027
sg17
S'6'
sg18
I3
sg19
S'35'
p2028
sa(dp2029
g3
I13
sg4
I27
sg5
(lp2030
Vdue to rapid increase in calcium permeability
p2031
aVdue to rapid decrease in potassium conductance
p2032
aVdue to rapid increase in sodium conductance
p2033
aVdue to significant outward chloride currents
p2034
asg11
S'Rapid upstroke characteristic of phase 0 depolarization in Purkinje and ventricular muscle cells:'
p2035
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2036
sg15
S'Q35#13'
p2037
sg17
S'13'
p2038
sg18
I2
sg19
S'35'
p2039
sa(dp2040
g3
I24
sg4
I10
sg5
(lp2041
Vphase 0
p2042
aVphase 1
p2043
aVphase 2
p2044
aVphase 3
p2045
aVphase 4
p2046
asg11
S'Phase of the cardiac action potential (in SA nodal cells, for example) that is associated with "diastolic depolarization":'
p2047
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2048
sg15
S'Q35#14'
p2049
sg17
S'14'
p2050
sg18
I4
sg19
S'35'
p2051
sa(dp2052
g3
I8
sg4
I15
sg5
(lp2053
Vcalcium, potassium, sodium
p2054
aVpotassium, calcium, sodium
p2055
aVsodium, calcium, potassium
p2056
asg11
S'Sequence of cardiac Purkinje fiber ion channel activation:'
p2057
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2058
sg15
S'Q35#16'
p2059
sg17
S'16'
p2060
sg18
I2
sg19
S'35'
p2061
sa(dp2062
g3
I11
sg4
I3
sg5
(lp2063
Vcalcium
p2064
aVpotassium
p2065
aVsodium
p2066
asg11
S'Activation of this ion channel mainly associated with cardiac cell repolarization:'
p2067
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions3/questionset3.htm'
p2068
sg15
S'Q35#17'
p2069
sg17
S'17'
p2070
sg18
I1
sg19
S'35'
p2071
sa(dp2072
g3
I15
sg4
I3
sg5
(lp2073
Vsodium
p2074
aVcalcium
p2075
aVpotassium
p2076
asg11
S'Principal ion responsible for action potentials in specialized conducting SA nodal and AV nodal tissues:'
p2077
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions4/questionset4.htm'
p2078
sg15
S'Q36#2'
p2079
sg17
S'2'
sg18
I1
sg19
S'36'
p2080
sa(dp2081
g3
I8
sg4
I9
sg5
(lp2082
Vdelayed afterdepolarization
p2083
aVearly afterdepolarization
p2084
aVreentry
p2085
aVeach mechanism equally likely
p2086
asg11
S'Most common cardiac conduction abnormality leading to arrhythmias:'
p2087
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions4/questionset4.htm'
p2088
sg15
S'Q36#8'
p2089
sg17
S'8'
sg18
I2
sg19
S'36'
p2090
sa(dp2091
g3
I10
sg4
I9
sg5
(lp2092
Vedrophonium (Tensilon)
p2093
aVatropine
p2094
aVisoproterenol (Isuprel)
p2095
asg11
S'More likely to decrease the slope of phase 4 depolarization:'
p2096
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions4/questionset4.htm'
p2097
sg15
S'Q36#11'
p2098
sg17
S'11'
p2099
sg18
I0
sg19
S'36'
p2100
sa(dp2101
g3
I19
sg4
I6
sg5
(lp2102
Vtype Ia
p2103
aVtype Ib
p2104
aVtype Ic
p2105
asg11
S'Antiarrhythmic drugs -- class I:\xc2\xa0 slow the rate of action potential rise and prolong ventricular effective refractory period'
p2106
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2107
sg15
S'Q37#1'
p2108
sg17
S'1'
sg18
I0
sg19
S'37'
p2109
sa(dp2110
g3
I7
sg4
I26
sg5
(lp2111
Vtocainide (Tonocard)
p2112
aVprocainamide (Procan SR, Pronestyl-SR)
p2113
aVmetoprolol (Lopressor)
p2114
aVquinidine gluconate (Quinaglute, Quinalan)
p2115
aVlidocaine (Xylocaine)
p2116
asg11
S'Antiarrhythmic drug with antimalarial and antipyretic effects:'
p2117
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2118
sg15
S'Q37#2'
p2119
sg17
S'2'
sg18
I3
sg19
S'37'
p2120
sa(dp2121
g3
I20
sg4
I28
sg5
(lp2122
Vdigitalis improves the inotropic state of the heart
p2123
aVdigitalis insures adequate renal excretion of quinidine
p2124
aVdigitalis enhances vagal tone and reduces AV nodal transmission
p2125
aVdigitalis blocks muscarinic receptors
p2126
asg11
S'In management of atrial fibrillation: the purpose of administering digitalis before quinidine gluconate (Quinaglute, Quinalan) --'
p2127
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2128
sg15
S'Q37#8'
p2129
sg17
S'8'
sg18
I2
sg19
S'37'
p2130
sa(dp2131
g3
I11
sg4
I24
sg5
(lp2132
Vquinidine gluconate (Quinaglute, Quinalan)
p2133
aVhydralazine (Apresoline)
p2134
aVprocainamide (Procan SR, Pronestyl-SR)
p2135
aVverapamil (Isoptin, Calan)
p2136
asg11
S'Antiarrhythmic drug: long-term use associated with a lupus-related side effect:'
p2137
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2138
sg15
S'Q37#14'
p2139
sg17
S'14'
p2140
sg18
I2
sg19
S'37'
p2141
sa(dp2142
g3
I6
sg4
I16
sg5
(lp2143
Vquinidine gluconate (Quinaglute, Quinalan)
p2144
aVprocainamide (Procan SR, Pronestyl-SR)
p2145
aVabout equal
p2146
asg11
S'Antiarrhythmic drug with more antimuscarinic activity:'
p2147
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2148
sg15
S'Q37#15'
p2149
sg17
S'15'
p2150
sg18
I0
sg19
S'37'
p2151
sa(dp2152
g3
I15
sg4
I23
sg5
(lp2153
Vserositis, arthralgia, arthritis
p2154
aVpluritis, pericarditis, parenchymal pulmonary disease
p2155
aVvasculitis
p2156
aVpositive antinuclear antibody test
p2157
aVmore frequent occurrence in slow acetylators
p2158
asg11
S'NOT a characteristics of procainamide (Procan SR, Pronestyl-SR)-mediated lupus erythematosus-like syndrome:'
p2159
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2160
sg15
S'Q37#17'
p2161
sg17
S'17'
p2162
sg18
I2
sg19
S'37'
p2163
sa(dp2164
g3
I12
sg4
I26
sg5
(lp2165
Vprocainamide (Procan SR, Pronestyl-SR)
p2166
aVdisopyramide (Norpace)
p2167
aVquinidine gluconate (Quinaglute, Quinalan)
p2168
aVlidocaine (Xylocaine)
p2169
aVesmolol (Brevibloc)
p2170
asg11
S'Not a first-line antiarrhythmic age and because of its negative inotropic effects:'
p2171
sg13
S'http://www.pharmacology2000.com/Cardio/antiarr/questions5/questionset5.htm'
p2172
sg15
S'Q37#18'
p2173
sg17
S'18'
p2174
sg18
I1
sg19
S'37'
p2175
sa(dp2176
g3
I5
sg4
I11
sg5
(lp2177
Visosorbide dinitrate (Isordil, Sorbitrate)
p2178
aVamyl nitrite
p2179
aVglyeryl trinitrate
p2180
asg11
S'Antianginal drug administered by inhalation:'
p2181
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2182
sg15
S'Q39#0'
p2183
sg17
S'0'
sg18
I1
sg19
S'39'
p2184
sa(dp2185
g3
I56
sg4
I65
sg5
(lp2186
Vthat the pain was due to myocardial oxygen insufficiency, relieved by the action of nitroglycerin on cardiac preload
p2187
aVthat the pain is more likely due to esophageal spasm, because if it were due to the heart, relief would have taken longer.
p2188
aVthe test is inconclusive, since nitrates relax almost all smooth muscle--terminating anginal symptoms or symptoms of esophageal spasm
p2189
asg11
S'A patient with a history of both angina and esophageal spasms is told by his physician that upon recurrence of pain, take a nitroglycerin tablet, sublingually and note what happens. When pain recurs, the patient takes the "nitro" and the pain goes away in about a minute. Reasonable analysis would suggest:'
p2190
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2191
sg15
S'Q39#1'
p2192
sg17
S'1'
sg18
I2
sg19
S'39'
p2193
sa(dp2194
g3
I15
sg4
I14
sg5
(lp2195
Vnifedipine (Procardia, Adalat)
p2196
aVnicardipine (Cardene)
p2197
aVdiltiazem (Cardiazem)
p2198
asg11
S'Calcium channel blocker(s) most likely to affect myocardial contractility and AV conduction:'
p2199
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2200
sg15
S'Q39#4'
p2201
sg17
S'4'
sg18
I2
sg19
S'39'
p2202
sa(dp2203
g3
I45
sg4
I57
sg5
(lp2204
VNifedipine (Procardia, Adalat) should not be used for angina.
p2205
aVNifedipine (Procardia, Adalat), a calcium channel blocker, causes significant vasodilation. Hypotension and reflex cardiac stimulation result in increased anginal episodes
p2206
aVNifedipine (Procardia, Adalat) in combination with propranolol, since propranolol would block reflex tachycardia due to nifedipine\u005c
p2207
asg11
S'70 year old male with confirmed multi-vessel coronary vascular disease also suffers from COAD [chronic obstructive airway disease] and exertional angina. He is prescribed nifedipine for his angina, but shortly after beginning the medication complains of increased angina incidence. Choose an explanation:'
p2208
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2209
sg15
S'Q39#5'
p2210
sg17
S'5'
sg18
I1
sg19
S'39'
p2211
sa(dp2212
g3
I48
sg4
I68
sg5
(lp2213
VDiltiazem (Cardiazem) is an effective antianginal drug which would be appropriate in this case.
p2214
aVDiltiazem (Cardiazem) is only effective in Prinzmetal\u005c
p2215
aVDiltiazem (Cardiazem) is not appropriate because of its negative inotropic properties (decrease myocardial contractility) which would worsen left ventricular failure
p2216
aV Diltiazem (Cardiazem) in combination with propranolol (Inderal) would work since reflex tachycardia would be blocked
p2217
asg11
S'A 60 year old patient with multivessel coronary vascular disease has suffered several myocardial infarctions. The patient is in moderate heart failure precariously controlled with diuretics and cardiac glycosides and has exertional anginal episodes about twice a day. Consider a calcium channel blocker in management of this patient:'
p2218
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2219
sg15
S'Q39#6'
p2220
sg17
S'6'
sg18
I2
sg19
S'39'
p2221
sa(dp2222
g3
I18
sg4
I20
sg5
(lp2223
Vdiltiazem (Cardiazem)
p2224
aVbepridil (Vascor)
p2225
aVnifedipine (Procardia, Adalat)
p2226
aVlisinopril (Prinvivil, Zestril)
p2227
asg11
S'Calcium and sodium channel blocker useful in treating chronic, stable angina not responsive to typical antianginal drugs:'
p2228
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions2/cv1.htm'
p2229
sg15
S'Q39#7'
p2230
sg17
S'7'
sg18
I1
sg19
S'39'
p2231
sa(dp2232
g3
I6
sg4
I5
sg5
(lp2233
Vtyrosine
p2234
aVtryptophan
p2235
aVarginine
p2236
aVproline
p2237
aVphenylalanine
p2238
asg11
S'\n\tNitric oxide: precursor amino acid'
p2239
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2240
sg15
S'Q40#2'
p2241
sg17
S'2'
sg18
I2
sg19
S'40'
p2242
sa(dp2243
g3
I3
sg4
I10
sg5
(lp2244
V< 5 seconds
p2245
aVthirty seconds
p2246
aVone-minute
p2247
aVthirty minutes
p2248
aV> one-hour
p2249
asg11
S'Nitric oxide half-life:'
p2250
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2251
sg15
S'Q40#3'
p2252
sg17
S'3'
sg18
I0
sg19
S'40'
p2253
sa(dp2254
g3
I5
sg4
I9
sg5
(lp2255
VNO synthase
p2256
aVreuptake
p2257
aVinteraction with hemoglobin
p2258
aVmonoamine oxidase
p2259
aVcatechol-O-methyltransferase
p2260
asg11
S'Nitric oxide mainly inactivated by:'
p2261
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2262
sg15
S'Q40#4'
p2263
sg17
S'4'
sg18
I2
sg19
S'40'
p2264
sa(dp2265
g3
I6
sg4
I11
sg5
(lp2266
Vincreased NO production
p2267
aVdecreased NO production
p2268
aVno effect on NO production
p2269
asg11
S'Decreased oxygenation \n\tand nitric oxide response:'
p2270
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2271
sg15
S'Q40#6'
p2272
sg17
S'6'
sg18
I0
sg19
S'40'
p2273
sa(dp2274
g3
I8
sg4
I7
sg5
(lp2275
Vveins produce more
p2276
aVarteries produce more
p2277
aVequal
p2278
asg11
S'Comparing arteries \n\tand veins: nitric oxide production'
p2279
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2280
sg15
S'Q40#7'
p2281
sg17
S'7'
sg18
I1
sg19
S'40'
p2282
sa(dp2283
g3
I7
sg4
I16
sg5
(lp2284
Vnitric oxide inhibits  platelet aggregation and adhesion
p2285
aVnitric oxide promotes platelet aggregation and adhesion
p2286
aVno effect
p2287
asg11
S'Nitric oxide \n\tand platelet aggregation and adhesion:'
p2288
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2289
sg15
S'Q40#8'
p2290
sg17
S'8'
sg18
I0
sg19
S'40'
p2291
sa(dp2292
g3
I8
sg4
I11
sg5
(lp2293
Vneuromuscular junction
p2294
aVinnervation of the corpora cavernosa
p2295
aVbasal ganglia
p2296
aVRenshaw cell
p2297
asg11
S'Probable site \n\twhere NO acts as a neurotransmitter:'
p2298
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions3/questionset3.htm'
p2299
sg15
S'Q40#9'
p2300
sg17
S'9'
sg18
I1
sg19
S'40'
p2301
sa(dp2302
g3
I6
sg4
I19
sg5
(lp2303
Vnitroprusside sodium (Nipride)
p2304
aVhydralazine (Apresoline)
p2305
aVsublingual nitroglycerin
p2306
aVpropranolol (Inderal)
p2307
aVminoxidil (Loniten)
p2308
asg11
S'Preferred for acute management of angina:'
p2309
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions4/questionset4.htm'
p2310
sg15
S'Q41#8'
p2311
sg17
S'8'
sg18
I2
sg19
S'41'
p2312
sa(dp2313
g3
I17
sg4
I11
sg5
(lp2314
Vcoronary vasodilation
p2315
aVdecreased afterload
p2316
aVdecreased preload
p2317
aVdecreased heart rate
p2318
aVdecreased contractility
p2319
asg11
S'Principal mechanism by which sublingual nitroglycerin terminates anginal episodes in patients with advanced atherosclerotic coronary vessel disease:'
p2320
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions4/questionset4.htm'
p2321
sg15
S'Q41#9'
p2322
sg17
S'9'
sg18
I2
sg19
S'41'
p2323
sa(dp2324
g3
I10
sg4
I8
sg5
(lp2325
Vphenylalanine
p2326
aVarginine
p2327
aVproline
p2328
aVtranylcypromine (Parnate)
p2329
aVtryptophan
p2330
asg11
S'Substrate for nitric oxide synthase for production of endogenous nitrates:'
p2331
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions4/questionset4.htm'
p2332
sg15
S'Q41#12'
p2333
sg17
S'12'
p2334
sg18
I1
sg19
S'41'
p2335
sa(dp2336
g3
I12
sg4
I3
sg5
(lp2337
Vsodium
p2338
aVcalcium
p2339
aVmagnesium
p2340
asg11
S'Major depolarizing current is carried by this ion in vascular smooth muscle:'
p2341
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2342
sg15
S'Q42#6'
p2343
sg17
S'6'
sg18
I1
sg19
S'42'
p2344
sa(dp2345
g3
I14
sg4
I5
sg5
(lp2346
Vsodium
p2347
aVcalcium
p2348
aVmagnesium
p2349
aVpotassium
p2350
aVchloride
p2351
asg11
S'In the heart, the"fast" response is mediated by this ion:'
p2352
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2353
sg15
S'Q42#7'
p2354
sg17
S'7'
sg18
I0
sg19
S'42'
p2355
sa(dp2356
g3
I13
sg4
I5
sg5
(lp2357
Vsodium
p2358
aVcalcium
p2359
aVmagnesium
p2360
aVpotassium
p2361
aVchloride
p2362
asg11
S'In the heart, the "slow" responses mediated by this ion:'
p2363
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2364
sg15
S'Q42#8'
p2365
sg17
S'8'
sg18
I1
sg19
S'42'
p2366
sa(dp2367
g3
I20
sg4
I5
sg5
(lp2368
Vsodium
p2369
aVcalcium
p2370
aVpotassium
p2371
aVchloride
p2372
aVmagnesium
p2373
asg11
S'Depolarization in the specialized conduction system, the SA. and AV nodal tissue, is mediated by this ion movement:'
p2374
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2375
sg15
S'Q42#9'
p2376
sg17
S'9'
sg18
I1
sg19
S'42'
p2377
sa(dp2378
g3
I10
sg4
I20
sg5
(lp2379
Vnicardipine (Cardene)
p2380
aVdiltiazem (Cardiazem)
p2381
aVamlodipine (Norvasc)
p2382
aVnifedipine (Procardia, Adalat)
p2383
aVall equal
p2384
asg11
S'Calcium channel blocker most likely to worsen congestive heart failure:'
p2385
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2386
sg15
S'Q42#11'
p2387
sg17
S'11'
p2388
sg18
I1
sg19
S'42'
p2389
sa(dp2390
g3
I17
sg4
I24
sg5
(lp2391
Vamlodipine (Norvasc)
p2392
aVverapamil (Isoptin, Calan)
p2393
aVnifedipine (Procardia, Adalat)
p2394
aVnimodipine (Nimotop)
p2395
aVdiltiazem (Cardiazem)
p2396
asg11
S'Calcium channel blocker approved for use in patients with CNS deficits following rupture of congenital intracranial aneurysm:'
p2397
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2398
sg15
S'Q42#17'
p2399
sg17
S'17'
p2400
sg18
I3
sg19
S'42'
p2401
sa(dp2402
g3
I8
sg4
I6
sg5
(lp2403
Vbeta-blockers
p2404
aVcalcium channel blockers
p2405
aVequally appropriate
p2406
asg11
S'Better drug class for management of variant angina:'
p2407
sg13
S'http://www.pharmacology2000.com/Cardio/coronary/questions5/questionset5.htm'
p2408
sg15
S'Q42#19'
p2409
sg17
S'19'
p2410
sg18
I1
sg19
S'42'
p2411
sa(dp2412
g3
I20
sg4
I16
sg5
(lp2413
Vbeta2 adrenergic receptors
p2414
aVbeta1 adrenergic receptors
p2415
aVdopamine D1 and D2 postsynaptic receptors
p2416
aVmuscarinic receptors
p2417
aVleukotriene receptors
p2418
asg11
S'Dopamine (Intropin) -mediated renal vasodilation is caused by which receptor(s) system(s):'
p2419
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions3/questionset3.htm'
p2420
sg15
S'Q44#6'
p2421
sg17
S'6'
sg18
I2
sg19
S'44'
p2422
sa(dp2423
g3
I14
sg4
I14
sg5
(lp2424
Vincreased rate
p2425
aVdecreased AV conduction
p2426
aVperipheral vasodilation
p2427
aVshifted the force-velocity curve upward
p2428
aVincreased diuresis
p2429
asg11
S'Most important cardiac effect produced by digoxin relative to management of congestive heart failure:'
p2430
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions3/questionset3.htm'
p2431
sg15
S'Q44#8'
p2432
sg17
S'8'
sg18
I3
sg19
S'44'
p2433
sa(dp2434
g3
I17
sg4
I17
sg5
(lp2435
Vamrinone (Inocor)
p2436
aVamiodarone (Cordarone)
p2437
aVmilrinone (Primacor)
p2438
aVlosartin (Cozaar)
p2439
aVtheophylline
p2440
asg11
S'Agent of choice among the phosphodiesterase inhibitors for short term parenteral support in severe heart failure patients:'
p2441
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions3/questionset3.htm'
p2442
sg15
S'Q44#9'
p2443
sg17
S'9'
sg18
I2
sg19
S'44'
p2444
sa(dp2445
g3
I15
sg4
I10
sg5
(lp2446
Vreduction in parasympathetic  tone
p2447
aVcirculating catecholamine levels
p2448
aVadrenergic nerve activity
p2449
asg11
S'Most important acute factor in changing the position of the force-velocity in ventricular function curves:'
p2450
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2451
sg15
S'Q45#0'
p2452
sg17
S'0'
sg18
I2
sg19
S'45'
p2453
sa(dp2454
g3
I5
sg4
I9
sg5
(lp2455
Vcalcium
p2456
aVcaffeine
p2457
aVcardiac glycosides
p2458
aVdisopyramide (Norpace)
p2459
aVtheophylline
p2460
asg11
S'Agents which decreased ventricular performance:'
p2461
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2462
sg15
S'Q45#6'
p2463
sg17
S'6'
sg18
I3
sg19
S'45'
p2464
sa(dp2465
g3
I15
sg4
I8
sg5
(lp2466
Vafterload
p2467
aVcirculating steroid levels
p2468
aVextent of ventricular dilatation
p2469
asg11
S'Ventricular performance in the failing heart (with no preload reserve) is determined by:'
p2470
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2471
sg15
S'Q45#8'
p2472
sg17
S'8'
sg18
I0
sg19
S'45'
p2473
sa(dp2474
g3
I21
sg4
I28
sg5
(lp2475
Vcardiac output increased; oxygen demand increased
p2476
aVcardiac output decreased; oxygen demand decreased
p2477
aVcardiac output decreased; oxygen demand increased
p2478
aVcardiac output increased; oxygen demand decreased
p2479
asg11
S'In the failing hard, the effect on cardiac output and oxygen demand when afterload increases (increased vasoconstriction):'
p2480
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2481
sg15
S'Q45#9'
p2482
sg17
S'9'
sg18
I2
sg19
S'45'
p2483
sa(dp2484
g3
I8
sg4
I26
sg5
(lp2485
Vdecreased due to reduced venous return (peripheral pooling)
p2486
aVincreased with due to enhanced venous return and ventricular filling
p2487
aVno effect in the normal heart
p2488
asg11
S'Effect of exercise on preload and ventricular filling:'
p2489
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2490
sg15
S'Q45#10'
p2491
sg17
S'10'
p2492
sg18
I1
sg19
S'45'
p2493
sa(dp2494
g3
I13
sg4
I7
sg5
(lp2495
Vnotable increase
p2496
aVdecrease
p2497
aVminor increase
p2498
aVno change
p2499
asg11
S'With exercise, what happens to arterial pressure (normal heart)?'
p2500
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2501
sg15
S'Q45#11'
p2502
sg17
S'11'
p2503
sg18
I2
sg19
S'45'
p2504
sa(dp2505
g3
I8
sg4
I8
sg5
(lp2506
Vtypically elevated
p2507
aVtypically depressed
p2508
aVno change from normal
p2509
asg11
S'Circulating norepinephrine levels in patients with heart failure:'
p2510
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions4/questionset4.htm'
p2511
sg15
S'Q45#14'
p2512
sg17
S'14'
p2513
sg18
I0
sg19
S'45'
p2514
sa(dp2515
g3
I6
sg4
I18
sg5
(lp2516
Vdobutamine (Dobutrex)
p2517
aVdigoxin (Lanoxin, Lanoxicaps)
p2518
aVamrinone (Inocor)
p2519
aVdopamine (Intropin)
p2520
asg11
S'Positive inotropic agent -- phosphodiesterase inhibitor'
p2521
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions5/questionset5.htm'
p2522
sg15
S'Q46#3'
p2523
sg17
S'3'
sg18
I2
sg19
S'46'
p2524
sa(dp2525
g3
I5
sg4
I27
sg5
(lp2526
Vcardiac output directly dependent on contractility and peripheral resistance
p2527
aVfactors affecting stroke volume include preload, afterload, and contractility
p2528
aVheart rate mainly depend on idioventricular rhythm
p2529
asg11
S'Cardiac output and tissue perfusion:'
p2530
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions5/questionset5.htm'
p2531
sg15
S'Q46#6'
p2532
sg17
S'6'
sg18
I1
sg19
S'46'
p2533
sa(dp2534
g3
I7
sg4
I11
sg5
(lp2535
Vblood viscosity
p2536
aVvessel radius
p2537
aVvessel length
p2538
aVintravascular volume
p2539
aVpulmonary artery pressure
p2540
asg11
S'Most significant factor in blood flow resistance:'
p2541
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions5/questionset5.htm'
p2542
sg15
S'Q46#8'
p2543
sg17
S'8'
sg18
I1
sg19
S'46'
p2544
sa(dp2545
g3
I7
sg4
I6
sg5
(lp2546
Vsympathetic
p2547
aVparasympathetic
p2548
aVequal; neither dominant
p2549
asg11
S'Dominant autonomic tone in vascular smooth muscle:'
p2550
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions5/questionset5.htm'
p2551
sg15
S'Q46#9'
p2552
sg17
S'9'
sg18
I0
sg19
S'46'
p2553
sa(dp2554
g3
I5
sg4
I9
sg5
(lp2555
Vreduced cardiac output
p2556
aVrenal failure
p2557
aVinadequate oxygenation
p2558
aVmicrocirculatory failure
p2559
asg11
S'Most critical failure in shock:'
p2560
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions5/questionset5.htm'
p2561
sg15
S'Q46#13'
p2562
sg17
S'13'
p2563
sg18
I3
sg19
S'46'
p2564
sa(dp2565
g3
I6
sg4
I6
sg5
(lp2566
Vperipheral edema
p2567
aVangina
p2568
aVpulmonary hypertension
p2569
aVdyspnea
p2570
asg11
S'Most common symptom of heart failure:'
p2571
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2572
sg15
S'Q47#0'
p2573
sg17
S'0'
sg18
I3
sg19
S'47'
p2574
sa(dp2575
g3
I13
sg4
I8
sg5
(lp2576
Vorthopnea
p2577
aVparoxysmal (nocturnal) dyspnea
p2578
aVcardiac dyspnea
p2579
asg11
S'Sudden onset of severe shortness of breath and coughing, awakening the patient:'
p2580
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2581
sg15
S'Q47#2'
p2582
sg17
S'2'
sg18
I1
sg19
S'47'
p2583
sa(dp2584
g3
I9
sg4
I13
sg5
(lp2585
Vprimarily affects Na/K ATPase binding
p2586
aVprimarily affects pharmacokinetic behavior
p2587
aVaffects both
p2588
aVaffects neither
p2589
asg11
S'Concerning digitalis glycosides:removal of glycoside moiety --'
p2590
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2591
sg15
S'Q47#5'
p2592
sg17
S'5'
sg18
I1
sg19
S'47'
p2593
sa(dp2594
g3
I8
sg4
I16
sg5
(lp2595
Vblocks beta-adrenergic receptors
p2596
aVactivates myocardial leukotrienes
p2597
aVinhibits Na/K ATPase
p2598
aVinhibits calcium transport
p2599
aVincreases circulating endothelin I
p2600
asg11
S'Cardiac glycosides: principal mechanism of action --'
p2601
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2602
sg15
S'Q47#7'
p2603
sg17
S'7'
sg18
I2
sg19
S'47'
p2604
sa(dp2605
g3
I9
sg4
I30
sg5
(lp2606
Vbenefits due to reduction in circulating angiotensin II levels
p2607
aVcontraindicated in diabetic patients
p2608
aVcontraindicated in hypertensive patients with hypertrophic left ventricles
p2609
aVreduces efficacy of diuretic treatment requiring higher diuretic dosages
p2610
asg11
S'Concerning the use of ACE inhibitors in heart disease:'
p2611
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2612
sg15
S'Q47#14'
p2613
sg17
S'14'
p2614
sg18
I0
sg19
S'47'
p2615
sa(dp2616
g3
I4
sg4
I17
sg5
(lp2617
Vproximal tubule
p2618
aVdistal  tubule
p2619
aVdescending limb -- loop of Henle
p2620
aVthick ascending limb -- loop of Henle
p2621
asg11
S'Site of action torsemide:'
p2622
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2623
sg15
S'Q47#16'
p2624
sg17
S'16'
p2625
sg18
I3
sg19
S'47'
p2626
sa(dp2627
g3
I14
sg4
I10
sg5
(lp2628
Vfive percent
p2629
aVten percent
p2630
aV25 percent
p2631
aVfifty percent
p2632
aV90 percent
p2633
asg11
S'Fraction of filtered solute load reabsorbed by thick ascending limb of loop of Henle:'
p2634
sg13
S'http://www.pharmacology2000.com/Cardio/CHF/questions6/questionset6.htm'
p2635
sg15
S'Q47#17'
p2636
sg17
S'17'
p2637
sg18
I2
sg19
S'47'
p2638
sa(dp2639
g3
I17
sg4
I14
sg5
(lp2640
Vfamilial combined hyperlipoproteinemia
p2641
aVfamilial ligand-defective ApoB
p2642
aVfamilial lipoprotein lipase or cofactor deficiency
p2643
aVfamilial dysbetalipoproteinemia
p2644
asg11
S'An attack of acute pancreatitis is likely to be the first presenting symptom of this lipoprotein disorder:'
p2645
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question1/questionset1.htm'
p2646
sg15
S'Q48#0'
p2647
sg17
S'0'
sg18
I2
sg19
S'48'
p2648
sa(dp2649
g3
I4
sg4
I8
sg5
(lp2650
Vdiabetes mellitus
p2651
aValcohol ingestion
p2652
aVcholestasis
p2653
aVlipodystrophy
p2654
aVthe estrogens
p2655
asg11
S'Secondary cause of hypercholesterolemia:'
p2656
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question1/questionset1.htm'
p2657
sg15
S'Q48#1'
p2658
sg17
S'1'
sg18
I2
sg19
S'48'
p2659
sa(dp2660
g3
I10
sg4
I10
sg5
(lp2661
Vdiet
p2662
aVgemfibrozil (Lopid)
p2663
aVbile acid-binding presence with niacin
p2664
asg11
S'Treatment of choice for hyperlipidemia associated with chronic nephrotic syndrome:'
p2665
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question1/questionset1.htm'
p2666
sg15
S'Q48#6'
p2667
sg17
S'6'
sg18
I2
sg19
S'48'
p2668
sa(dp2669
g3
I15
sg4
I26
sg5
(lp2670
Vgemfibrozil (Lopid)
p2671
aVniacin (vitamin B3)
p2672
aVcholestyramine (Questran, Questran Light)
p2673
aVclofibrate (Abitrate, Atromid-S)
p2674
aVlovastatin (Mevacor)
p2675
asg11
S'Anti-lipid drug that usually causes cutaneous vasodilation after each dose when the drug is started'
p2676
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question1/questionset1.htm'
p2677
sg15
S'Q48#7'
p2678
sg17
S'7'
sg18
I1
sg19
S'48'
p2679
sa(dp2680
g3
I13
sg4
I20
sg5
(lp2681
Vpravastatin (Pravachol)
p2682
aVniacin (vitamin B3)
p2683
aVgemfibrozil (Lopid)
p2684
aVcholestyramine (Questran, Questran Light)
p2685
asg11
S'Constipation and a bloating sensation -- most common complaints of this antilipidemic drug:'
p2686
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question2/questionset2.htm'
p2687
sg15
S'Q49#0'
p2688
sg17
S'0'
sg18
I3
sg19
S'49'
p2689
sa(dp2690
g3
I8
sg4
I20
sg5
(lp2691
Vcholestyramine (Questran, Questran Light)
p2692
aVgemfibrozil (Lopid)
p2693
aVpravastatin (Pravachol)
p2694
aVniacin (vitamin B3)
p2695
asg11
S'Antilipid medication -- structural analog of HMG-CoA intermediate'
p2696
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question2/questionset2.htm'
p2697
sg15
S'Q49#1'
p2698
sg17
S'1'
sg18
I2
sg19
S'49'
p2699
sa(dp2700
g3
I14
sg4
I7
sg5
(lp2701
Vbile acid-binding resins
p2702
aVreductase inhibitors
p2703
aVnicotinic acid
p2704
asg11
S'Drugs of this antilipidemic class may cause in a few patients rhabdomyolysis and myoglobinuria:'
p2705
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question2/questionset2.htm'
p2706
sg15
S'Q49#2'
p2707
sg17
S'2'
sg18
I1
sg19
S'49'
p2708
sa(dp2709
g3
I6
sg4
I19
sg5
(lp2710
Vniacin (vitamin B3)
p2711
aVcolestipol (Colestid)
p2712
aVpravastatin (Pravachol)
p2713
aVclofibrate (Abitrate, Atromid-S)
p2714
asg11
S'Very large polymeric cationic exchange resins:'
p2715
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question2/questionset2.htm'
p2716
sg15
S'Q49#3'
p2717
sg17
S'3'
sg18
I1
sg19
S'49'
p2718
sa(dp2719
g3
I25
sg4
I21
sg5
(lp2720
Vclofibrate (Abitrate, Atromid-S)
p2721
aVgemfibrozil (Lopid)
p2722
aVcholestyramine (Questran, Questran Light)
p2723
aVpravastatin (Pravachol)
p2724
asg11
S'Antilipidemic drug most likely to reduce serum digoxin (Lanoxin, Lanoxicaps) levels, serum vancomycin (Vancocin) levels, and thiazide levels:'
p2725
sg13
S'http://www.pharmacology2000.com/Cardio/hypo/question2/questionset2.htm'
p2726
sg15
S'Q49#4'
p2727
sg17
S'4'
sg18
I2
sg19
S'49'
p2728
sa(dp2729
g3
I11
sg4
I6
sg5
(lp2730
Vnoradrenergic
p2731
aVGABA system
p2732
aVcholinergic
p2733
aVglycine system
p2734
asg11
S'Benzodiazepine pharmacology is most closely linked to which neurotransmitter system?'
p2735
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2736
sg15
S'Q50#0'
p2737
sg17
S'0'
sg18
I1
sg19
S'50'
p2738
sa(dp2739
g3
I6
sg4
I13
sg5
(lp2740
Vdiazepam (Valium)
p2741
aVbuspirone (BuSpar)
p2742
aVtriazolam (Halcion)
p2743
aVphenobarbital
p2744
asg11
S'Anxiolytic drug acting through serotonin receptors:'
p2745
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2746
sg15
S'Q50#1'
p2747
sg17
S'1'
sg18
I1
sg19
S'50'
p2748
sa(dp2749
g3
I32
sg4
I53
sg5
(lp2750
VBuspirone (BuSpar) dosage too low.
p2751
aVBuspirone (BuSpar) does not exhibit cross-tolerance with sedative-hypnotic/benzodiazepines.
p2752
aVManagement of alcohol or benzodiazepine withdrawal must be managed with a stronger drug, such as haloperidol.
p2753
aVBuspirone (BuSpar) is too rapidly inactivated (first-pass effect) to be useful in managing withdrawal.
p2754
asg11
S'A chronic alcohol and diazepam abuser is hospitalized for management of withdrawal symptoms. Buspirone, an anxiolytic, is administered to alleviate withdrawal, but the symptoms continue and worsen. Why?'
p2755
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2756
sg15
S'Q50#3'
p2757
sg17
S'3'
sg18
I1
sg19
S'50'
p2758
sa(dp2759
g3
I2
sg4
I16
sg5
(lp2760
Vdiazepam (Valium)
p2761
aVflurazepam (Dalmane)
p2762
aVtriazolam (Halcion)
p2763
aVbuspirone (BuSpar)
p2764
asg11
S'Short-acting benzodiazepine'
p2765
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2766
sg15
S'Q50#4'
p2767
sg17
S'4'
sg18
I2
sg19
S'50'
p2768
sa(dp2769
g3
I9
sg4
I42
sg5
(lp2770
VLorazepam (Ativan) because of first-pass effects and because it lacks long-acting metabolites.
p2771
aVOxazepam (Serax) since it has no long-acting metabolites and is conjugated to an inactive glucuronide directly.
p2772
aVBuspirone (BuSpar) since it has limited abuse potential
p2773
asg11
S'Benzodiazepine most appropriate in patients with impaired hepatic function:'
p2774
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2775
sg15
S'Q50#5'
p2776
sg17
S'5'
sg18
I1
sg19
S'50'
p2777
sa(dp2778
g3
I7
sg4
I4
sg5
(lp2779
Vsodium
p2780
aVcalcium
p2781
aVchloride
p2782
aVpotassium
p2783
asg11
S'Ion channel that contains the GABA receptor:'
p2784
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2785
sg15
S'Q50#8'
p2786
sg17
S'8'
sg18
I2
sg19
S'50'
p2787
sa(dp2788
g3
I5
sg4
I15
sg5
(lp2789
Vantagonized by flumazenil (Romazicon)
p2790
aVmuscle relaxation
p2791
aVminimal hypnotic properties
p2792
aVLong duration of action
p2793
asg11
S'Zolpidem (Ambien):'
p2794
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2795
sg15
S'Q50#9'
p2796
sg17
S'9'
sg18
I0
sg19
S'50'
p2797
sa(dp2798
g3
I5
sg4
I16
sg5
(lp2799
Vpropranolol (Inderal)
p2800
aVbuspirone (BuSpar)
p2801
aVphenobarbital (Luminal)
p2802
aVall  of the above
p2803
asg11
S'Antianxiety drug(s)'
p2804
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2805
sg15
S'Q50#12'
p2806
sg17
S'12'
p2807
sg18
I3
sg19
S'50'
p2808
sa(dp2809
g3
I8
sg4
I13
sg5
(lp2810
Vamphetamine
p2811
aVbuspirone (BuSpar)
p2812
aVflumazenil (Romazicon)
p2813
aVnaltrexone (ReVia)
p2814
asg11
S'Most useful in reversing symptoms of benzodiazepine overdosage:'
p2815
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2816
sg15
S'Q50#14'
p2817
sg17
S'14'
p2818
sg18
I2
sg19
S'50'
p2819
sa(dp2820
g3
I10
sg4
I16
sg5
(lp2821
Vdiazepam (Valium)
p2822
aVphenobarbital (Luminal)
p2823
aVclonazepam (Klonopin)
p2824
aVbuspirone (BuSpar)
p2825
asg11
S'Contraindicated in patients with a history of acute intermittent porphyria:'
p2826
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2827
sg15
S'Q50#16'
p2828
sg17
S'16'
p2829
sg18
I1
sg19
S'50'
p2830
sa(dp2831
g3
I2
sg4
I16
sg5
(lp2832
Vdiazepam (Valium)
p2833
aVbuspirone (BuSpar)
p2834
aVtriazolam (Halcion)
p2835
aVflumazenil (Romazicon)
p2836
asg11
S'Pupillary constriction:'
p2837
sg13
S'http://www.pharmacology2000.com/Central/sedhyp/questions2/sedhyp1.htm'
p2838
sg15
S'Q50#17'
p2839
sg17
S'17'
p2840
sg18
I1
sg19
S'50'
p2841
sa(dp2842
g3
I8
sg4
I13
sg5
(lp2843
Vmorphine
p2844
aVmeperidine (Demerol)
p2845
aVpentazocine (Talwain)
p2846
aVoxycodone (Roxicodone)
p2847
asg11
S'An opioid with both agonist and antagonist properties:'
p2848
sg13
S'http://www.pharmacology2000.com/Central/Opioid/questions2/opi1.htm'
p2849
sg15
S'Q54#0'
p2850
sg17
S'0'
sg18
I2
sg19
S'54'
p2851
sa(dp2852
g3
I7
sg4
I7
sg5
(lp2853
Vcardiac arrhythmias
p2854
aVrespiratory depression
p2855
aVconvulsions
p2856
aVendogenous depression
p2857
asg11
S'Narcotic agonists: most serious adverse effect:'
p2858
sg13
S'http://www.pharmacology2000.com/Central/Opioid/questions2/opi1.htm'
p2859
sg15
S'Q54#4'
p2860
sg17
S'4'
sg18
I1
sg19
S'54'
p2861
sa(dp2862
g3
I10
sg4
I14
sg5
(lp2863
Vmorphine
p2864
aVfentanyl (Sublimaze)
p2865
aVcodeine
p2866
aVnaloxone (Narcan)
p2867
aVmeperidine (Demerol) 
p2868
asg11
S'Principal alkaloid in opium (derived from opium poppy)'
p2869
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2870
sg15
S'Q55#1'
p2871
sg17
S'1'
sg18
I0
sg19
S'55'
p2872
sa(dp2873
g3
I25
sg4
I8
sg5
(lp2874
Vfull agonist
p2875
aVpure antagonist
p2876
aVmixed agonist-antagonist
p2877
aVendorphin
p2878
aVdynorphins
p2879
asg11
S'Descriptive of the drug that may have an agonist effect at one opioid receptor site and an antagonist effect at another opioid receptor site.'
p2880
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2881
sg15
S'Q55#2'
p2882
sg17
S'2'
sg18
I2
sg19
S'55'
p2883
sa(dp2884
g3
I24
sg4
I14
sg5
(lp2885
Vpreproenkephalin (proenkephalin A)
p2886
aVprepro-opiomelanocortin (POMC)
p2887
aVpreprodynorphin (proenkephalin B)
p2888
asg11
S'Endogenous opioid precursor that contains the met-enkephalin sequence, beta-endorphins, and several nonopioid peptides including ACTH, beta-lipotropin, and melanocyte-stimulating hormone.'
p2889
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2890
sg15
S'Q55#3'
p2891
sg17
S'3'
sg18
I1
sg19
S'55'
p2892
sa(dp2893
g3
I5
sg4
I6
sg5
(lp2894
Vfat
p2895
aVskeletal muscle
p2896
aVspleen
p2897
aVliver
p2898
aVlungs
p2899
asg11
S'Main tissue reservoir for opioids:'
p2900
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2901
sg15
S'Q55#4'
p2902
sg17
S'4'
sg18
I1
sg19
S'55'
p2903
sa(dp2904
g3
I18
sg4
I3
sg5
(lp2905
VKappa
p2906
aVDelta
p2907
aVMu
p2908
asg11
S'Analgesia, euphoria, respiratory depression associated with morphine are probably mediated mainly through this opioid receptor type:'
p2909
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2910
sg15
S'Q55#9'
p2911
sg17
S'9'
sg18
I2
sg19
S'55'
p2912
sa(dp2913
g3
I7
sg4
I23
sg5
(lp2914
Vreduced patient responsiveness
p2915
aValveolar PCO2 increased
p2916
aVdepressed patient response to a carbon dioxide challenge
p2917
aVincreased levels of alkaline phosphatase
p2918
aVincreased levels of creatinine
p2919
asg11
S'Most reliable indicator of opioid-mediated respiratory depression:'
p2920
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2921
sg15
S'Q55#12'
p2922
sg17
S'12'
p2923
sg18
I2
sg19
S'55'
p2924
sa(dp2925
g3
I11
sg4
I26
sg5
(lp2926
Voral pentazocine (Talwain)
p2927
aVoral propoxyphene (Darvon)
p2928
aVintravenous, rapidly infused, alfentanil
p2929
aVintravenous naloxone (Narcan)
p2930
aVintravenous  naltrexone (ReVia)
p2931
asg11
S'Opioid + Route of Administration most likely associated with truncal rigidity:'
p2932
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2933
sg15
S'Q55#13'
p2934
sg17
S'13'
p2935
sg18
I2
sg19
S'55'
p2936
sa(dp2937
g3
I11
sg4
I6
sg5
(lp2938
Vanalgesia
p2939
aVbradycardia
p2940
aVrespiratory depression
p2941
aVmiosis
p2942
aVeuphoria
p2943
asg11
S'Opioid effect least likely to exhibit tolerance following prolonged opioid administration:'
p2944
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question1/questionset1.htm'
p2945
sg15
S'Q55#14'
p2946
sg17
S'14'
p2947
sg18
I3
sg19
S'55'
p2948
sa(dp2949
g3
I7
sg4
I16
sg5
(lp2950
Vconstipation
p2951
aVconstriction of biliary smooth muscle
p2952
aVenhanced renal function
p2953
aVlimited direct cardiovascular effects
p2954
aVmay prolong labor
p2955
asg11
S'Physiological effect NOT typically associated with opioids:'
p2956
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question3/questionset3.htm'
p2957
sg15
S'Q56#0'
p2958
sg17
S'0'
sg18
I2
sg19
S'56'
p2959
sa(dp2960
g3
I2
sg4
I20
sg5
(lp2961
Vnaloxone (Narcan)
p2962
aVnaltrexone (ReVia)
p2963
aVhydromorphone (Dilaudid)
p2964
aVnalbuphine (Nubain)
p2965
aVdiphenoxylate (Lomotil)
p2966
asg11
S'Mixed agonist-antagonist:'
p2967
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question3/questionset3.htm'
p2968
sg15
S'Q56#1'
p2969
sg17
S'1'
sg18
I3
sg19
S'56'
p2970
sa(dp2971
g3
I7
sg4
I24
sg5
(lp2972
Vnaloxone (Narcan)
p2973
aVnalmefene (Revex)
p2974
aVnaltrexone (ReVia)
p2975
aVall about equal duration of action
p2976
aVthese agents are not opioid antagonists
p2977
asg11
S'Opioid antagonist with shortest duration of action:'
p2978
sg13
S'http://www.pharmacology2000.com/Central/Opioid/question3/questionset3.htm'
p2979
sg15
S'Q56#6'
p2980
sg17
S'6'
sg18
I0
sg19
S'56'
p2981
sa(dp2982
g3
I4
sg4
I40
sg5
(lp2983
VMore soluble in blood leads to more rapid induction.
p2984
aVAnesthetic tension in the blood rises more rapidly for highly soluble drugs.
p2985
aVBrain concentration of nitrous oxide rises rapidly.
p2986
aVRate of pulmonary blood flow significantly affects time to anesthetic equilibrium.
p2987
asg11
S'Properties of inhalational anesthetics:'
p2988
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions2/GA1.htm'
p2989
sg15
S'Q57#0'
p2990
sg17
S'0'
sg18
I2
sg19
S'57'
p2991
sa(dp2992
g3
I6
sg4
I20
sg5
(lp2993
Vlipid solubility
p2994
aVspeed of induction.
p2995
aVpresence of a "second gas effect"
p2996
aVminimum alveolar concentration (MAC value)
p2997
asg11
S'Accepted measure of anesthetic potency.'
p2998
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions2/GA1.htm'
p2999
sg15
S'Q57#1'
p3000
sg17
S'1'
sg18
I3
sg19
S'57'
p3001
sa(dp3002
g3
I15
sg4
I4
sg5
(lp3003
Visoflurane
p3004
aVenflurane
p3005
aVhalothane
p3006
aVdesflurane
p3007
asg11
S'Unpredictable hepatitis occurrence has been one factor that reduce the use of this inhalational anesthetic:'
p3008
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions2/GA1.htm'
p3009
sg15
S'Q57#2'
p3010
sg17
S'2'
sg18
I2
sg19
S'57'
p3011
sa(dp3012
g3
I15
sg4
I5
sg5
(lp3013
Vnitrous oxide
p3014
aVhalothane
p3015
aVthiopental
p3016
aVfentanyl
p3017
asg11
S'Very brief anesthetic effects of this barbiturate is explained by "rapid redistribution":'
p3018
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions2/GA1.htm'
p3019
sg15
S'Q57#3'
p3020
sg17
S'3'
sg18
I2
sg19
S'57'
p3021
sa(dp3022
g3
I2
sg4
I9
sg5
(lp3023
Vpropofol
p3024
aVdroperidol + fentanyl citrate
p3025
aVketamine
p3026
aVenflurane + hydoxyzine
p3027
asg11
S'Neurolept analgesia:'
p3028
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions2/GA1.htm'
p3029
sg15
S'Q57#4'
p3030
sg17
S'4'
sg18
I1
sg19
S'57'
p3031
sa(dp3032
g3
I6
sg4
I37
sg5
(lp3033
Vpatient age
p3034
aVRate of hepatic anesthetic metabolism
p3035
aVanesthetic partial pressure (tension) in brain
p3036
aVrate of transfer of gas from the blood to alveoli
p3037
aVrate of redistribution of the anesthetic from the brain to other tissues
p3038
asg11
S'Depth of anesthesia primarily depends on:'
p3039
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions3/questionset3.htm'
p3040
sg15
S'Q58#1'
p3041
sg17
S'1'
sg18
I2
sg19
S'58'
p3042
sa(dp3043
g3
I16
sg4
I14
sg5
(lp3044
Vhalothane (Fluothane)
p3045
aVether
p3046
aVnitrous oxide
p3047
aVisoflurane (Forane)
p3048
aVall are equal
p3049
asg11
S'Fastest rate of rise of arterial gas tension (as% of inspired tension):'
p3050
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions3/questionset3.htm'
p3051
sg15
S'Q58#2'
p3052
sg17
S'2'
sg18
I2
sg19
S'58'
p3053
sa(dp3054
g3
I17
sg4
I14
sg5
(lp3055
Vdifferent rates of anesthetic metabolism
p3056
aVdifferential excretion rates
p3057
aVanesthetic physical properties, e.g. solubility
p3058
asg11
S'Differences between anesthetics in terms of rate of rise of arterial gas tension are primarily due to:'
p3059
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions3/questionset3.htm'
p3060
sg15
S'Q58#3'
p3061
sg17
S'3'
sg18
I2
sg19
S'58'
p3062
sa(dp3063
g3
I5
sg4
I50
sg5
(lp3064
VThe more soluble in age and is in the blood the less must be dissolved to raise its partial pressure (tension)
p3065
aV Inhalational agent solubility is a relatively unimportant factor in determining the speed of induction recovery
p3066
aVInduction times may be prolonged with methoxyflurane because of its high solubility
p3067
asg11
S'Anesthetic solubility in the blood:'
p3068
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions3/questionset3.htm'
p3069
sg15
S'Q58#6'
p3070
sg17
S'6'
sg18
I2
sg19
S'58'
p3071
sa(dp3072
g3
I5
sg4
I5
sg5
(lp3073
V0.5-1
p3074
aV2-4
p3075
aV5-10
p3076
aV> 10
p3077
asg11
S'Therapeutics-index range -- general anesthetics:'
p3078
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3079
sg15
S'Q59#0'
p3080
sg17
S'0'
sg18
I1
sg19
S'59'
p3081
sa(dp3082
g3
I1
sg4
I48
sg5
(lp3083
VAlveolar gas concentration that will produce retrograde amnesia in at least 20% of patients:
p3084
aVAlveolar gas concentration that will produce immobility in 50% of patients exposed to Led Zeppelin
p3085
aVAlveolar gas concentration that will produce immobility in 50% of patients exposed to painful stimuli
p3086
asg11
S'MAC:'
p3087
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3088
sg15
S'Q59#2'
p3089
sg17
S'2'
sg18
I2
sg19
S'59'
p3090
sa(dp3091
g3
I3
sg4
I69
sg5
(lp3092
VAt equilibrium the partial pressure of the anesthetic gas in the lung is usually significantly higher than the partial pressure of the gas in the brain.
p3093
aVConcerning anesthetic gases -- there is a rapid equilibrium between blood and brain partial pressures
p3094
aVMAC values are highly dependent on the nature of the painful stimulus
p3095
aVMAC values are relatively sensitive to patient gender, height, weight, and anesthesia duration
p3096
asg11
S'Anesthetic potency --'
p3097
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3098
sg15
S'Q59#3'
p3099
sg17
S'3'
sg18
I1
sg19
S'59'
p3100
sa(dp3101
g3
I21
sg4
I6
sg5
(lp3102
Vamnesia/analgesia
p3103
aVdelirium
p3104
aVsurgical anesthesia
p3105
aVmedullary depression
p3106
asg11
S'Apnea, non-reacted dilated pupils, circulatory failure, and hypertension are most likely associated with this stage of general anesthesia:'
p3107
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3108
sg15
S'Q59#5'
p3109
sg17
S'5'
sg18
I3
sg19
S'59'
p3110
sa(dp3111
g3
I26
sg4
I6
sg5
(lp3112
Vanalgesia/amnesia
p3113
aVdelirium
p3114
aVsurgical anesthesia
p3115
aVmedullary depression
p3116
asg11
S'Central gaze, constricted pupils, regular aspirations, and the anesthetic depth is sufficient that noxious stimuli does not cause reflexes or excessive autonomic effects'
p3117
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3118
sg15
S'Q59#6'
p3119
sg17
S'6'
sg18
I2
sg19
S'59'
p3120
sa(dp3121
g3
I5
sg4
I25
sg5
(lp3122
Vusually adequate analgesia
p3123
aVLikely to provide adequate muscle relaxation
p3124
aVcommonly used in adults; less likely to be used in children
p3125
aVreversible reduction of GFR
p3126
asg11
S'Halothane (Fluothane) --'
p3127
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3128
sg15
S'Q59#7'
p3129
sg17
S'7'
sg18
I3
sg19
S'59'
p3130
sa(dp3131
g3
I5
sg4
I34
sg5
(lp3132
VWidely used in pediatric cases
p3133
aVmay cause concern if patient has a seizure-disorder history
p3134
aVskeletal muscle relaxation:inadequate for surgery
p3135
aVDifficult adjustment of anesthesia depth due to significant effects on pulse and respiration
p3136
asg11
S'Enflurane (Ethrane)--'
p3137
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3138
sg15
S'Q59#8'
p3139
sg17
S'8'
sg18
I1
sg19
S'59'
p3140
sa(dp3141
g3
I23
sg4
I12
sg5
(lp3142
Venflurane (Ethrane)
p3143
aVhalothane (Fluothane)
p3144
aVisoflurane (Forane)
p3145
asg11
S'Considering enflurane (Ethrane), halothane (Fluothane), and isoflurane (Forane) -- cardiac output is well maintained --'
p3146
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3147
sg15
S'Q59#9'
p3148
sg17
S'9'
sg18
I2
sg19
S'59'
p3149
sa(dp3150
g3
I5
sg4
I45
sg5
(lp3151
Vminimal muscle relaxation
p3152
aVpromotes uterine muscle contraction; desirable if uterine contraction is required  to limit blood loss
p3153
aVstimulates airway reflexes -- increasing secretions, coughing, and laryngospasm
p3154
aVconvulsive activity is associated with isoflurane (Forane), similar to enflurane (Ethrane)
p3155
asg11
S'Isoflurane (Forane):'
p3156
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions4/questionset4.htm'
p3157
sg15
S'Q59#10'
p3158
sg17
S'10'
p3159
sg18
I2
sg19
S'59'
p3160
sa(dp3161
g3
I5
sg4
I35
sg5
(lp3162
Vexcellent analgesic
p3163
aVrapid recovery (20-30 minutes) due to rapid hepatic metabolism
p3164
aVabsence of  respiratory depression
p3165
aVcrosses the placental barrier, depressing the fetus
p3166
aVsignificant cardiovascular effects, except in the presence of hypovolemia
p3167
asg11
S'Thiopental (Pentothal):'
p3168
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions5/questionset5.htm'
p3169
sg15
S'Q60#3'
p3170
sg17
S'3'
sg18
I3
sg19
S'60'
p3171
sa(dp3172
g3
I8
sg4
I30
sg5
(lp3173
Vadvantage: combination with opioids do not result in significant cardiovascular depression
p3174
aVCentral nervous system depression can be reversed with naltrexone (ReVia)
p3175
aVEffective analgesic
p3176
aVAssociated with anterograde amnesia
p3177
asg11
S'Benzodiazepines: Diazepam (Valium) pharmacology --'
p3178
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions5/questionset5.htm'
p3179
sg15
S'Q60#6'
p3180
sg17
S'6'
sg18
I3
sg19
S'60'
p3181
sa(dp3182
g3
I2
sg4
I41
sg5
(lp3183
Vhaloperidol (Haldol) + nitrous oxide
p3184
aVchlorpromazine (Thorazine) +  midazolam (Versed)
p3185
aVdroperidol (Inapsine) + nitrous oxide
p3186
aVfentanyl (Sublimaze) + meperidine (Demerol)
p3187
aVfentanyl (Sublimaze) + droperidol (Inapsine)
p3188
asg11
S'Innovar --'
p3189
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions5/questionset5.htm'
p3190
sg15
S'Q60#16'
p3191
sg17
S'16'
p3192
sg18
I4
sg19
S'60'
p3193
sa(dp3194
g3
I5
sg4
I23
sg5
(lp3195
Vsimilar to sufentanil (Sufenta)
p3196
aVsimilar enflurane (Ethrane)
p3197
aVsimilar to thiopental (Pentothal)
p3198
aVsimilar to ketamine (Ketalar)
p3199
asg11
S'Propofol (Diprivan):'
p3200
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions6/questionset6.htm'
p3201
sg15
S'Q61#1'
p3202
sg17
S'1'
sg18
I2
sg19
S'61'
p3203
sa(dp3204
g3
I7
sg4
I28
sg5
(lp3205
Vreduction in the requirement for inhalational agents
p3206
aVreduction in the acidity and volume of gastric contents
p3207
aVrelief of preoperative pain
p3208
aVreduction inside effects associated with some inhalational agents
p3209
asg11
S'A primary goal in preanesthetic medication --'
p3210
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions6/questionset6.htm'
p3211
sg15
S'Q61#3'
p3212
sg17
S'3'
sg18
I2
sg19
S'61'
p3213
sa(dp3214
g3
I12
sg4
I12
sg5
(lp3215
V chlorpromazine (Thorazine)
p3216
aVhaloperidol (Haldol)
p3217
aVondansetron (Zofran)
p3218
asg11
S'Antiemetic drug that works through serotonin (subtype 3) receptor blockade'
p3219
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions6/questionset6.htm'
p3220
sg15
S'Q61#16'
p3221
sg17
S'16'
p3222
sg18
I2
sg19
S'61'
p3223
sa(dp3224
g3
I11
sg4
I14
sg5
(lp3225
Vhydroxyzine (Atarax,Vistaril)
p3226
aVchlorpromazine (Thorazine)
p3227
aVondansetron (Zofran)
p3228
asg11
S'Least likely to cause hypotension or sedation while providing antiemetic effect:'
p3229
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions6/questionset6.htm'
p3230
sg15
S'Q61#18'
p3231
sg17
S'18'
p3232
sg18
I2
sg19
S'61'
p3233
sa(dp3234
g3
I6
sg4
I15
sg5
(lp3235
Vchlorpromazine (Thorazine)
p3236
aVhaloperidol (Haldol)
p3237
aVhydroxyzine (Atarax,Vistaril)
p3238
aVtropisetron
p3239
asg11
S'Antiemetic drug with least side effects'
p3240
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions6/questionset6.htm'
p3241
sg15
S'Q61#19'
p3242
sg17
S'19'
p3243
sg18
I3
sg19
S'61'
p3244
sa(dp3245
g3
I10
sg4
I4
sg5
(lp3246
Vcholinomimetic properties
p3247
aVanxiolytic
p3248
aVbronchoconstriction
p3249
asg11
S' Hydroxyzine (Atarax,Vistaril) as a preanesthetic agent:'
p3250
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions7/questionset7.htm'
p3251
sg15
S'Q62#1'
p3252
sg17
S'1'
sg18
I1
sg19
S'62'
p3253
sa(dp3254
g3
I5
sg4
I6
sg5
(lp3255
Vatropine
p3256
aVscopolamine
p3257
aVglycopyrrolate (Robinul)
p3258
asg11
S'Post-anesthesia emergence symptoms more common:'
p3259
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions7/questionset7.htm'
p3260
sg15
S'Q62#3'
p3261
sg17
S'3'
sg18
I1
sg19
S'62'
p3262
sa(dp3263
g3
I7
sg4
I12
sg5
(lp3264
Vhalothane (Fluothane)
p3265
aVenflurane (Ethrane)
p3266
aVisoflurane (Forane)
p3267
asg11
S'Anesthetic most likely to cause seizure activity'
p3268
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3269
sg15
S'Q63#0'
p3270
sg17
S'0'
sg18
I1
sg19
S'63'
p3271
sa(dp3272
g3
I6
sg4
I53
sg5
(lp3273
VAnticonvulsant medication should be slowly reduced in dosage and stopped  several days before surgery
p3274
aVPhenobarbital (Luminal) may increase anesthetic agent metabolism
p3275
aVIncreased metabolism of  volatile, halogenated anesthetics decrease organ toxicity risk
p3276
aVthe following surgery, anticonvulsant medication should be held until the patient is able to take the medication orally
p3277
asg11
S'Anticonvulsant medication and inhalational anesthetic use:'
p3278
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3279
sg15
S'Q63#1'
p3280
sg17
S'1'
sg18
I1
sg19
S'63'
p3281
sa(dp3282
g3
I10
sg4
I16
sg5
(lp3283
Vcarbamazepine (Tegretol)
p3284
aVprimidone (Mysoline)
p3285
aVethosuximide (Zarontin)
p3286
aVphenytoin (Dilantin)
p3287
asg11
S'A drug of choice in management of petit mal epilepsy:'
p3288
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3289
sg15
S'Q63#2'
p3290
sg17
S'2'
sg18
I2
sg19
S'63'
p3291
sa(dp3292
g3
I9
sg4
I18
sg5
(lp3293
Vsevoflurane (Sevorane, Ultane)
p3294
aVdesflurane (Suprane)
p3295
aVenflurane (Ethrane)
p3296
aVisoflurane (Forane)
p3297
asg11
S'Inhalational anesthetic most likely to cause EEG seizure activity'
p3298
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3299
sg15
S'Q63#5'
p3300
sg17
S'5'
sg18
I2
sg19
S'63'
p3301
sa(dp3302
g3
I10
sg4
I12
sg5
(lp3303
Vhalothane (Fluothane)
p3304
aVisoflurane (Forane)
p3305
aVenflurane (Ethrane)
p3306
asg11
S'Inhalational anesthetic agent with least effect on cerebral blood flow'
p3307
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3308
sg15
S'Q63#11'
p3309
sg17
S'11'
p3310
sg18
I1
sg19
S'63'
p3311
sa(dp3312
g3
I3
sg4
I20
sg5
(lp3313
Vthiopental (Pentothal)
p3314
aVetomidate (Amidate)
p3315
aVhalothane (Fluothane)
p3316
aVmidazolam (Versed)
p3317
aVpropofol (Diprivan)
p3318
asg11
S'direct cerebral vasodilation:'
p3319
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3320
sg15
S'Q63#12'
p3321
sg17
S'12'
p3322
sg18
I2
sg19
S'63'
p3323
sa(dp3324
g3
I16
sg4
I21
sg5
(lp3325
Vketamine (Ketalar)
p3326
aVpropofol (Diprivan)
p3327
aVnitrous oxide + intravenous anesthetic
p3328
aVnitrous oxide  + volatile anesthetics
p3329
aVnitrous oxide alone
p3330
asg11
S'Anesthetic or anesthetic combination least likely to change cerebral blood flow or cause direct cerebral vasodilation:'
p3331
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions8/questionset8.htm'
p3332
sg15
S'Q63#13'
p3333
sg17
S'13'
p3334
sg18
I2
sg19
S'63'
p3335
sa(dp3336
g3
I3
sg4
I18
sg5
(lp3337
Vdirect acting  vasodilator
p3338
aVsignificant cardiovascular depression
p3339
aVreduced adrenocortical response to stress was prolonged use
p3340
aVincreased CBF
p3341
aVincreased CMR
p3342
asg11
S'Etomidate: --'
p3343
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions9/questionset9.htm'
p3344
sg15
S'Q64#10'
p3345
sg17
S'10'
p3346
sg18
I2
sg19
S'64'
p3347
sa(dp3348
g3
I5
sg4
I12
sg5
(lp3349
Vincreased ICP
p3350
aVincreased CBF
p3351
aVincreased CMR
p3352
aVlonger-lasting ventilatory depression compared to barbiturates
p3353
asg11
S'Propofol (Diprivan) --'
p3354
sg13
S'http://www.pharmacology2000.com/Central/General_Anesthesia/questions9/questionset9.htm'
p3355
sg15
S'Q64#11'
p3356
sg17
S'11'
p3357
sg18
I3
sg19
S'64'
p3358
sa(dp3359
g3
I8
sg4
I10
sg5
(lp3360
VEster-type agents
p3361
aVAmide-type agents
p3362
aVno difference in duration of action
p3363
asg11
S'Local anesthetics types: shorter duration of action'
p3364
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3365
sg15
S'Q65#1'
p3366
sg17
S'1'
sg18
I0
sg19
S'65'
p3367
sa(dp3368
g3
I5
sg4
I16
sg5
(lp3369
VLocal anesthetics are weak acids
p3370
aVLocal anesthetics are weak bases
p3371
aVLocal anesthetics have no ionizable groups
p3372
asg11
S'Local anesthetics: acid/base properties'
p3373
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3374
sg15
S'Q65#2'
p3375
sg17
S'2'
sg18
I1
sg19
S'65'
p3376
sa(dp3377
g3
I6
sg4
I5
sg5
(lp3378
V6.0-7.0
p3379
aV7.0-8.0
p3380
aV8.0-9.0
p3381
aV> 9.0
p3382
asg11
S'pKa range for most local anesthetics'
p3383
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3384
sg15
S'Q65#3'
p3385
sg17
S'3'
sg18
I2
sg19
S'65'
p3386
sa(dp3387
g3
I13
sg4
I17
sg5
(lp3388
VExtracellular pH in infected tissue is higher
p3389
aVExtracellular pH in infected tissue is  lower
p3390
aVabout the same
p3391
asg11
S'Influence on tissue infection on pH, compared to normal physiological pH.'
p3392
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3393
sg15
S'Q65#4'
p3394
sg17
S'4'
sg18
I1
sg19
S'65'
p3395
sa(dp3396
g3
I9
sg4
I14
sg5
(lp3397
Vgreater effect (greater anesthesia)
p3398
aVreduced effect (reduced anesthesia)
p3399
aVno difference
p3400
asg11
S'Effectiveness of local anesthetics when injected into infected tissue:'
p3401
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3402
sg15
S'Q65#5'
p3403
sg17
S'5'
sg18
I1
sg19
S'65'
p3404
sa(dp3405
g3
I10
sg4
I31
sg5
(lp3406
Vthe receptor is localized on the external cell membrane surface
p3407
aVthe receptor is localized on the internal membrane surface
p3408
aVthe receptor is a nuclear receptor (located near the nucleolus)
p3409
asg11
S'Localization of local anesthetic receptor relative to the cell membrane:'
p3410
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3411
sg15
S'Q65#6'
p3412
sg17
S'6'
sg18
I1
sg19
S'65'
p3413
sa(dp3414
g3
I2
sg4
I9
sg5
(lp3415
Vlidocaine (Xylocaine)
p3416
aVmepivacaine (Carbocaine)
p3417
aVequal
p3418
asg11
S'Greatest vasodilation:'
p3419
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3420
sg15
S'Q65#8'
p3421
sg17
S'8'
sg18
I0
sg19
S'65'
p3422
sa(dp3423
g3
I17
sg4
I16
sg5
(lp3424
Vprocaine (Novocain)
p3425
aVmepivacaine (Carbocaine)
p3426
aVlidocaine (Xylocaine)
p3427
aVbupivacaine (Marcaine)
p3428
asg11
S'Inclusion of a vasoconstrictor in the local anesthetic solution is least likely to prolong the action of:'
p3429
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3430
sg15
S'Q65#12'
p3431
sg17
S'12'
p3432
sg18
I3
sg19
S'65'
p3433
sa(dp3434
g3
I11
sg4
I18
sg5
(lp3435
Venhanced local anesthetic effectiveness
p3436
aVreduced local anesthetic effectiveness
p3437
aVno clonidine (Catapres) influence on local anesthetic efficacy
p3438
asg11
S'Effect of clonidine (Catapres) addition to local anesthetic solutions:'
p3439
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3440
sg15
S'Q65#15'
p3441
sg17
S'15'
p3442
sg18
I0
sg19
S'65'
p3443
sa(dp3444
g3
I19
sg4
I5
sg5
(lp3445
Vintercostal
p3446
aVbrachial plexus
p3447
aVsciatic nerve
p3448
asg11
S'Based on comparative vascularity, maximum local anesthetic blood levels as a function of injection sites for regional anesthesia:'
p3449
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3450
sg15
S'Q65#17'
p3451
sg17
S'17'
p3452
sg18
I0
sg19
S'65'
p3453
sa(dp3454
g3
I7
sg4
I6
sg5
(lp3455
VAmide agents
p3456
aVEster agents
p3457
aVno difference
p3458
asg11
S'Type of local anesthetic with wider distribution:'
p3459
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3460
sg15
S'Q65#18'
p3461
sg17
S'18'
p3462
sg18
I0
sg19
S'65'
p3463
sa(dp3464
g3
I15
sg4
I5
sg5
(lp3465
VHeart
p3466
aVBrain
p3467
aVLung
p3468
aVKidney
p3469
aVFat
p3470
asg11
S'Following IV infusion of lidocaine (Xylocaine): initial high uptake into this organ:'
p3471
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions1/questionset1.htm'
p3472
sg15
S'Q65#19'
p3473
sg17
S'19'
p3474
sg18
I2
sg19
S'65'
p3475
sa(dp3476
g3
I11
sg4
I10
sg5
(lp3477
Venhanced accumulation
p3478
aVreduced accumulation
p3479
aVno effect on local anesthetic accumulation
p3480
asg11
S'Effect of fetal acidosis on local anesthetic accumulation in the fetus'
p3481
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3482
sg15
S'Q66#3'
p3483
sg17
S'3'
sg18
I0
sg19
S'66'
p3484
sa(dp3485
g3
I5
sg4
I7
sg5
(lp3486
Vrapid hydrolysis
p3487
aVhepatic mediation
p3488
aVsignificant renal excretion
p3489
asg11
S'Clearance: amide local anesthetic'
p3490
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3491
sg15
S'Q66#4'
p3492
sg17
S'4'
sg18
I1
sg19
S'66'
p3493
sa(dp3494
g3
I7
sg4
I16
sg5
(lp3495
Vprilocaine (Citanest)
p3496
aVropivacaine (Naropin)
p3497
aVlidocaine (Xylocaine)
p3498
aVmepivacaine (Carbocaine)
p3499
asg11
S'Slows metabolism among the amide-type local anesthetics'
p3500
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3501
sg15
S'Q66#6'
p3502
sg17
S'6'
sg18
I1
sg19
S'66'
p3503
sa(dp3504
g3
I7
sg4
I12
sg5
(lp3505
Vtetracaine (pontocaine)
p3506
aVprocaine (Novocain)
p3507
aVchloroprocaine (Nesacaine)
p3508
asg11
S'Local anesthetic most rapidly metabolized by cholinesterase'
p3509
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3510
sg15
S'Q66#8'
p3511
sg17
S'8'
sg18
I2
sg19
S'66'
p3512
sa(dp3513
g3
I6
sg4
I14
sg5
(lp3514
Vdirectly proportional to hydrolytic rate
p3515
aVinversely proportional to hydrolytic rate
p3516
aVindependent of hydrolytic rate
p3517
asg11
S'Systemic toxicity of ester-type local anesthetics:'
p3518
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3519
sg15
S'Q66#9'
p3520
sg17
S'9'
sg18
I1
sg19
S'66'
p3521
sa(dp3522
g3
I14
sg4
I10
sg5
(lp3523
Vreduced duration
p3524
aVincreased duration
p3525
aVno effect on duration of action
p3526
asg11
S'Effects on ester-type local anesthetic duration of action in patients with atypical plasma cholinesterase:'
p3527
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3528
sg15
S'Q66#11'
p3529
sg17
S'11'
p3530
sg18
I1
sg19
S'66'
p3531
sa(dp3532
g3
I11
sg4
I20
sg5
(lp3533
Vlidocaine (Xylocaine)
p3534
aVbupivacaine (Marcaine)
p3535
aVmepivacaine (Carbocaine)
p3536
aVprilocaine (Citanest)
p3537
aVprocaine (Novocain)
p3538
asg11
S'Local anesthetic which may cause cyanosis secondary to reduced oxygen transport'
p3539
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3540
sg15
S'Q66#14'
p3541
sg17
S'14'
p3542
sg18
I3
sg19
S'66'
p3543
sa(dp3544
g3
I8
sg4
I18
sg5
(lp3545
Vmepivacaine (Carbocaine)
p3546
aVbupivacaine (Marcaine)
p3547
aVdibucaine (Nupercainal, generic)
p3548
aVprocaine (Novocain)
p3549
asg11
S'Most slowly eliminated among amide derivative local anesthetics:'
p3550
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions2/questionset2.htm'
p3551
sg15
S'Q66#15'
p3552
sg17
S'15'
p3553
sg18
I2
sg19
S'66'
p3554
sa(dp3555
g3
I7
sg4
I11
sg5
(lp3556
Vcommon
p3557
aVmainly associated with amide-type agents
p3558
aVmay be caused by preservatives
p3559
asg11
S'Allergic reactions to local anesthetics: characteristics'
p3560
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3561
sg15
S'Q67#2'
p3562
sg17
S'2'
sg18
I2
sg19
S'67'
p3563
sa(dp3564
g3
I9
sg4
I19
sg5
(lp3565
Vdosage too high
p3566
aVaccidental direct intravascular injection during peripheral nerve block or epidural anesthesia
p3567
aVexcessive absorption from injection site
p3568
asg11
S'Most common cause of toxic plasma local anesthetic concentrations'
p3569
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3570
sg15
S'Q67#7'
p3571
sg17
S'7'
sg18
I1
sg19
S'67'
p3572
sa(dp3573
g3
I7
sg4
I14
sg5
(lp3574
Vtonic-clonic seizures
p3575
aVskeletal muscle fasciculation
p3576
aVtongue and circumoral numbness
p3577
aVtinnitus, vertigo, restlessness
p3578
asg11
S'Earliest symptom associated with local anesthetic toxicity'
p3579
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3580
sg15
S'Q67#9'
p3581
sg17
S'9'
sg18
I2
sg19
S'67'
p3582
sa(dp3583
g3
I6
sg4
I44
sg5
(lp3584
Vrate of injection -- injection rate more important than total amount of drug injected
p3585
aVdirect relationship between PaCO2 and local anesthetic seizure thresholds
p3586
aVhypokalemia: increased local anesthetic toxicity
p3587
aVReduced lidocaine (Xylocaine) toxicity in patients treated perioperatively with mexiletine (Mexitil)
p3588
asg11
S'Factors influencing local anesthetic CNS toxicity:'
p3589
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3590
sg15
S'Q67#11'
p3591
sg17
S'11'
p3592
sg18
I0
sg19
S'67'
p3593
sa(dp3594
g3
I14
sg4
I10
sg5
(lp3595
Vcauda equina syndrome
p3596
aVtransient radicular irritation
p3597
aVanterior spinal artery syndrome
p3598
asg11
S'Local anesthetic Neurotoxicity symptoms: moderate/severe lower back, buttocks, posterior thigh pain'
p3599
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3600
sg15
S'Q67#14'
p3601
sg17
S'14'
p3602
sg18
I1
sg19
S'67'
p3603
sa(dp3604
g3
I13
sg4
I10
sg5
(lp3605
Vtransient radicular irritation
p3606
aVcauda equina syndrome
p3607
aVanterior spinal artery syndrome
p3608
asg11
S'Local anesthetic neurotoxicity symptoms: sensory anesthesia; bowel & bladder sphincter dysfunction'
p3609
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions3/questionset3.htm'
p3610
sg15
S'Q67#15'
p3611
sg17
S'15'
p3612
sg18
I1
sg19
S'67'
p3613
sa(dp3614
g3
I10
sg4
I4
sg5
(lp3615
Vstimulation
p3616
aVinhibition
p3617
aVno effect
p3618
asg11
S'Bupivacaine (Marcaine) effects on ventilatory response carbon dioxide:'
p3619
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3620
sg15
S'Q68#4'
p3621
sg17
S'4'
sg18
I0
sg19
S'68'
p3622
sa(dp3623
g3
I6
sg4
I19
sg5
(lp3624
Vprevention and treatment of cardiac arrhythmias
p3625
aVmanagement of increased intracranial pressure
p3626
aVregional anesthetia
p3627
aVanalgesia
p3628
aVmanagement of grand mal seizure
p3629
asg11
S'Most frequent use of local anesthetics:'
p3630
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3631
sg15
S'Q68#5'
p3632
sg17
S'5'
sg18
I2
sg19
S'68'
p3633
sa(dp3634
g3
I17
sg4
I17
sg5
(lp3635
Vlidocaine (Xylocaine)
p3636
aVprilocaine (Citanest)
p3637
aVdyclonine (Dyclone)
p3638
aVcocaine
p3639
aVbupivacaine (Marcaine)
p3640
asg11
S'Appropriate local anesthetic for patients allergic to bupivacaine (Marcaine) and procaine (Novocain):'
p3641
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3642
sg15
S'Q68#16'
p3643
sg17
S'16'
p3644
sg18
I2
sg19
S'68'
p3645
sa(dp3646
g3
I8
sg4
I12
sg5
(lp3647
Vropivacaine (Naropin)
p3648
aVbupivacaine (Marcaine)
p3649
aVlidocaine (Xylocaine)
p3650
asg11
S'Most common local anesthetic choice for local infiltration'
p3651
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3652
sg15
S'Q68#17'
p3653
sg17
S'17'
p3654
sg18
I2
sg19
S'68'
p3655
sa(dp3656
g3
I11
sg4
I12
sg5
(lp3657
Vmotor first
p3658
aVsensory first
p3659
aVdepended on anatomical locations within the nerve fiber
p3660
asg11
S'In mixed peripheral nerves (motor/sensory)-- sequence of anesthesia'
p3661
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3662
sg15
S'Q68#19'
p3663
sg17
S'19'
p3664
sg18
I2
sg19
S'68'
p3665
sa(dp3666
g3
I23
sg4
I31
sg5
(lp3667
Vlidocaine (Xylocaine) is more lipophilic
p3668
aVbupivacaine (Marcaine) is subject to extensive ester hydrolysis
p3669
aVlidocaine (Xylocaine) is present to a greater extent in an un-ionized form
p3670
asg11
S'And peripheral nerve blockade, why lidocaine (Xylocaine) has a shorter time to onset compared to bupivacaine (Marcaine):'
p3671
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3672
sg15
S'Q68#20'
p3673
sg17
S'20'
p3674
sg18
I2
sg19
S'68'
p3675
sa(dp3676
g3
I11
sg4
I16
sg5
(lp3677
Vropivacaine (Naropin)
p3678
aVbupivacaine (Marcaine)
p3679
aVtetracaine (pontocaine)
p3680
aVlidocaine (Xylocaine)
p3681
asg11
S' Local anesthetic not recommended for their block or for local infiltration:'
p3682
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3683
sg15
S'Q68#21'
p3684
sg17
S'21'
p3685
sg18
I2
sg19
S'68'
p3686
sa(dp3687
g3
I7
sg4
I12
sg5
(lp3688
Vlidocaine (Xylocaine)
p3689
aVprilocaine (Citanest)
p3690
aVbupivacaine (Marcaine)
p3691
asg11
S'Local anesthetic not recommended for Bier block'
p3692
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3693
sg15
S'Q68#22'
p3694
sg17
S'22'
p3695
sg18
I2
sg19
S'68'
p3696
sa(dp3697
g3
I5
sg4
I16
sg5
(lp3698
Vtetracaine (pontocaine)
p3699
aVchloroprocaine (Nesacaine)
p3700
aVlidocaine (Xylocaine)
p3701
aV bupivacaine (Marcaine)
p3702
asg11
S'Not suitable for spinal anesthesia:'
p3703
sg13
S'http://www.pharmacology2000.com/Central/Local_Anes/questions4/questionset4.htm'
p3704
sg15
S'Q68#31'
p3705
sg17
S'31'
p3706
sg18
I1
sg19
S'68'
p3707
sa(dp3708
g3
I8
sg4
I14
sg5
(lp3709
Vchloral hydrate (Noctec)
p3710
aVhaloperidol (Haldol)
p3711
aVlithium
p3712
aVmeprobamate (Miltown)
p3713
asg11
S'Side effects include anti-cholinergic, anti-adrenergic and extrapyramidal'
p3714
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3715
sg15
S'Q69#0'
p3716
sg17
S'0'
sg18
I1
sg19
S'69'
p3717
sa(dp3718
g3
I7
sg4
I13
sg5
(lp3719
Vabnormal glycine metabolism
p3720
aVdecreased brain GABA
p3721
aVdopaminergic abnormality
p3722
aVhigh levels of CNS VMA
p3723
asg11
S'Neurochemical abnormality most closely associated with schizophrenia:'
p3724
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3725
sg15
S'Q69#1'
p3726
sg17
S'1'
sg18
I2
sg19
S'69'
p3727
sa(dp3728
g3
I13
sg4
I16
sg5
(lp3729
Vclozapine (Clozaril)
p3730
aVthioridazine (Mellaril)
p3731
aVhaloperidol (Haldol)
p3732
aVchlorpromazine (Thorazine)
p3733
asg11
S'Antipsychotic most appropriate in elderly patients with prostatic hypertrophy and chronic constipation.'
p3734
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3735
sg15
S'Q69#2'
p3736
sg17
S'2'
sg18
I2
sg19
S'69'
p3737
sa(dp3738
g3
I4
sg4
I12
sg5
(lp3739
Vhaloperidol (Haldol)
p3740
aVloxapine (Loxitane)
p3741
aVclozapine (Clozaril)
p3742
asg11
S'Least extrapyramidal side effects:'
p3743
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3744
sg15
S'Q69#3'
p3745
sg17
S'3'
sg18
I2
sg19
S'69'
p3746
sa(dp3747
g3
I26
sg4
I16
sg5
(lp3748
Vtrifluoperazine (Stelazine)
p3749
aVclozapine (Clozaril)
p3750
aVbenztropine (Cogentin)
p3751
aVmolindone (Moban)
p3752
asg11
S'A schizophrenic patient has been treated with haloperidol, loxapine, thiothixene and lithium. If paranoid delusions persist, what other drug might be tried?'
p3753
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3754
sg15
S'Q69#4'
p3755
sg17
S'4'
sg18
I1
sg19
S'69'
p3756
sa(dp3757
g3
I31
sg4
I27
sg5
(lp3758
Vtardive dyskinesia: reduce fluphenazine (Prolixin) dosage
p3759
aVacute dystonia: benztropine (Cogentin)
p3760
aVacute dystonia:L-DOPA
p3761
aVacute dystonia: diphenhydramine (Benadryl)
p3762
asg11
S'Patient treated with fluphenazine presents the following day with a unilateral stiff , sore neck and back; What was the neurological reaction--which drug treatments might be appropriate?'
p3763
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3764
sg15
S'Q69#5'
p3765
sg17
S'5'
sg18
I3
sg19
S'69'
p3766
sa(dp3767
g3
I6
sg4
I6
sg5
(lp3768
Vtardive dyskinesia
p3769
aVperioral tremor
p3770
aVakathisia
p3771
aVpseudoparkinsonism
p3772
asg11
S'Most common antipsychotic neurological side effect:'
p3773
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3774
sg15
S'Q69#6'
p3775
sg17
S'6'
sg18
I2
sg19
S'69'
p3776
sa(dp3777
g3
I15
sg4
I16
sg5
(lp3778
Vchlorpromazine (Thorazine)
p3779
aVcarbamazepine (Tegretol)
p3780
aVphenelzine (Nardil)
p3781
aVamantidine (Symmetrel)
p3782
asg11
S'Accepted first alternative for treating patients with bipolar disorder not adequately responsive to lithium.'
p3783
sg13
S'http://www.pharmacology2000.com/Central/psychotics/questions/questions2/psycho1.htm'
p3784
sg15
S'Q69#9'
p3785
sg17
S'9'
sg18
I1
sg19
S'69'
p3786
sa(dp3787
g3
I2
sg4
I20
sg5
(lp3788
Vthioridazine (Mellaril)
p3789
aVchlorpromazine (Thorazine)
p3790
aVthiothixene (Navane)
p3791
aVhaloperidol (Haldol)
p3792
aVfluphenazine (Prolixin)
p3793
asg11
S'Butyrophenone antipsychotic:'
p3794
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3795
sg15
S'Q70#0'
p3796
sg17
S'0'
sg18
I3
sg19
S'70'
p3797
sa(dp3798
g3
I11
sg4
I16
sg5
(lp3799
Vthiothixene (Navane)
p3800
aVhaloperidol (Haldol)
p3801
aVchlorpromazine (Thorazine)
p3802
aVolanzapine (Zyprexa)
p3803
asg11
S'Associated with a LOW clinical potency but HIGH degree of sedation:'
p3804
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3805
sg15
S'Q70#3'
p3806
sg17
S'3'
sg18
I2
sg19
S'70'
p3807
sa(dp3808
g3
I6
sg4
I20
sg5
(lp3809
Vfluphenazine (Prolixin)
p3810
aVhaloperidol (Haldol)
p3811
aVclozapine (Clozaril)
p3812
aVthiothixene (Navane)
p3813
aVchlorpromazine (Thorazine)
p3814
asg11
S'Antipsychotic drug with least extrapyramidal toxicity:'
p3815
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3816
sg15
S'Q70#4'
p3817
sg17
S'4'
sg18
I2
sg19
S'70'
p3818
sa(dp3819
g3
I6
sg4
I22
sg5
(lp3820
Vchlorpromazine (Thorazine)
p3821
aVthiothixene (Navane)
p3822
aVclozapine (Clozaril)
p3823
aVolanzapine (Zyprexa)
p3824
aVall about equal in hypotensive action
p3825
asg11
S'Antipsychotic drug:least hypotensive effect:'
p3826
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3827
sg15
S'Q70#5'
p3828
sg17
S'5'
sg18
I3
sg19
S'70'
p3829
sa(dp3830
g3
I8
sg4
I20
sg5
(lp3831
Vchlorpromazine (Thorazine)
p3832
aVhaloperidol (Haldol)
p3833
aVperphenazine (Trilafon)
p3834
aVolanzapine (Zyprexa)
p3835
aVthiothixene (Navane)
p3836
asg11
S'Least likely to cause an increase in prolactin:'
p3837
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3838
sg15
S'Q70#8'
p3839
sg17
S'8'
sg18
I3
sg19
S'70'
p3840
sa(dp3841
g3
I15
sg4
I7
sg5
(lp3842
Vmuscarinic cholinergic
p3843
aValpha adrenergic
p3844
aVdopamine
p3845
aVserotonin
p3846
aVGABA
p3847
asg11
S'Blockade of this receptor system most likely associated with akisthisia side effect of antipsychotic treatment:'
p3848
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3849
sg15
S'Q70#10'
p3850
sg17
S'10'
p3851
sg18
I2
sg19
S'70'
p3852
sa(dp3853
g3
I13
sg4
I8
sg5
(lp3854
Valpha-adrenergic
p3855
aVdopamine
p3856
aVmuscarinic cholinergic
p3857
aVserotonergic
p3858
aVnone-of the above
p3859
asg11
S'Toxic-confusion states due to antipsychotic medication associated with effects on this receptor system'
p3860
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3861
sg15
S'Q70#11'
p3862
sg17
S'11'
p3863
sg18
I2
sg19
S'70'
p3864
sa(dp3865
g3
I13
sg4
I13
sg5
(lp3866
Volanzapine (Zyprexa)
p3867
aVrisperidone (Risperdal)
p3868
aVpimozide (Orap)
p3869
aVclozapine
p3870
asg11
S'Antipsychotic drug most likely to induce agranulocytosis (around 2% frequency)'
p3871
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3872
sg15
S'Q70#12'
p3873
sg17
S'12'
p3874
sg18
I3
sg19
S'70'
p3875
sa(dp3876
g3
I10
sg4
I39
sg5
(lp3877
Vincrease antipsychotic drug dose
p3878
aVadd a tricyclic antidepressants to the drug regimen
p3879
aVadd benztropine (Cogentin)
p3880
aVstart high-dose diazepam (30-40 milligrams per day)
p3881
aVno pharmacological intervention is helpful after tardive dyskinesia is induced by antipsychotic treatment
p3882
asg11
S'Reasonable pharmacological step(s) to treat tardive dyskinesia:'
p3883
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question2/questionset2.htm'
p3884
sg15
S'Q70#14'
p3885
sg17
S'14'
p3886
sg18
I3
sg19
S'70'
p3887
sa(dp3888
g3
I7
sg4
I8
sg5
(lp3889
Vtypical rendogenous depression
p3890
aVschizophrenia
p3891
aVanxiety
p3892
aVbipolar disorder
p3893
aVenuresis
p3894
asg11
S'Lithium carbonate is the preferred treatment for:'
p3895
sg13
S'http://www.pharmacology2000.com/Central/psychotics/question5/questionset5.htm'
p3896
sg15
S'Q71#1'
p3897
sg17
S'1'
sg18
I3
sg19
S'71'
p3898
sa(dp3899
g3
I4
sg4
I4
sg5
(lp3900
Vdiazepam
p3901
aVparoxetine
p3902
aVoxazepam
p3903
aVmethylphenidate
p3904
asg11
S'Anxiety associated with depression:'
p3905
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3906
sg15
S'Q72#2'
p3907
sg17
S'2'
sg18
I1
sg19
S'72'
p3908
sa(dp3909
g3
I13
sg4
I4
sg5
(lp3910
Vimipramine
p3911
aVamoxapine
p3912
aVsertraline
p3913
aVphenelzine
p3914
asg11
S'Most likely to be prescribed first for management of mild to moderate depression:'
p3915
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3916
sg15
S'Q72#4'
p3917
sg17
S'4'
sg18
I2
sg19
S'72'
p3918
sa(dp3919
g3
I28
sg4
I4
sg5
(lp3920
Vimipramine
p3921
aVfluoxetine
p3922
aVphenelzine
p3923
aVamitriptyline
p3924
asg11
S'An elderly male with a history of coronary vascular disease (myocardial infarction and second degree heart block) presents with endogenous depression. Appropriate antidepressant medication would be:'
p3925
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3926
sg15
S'Q72#6'
p3927
sg17
S'6'
sg18
I1
sg19
S'72'
p3928
sa(dp3929
g3
I35
sg4
I45
sg5
(lp3930
VNormally, tranylcypromine causes hypertension
p3931
aVTranylcypromine, a beta-blocker, unmasked essential hypertension.
p3932
aVTranylcypromine, an MAO inhibitor, can cause hypertensive reactions in patients who have ingested tyramine-containing foods.
p3933
aVTyanylcypromine, a first-generation tricyclic antdepressant, produces hypertensive responses as a side effect.
p3934
asg11
S'A depressed patient treated with tranylcypromine presents to the emergency department with a pounding headache. The patient had just eaten dinner, enjoying a red wine with the meal. Suggest possible cause for these symptoms:'
p3935
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3936
sg15
S'Q72#7'
p3937
sg17
S'7'
sg18
I2
sg19
S'72'
p3938
sa(dp3939
g3
I13
sg4
I4
sg5
(lp3940
Vclomipramine
p3941
aVfluvoxamine
p3942
aVimipramine
p3943
aVphenelzine
p3944
asg11
S'Drug treatment for obsessive-compulsive disorder in a patient with significant myocardial disease.'
p3945
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3946
sg15
S'Q72#9'
p3947
sg17
S'9'
sg18
I1
sg19
S'72'
p3948
sa(dp3949
g3
I6
sg4
I26
sg5
(lp3950
Vlithium-induced osmotic diuresis, similar to mannitor
p3951
aVlithium inhibits sodium exchange in the ascending loop of Henle
p3952
aVlithium activates carbonic anhydrase
p3953
aVlithium inhibits ADH receptor.
p3954
asg11
S'Polyuria associated with lithium caused by:'
p3955
sg13
S'http://www.pharmacology2000.com/Central/Antidepressant/questions2/dep1.htm'
p3956
sg15
S'Q72#11'
p3957
sg17
S'11'
p3958
sg18
I3
sg19
S'72'
p3959
sa(dp3960
g3
I11
sg4
I5
sg5
(lp3961
VParkinson\u005c
p3962
aVWilson\u005c
p3963
aVHuntington\u005c
p3964
aVTourette\u005c
p3965
aVThyrotoxicosis
p3966
asg11
S'Neurologic dysfunction is associated with this recessively-inherited disorder of copper metabolism:'
p3967
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p3968
sg15
S'Q73#0'
p3969
sg17
S'0'
sg18
I1
sg19
S'73'
p3970
sa(dp3971
g3
I20
sg4
I9
sg5
(lp3972
VParkinsonian syndrome
p3973
aVakathisia
p3974
aVtardive dyskinesia
p3975
aVacute dystonia
p3976
aVperioral tremor
p3977
asg11
S'A drug-induced dyskinesia -- typically induced by long-term use of phenothiazine antipsychotics;in adults, may not be reversible'
p3978
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p3979
sg15
S'Q73#1'
p3980
sg17
S'1'
sg18
I2
sg19
S'73'
p3981
sa(dp3982
g3
I22
sg4
I4
sg5
(lp3983
VWilson\u005c
p3984
aVTourette\u005c
p3985
aVHuntington\u005c
p3986
aVParkinsonism
p3987
asg11
S'Dominantly-inherited: associated with progressive chorea & dementia, typically beginning in adulthood --possibly due to overactivity of dopaminergic nigrostriatal pathways'
p3988
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p3989
sg15
S'Q73#3'
p3990
sg17
S'3'
sg18
I2
sg19
S'73'
p3991
sa(dp3992
g3
I20
sg4
I10
sg5
(lp3993
VGABA receptors
p3994
aVglutamate receptors
p3995
aVadrenergic receptors
p3996
aVadenosine receptors
p3997
aVmuscarinic receptors
p3998
asg11
S'Essential tremor: receptor system most likely to be involved given that propranolol or metoprolol may improve the syndrome.'
p3999
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p4000
sg15
S'Q73#4'
p4001
sg17
S'4'
sg18
I2
sg19
S'73'
p4002
sa(dp4003
g3
I17
sg4
I5
sg5
(lp4004
Vorphenadrine
p4005
aVamitriptyline
p4006
aVselegiline
p4007
aVamantadine
p4008
aVlevodopa
p4009
asg11
S"Antimuscarinic drug(s) used in management of Parkinson's disease include(s):"
p4010
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p4011
sg15
S'Q73#8'
p4012
sg17
S'8'
sg18
I0
sg19
S'73'
p4013
sa(dp4014
g3
I12
sg4
I5
sg5
(lp4015
Vamantadine
p4016
aVlevodopa
p4017
aVbromocriptine
p4018
aVselegiline
p4019
aVphenothiazine
p4020
asg11
S'In lower doses, this agent can be used to treat hyperprolactinemia:'
p4021
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/question1/questionset1.htm'
p4022
sg15
S'Q73#9'
p4023
sg17
S'9'
sg18
I2
sg19
S'73'
p4024
sa(dp4025
g3
I5
sg4
I6
sg5
(lp4026
Vrigidity
p4027
aVhyperkinesia
p4028
aVtremor
p4029
aVpostural disturbances.
p4030
asg11
S'Neurological presentations of Parkinsonism EXCEPT:'
p4031
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/questions2/park1.htm'
p4032
sg15
S'Q74#1'
p4033
sg17
S'1'
sg18
I1
sg19
S'74'
p4034
sa(dp4035
g3
I11
sg4
I4
sg5
(lp4036
Vtremor
p4037
aVrigidity
p4038
aVmicrographia
p4039
aVsialorrhea
p4040
asg11
S"ANS (autonomic nervous system) manifestations in Parkinson's disease:"
p4041
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/questions2/park1.htm'
p4042
sg15
S'Q74#2'
p4043
sg17
S'2'
sg18
I3
sg19
S'74'
p4044
sa(dp4045
g3
I8
sg4
I4
sg5
(lp4046
Vamantadine
p4047
aVL-DOPA
p4048
aVselegiline
p4049
aVpergolide
p4050
asg11
S"Primary drug used in managing Parkinson's disease"
p4051
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/questions2/park1.htm'
p4052
sg15
S'Q74#4'
p4053
sg17
S'4'
sg18
I1
sg19
S'74'
p4054
sa(dp4055
g3
I4
sg4
I31
sg5
(lp4056
Vnot itself pharmacologically active
p4057
aVcannot cross the blood-brain barrier
p4058
aVcan be curative if initiated early enough.
p4059
aVmetabolized only in the brain--due to the presence of a unique dopa-decarboxylase
p4060
asg11
S'Pharmacological characteristics of L-DOPA'
p4061
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/questions2/park1.htm'
p4062
sg15
S'Q74#6'
p4063
sg17
S'6'
sg18
I0
sg19
S'74'
p4064
sa(dp4065
g3
I11
sg4
I4
sg5
(lp4066
Vbenztropine
p4067
aVselegiline
p4068
aVbromocriptine
p4069
aVamantadine
p4070
asg11
S'Anti-Parkinson Drug that probably acts by direct dopamine receptor simulation.'
p4071
sg13
S'http://www.pharmacology2000.com/Central/Parkinson/questions2/park1.htm'
p4072
sg15
S'Q74#7'
p4073
sg17
S'7'
sg18
I2
sg19
S'74'
p4074
sa(dp4075
g3
I7
sg4
I5
sg5
(lp4076
Vprimidone
p4077
aVethosuximide
p4078
aVphenytoin
p4079
aVi.v. diazepam
p4080
asg11
S'Drug of first choice for absence seizures'
p4081
sg13
S'http://www.pharmacology2000.com/Central/Epilepsy/questions1/epi1.htm'
p4082
sg15
S'Q76#0'
p4083
sg17
S'0'
sg18
I1
sg19
S'76'
p4084
sa(dp4085
g3
I9
sg4
I20
sg5
(lp4086
Vphenytoin, carbamazepine, phenobarbital
p4087
aVethosuximide, valproate, trimethadione
p4088
aVcarbamazepine, ethosuximide, valproate
p4089
aVvalproate, carbamazepine, trimethadione
p4090
asg11
S'Drugs in order of preference for managing absence seizures:'
p4091
sg13
S'http://www.pharmacology2000.com/Central/Epilepsy/questions1/epi1.htm'
p4092
sg15
S'Q76#3'
p4093
sg17
S'3'
sg18
I1
sg19
S'76'
p4094
sa(dp4095
g3
I23
sg4
I4
sg5
(lp4096
Vtrimethadione
p4097
aVpentazocine
p4098
aVethosuximide
p4099
aVtriazolam
p4100
asg11
S'Antiepileptic drug: causes neutropenia (7%), sedation, nausea; a drug of choice in treating absence seizures.'
p4101
sg13
S'http://www.pharmacology2000.com/Central/Epilepsy/questions1/epi1.htm'
p4102
sg15
S'Q76#4'
p4103
sg17
S'4'
sg18
I2
sg19
S'76'
p4104
sa(dp4105
g3
I2
sg4
I20
sg5
(lp4106
Vpancuronium (Pavulon)
p4107
aVpipecuronium (Arduan)
p4108
aVatracurium (Tracrium)
p4109
aVgallamine (Flaxedil)
p4110
aVvecuronium (Norcuron)
p4111
asg11
S'isoquinoline derivative:'
p4112
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions1/questionset1.htm'
p4113
sg15
S'Q77#0'
p4114
sg17
S'0'
sg18
I2
sg19
S'77'
p4115
sa(dp4116
g3
I7
sg4
I32
sg5
(lp4117
VGenerally favored Route of Administration
p4118
aVperipheral symptoms common
p4119
aVmajor disadvantage is the maintenance of integrity of delivery catheter
p4120
aVtolerance does not develop
p4121
aVSignificant improvement of the quality of life is not seen
p4122
asg11
S'Concerning intrathecal baclofen (Lioresal):'
p4123
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions1/questionset1.htm'
p4124
sg15
S'Q77#7'
p4125
sg17
S'7'
sg18
I2
sg19
S'77'
p4126
sa(dp4127
g3
I5
sg4
I28
sg5
(lp4128
Vadvantages for patients with spasticity (several types)
p4129
aVfacilitates nociceptor transmission in dorsal horn
p4130
aVsignificantly more efficacious compared to diazepam (Valium)
p4131
aVadverse effects: hypertension
p4132
asg11
S'Tizanidine (Zanaflex) pharmacology:'
p4133
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions1/questionset1.htm'
p4134
sg15
S'Q77#8'
p4135
sg17
S'8'
sg18
I0
sg19
S'77'
p4136
sa(dp4137
g3
I12
sg4
I12
sg5
(lp4138
Vbaclofen (Lioresal)
p4139
aVdantrolene (Dantrium)
p4140
aVtizanidine (Zanaflex)
p4141
asg11
S'Spasmolytic:: acts by interfering with muscle fiber excitation-coupling mechanism.'
p4142
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions1/questionset1.htm'
p4143
sg15
S'Q77#9'
p4144
sg17
S'9'
sg18
I1
sg19
S'77'
p4145
sa(dp4146
g3
I2
sg4
I20
sg5
(lp4147
Vpancuronium (Pavulon)
p4148
aVvecuronium (Norcuron)
p4149
aVdoxacurium (Nuromax)
p4150
aVpipecuronium (Arduan)
p4151
aVroncuronium (Zemuron)
p4152
asg11
S'Isoquinoline derivative:'
p4153
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4154
sg15
S'Q78#1'
p4155
sg17
S'1'
sg18
I2
sg19
S'78'
p4156
sa(dp4157
g3
I2
sg4
I17
sg5
(lp4158
Vtubocurarine
p4159
aVmivacurium (Mivacron)
p4160
aVatracurium (Tracrium)
p4161
aVcisatracurium (Nimbex)
p4162
aVdoxacurium (Nuromax)
p4163
asg11
S'Hofmann elimination:'
p4164
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4165
sg15
S'Q78#3'
p4166
sg17
S'3'
sg18
I3
sg19
S'78'
p4167
sa(dp4168
g3
I7
sg4
I13
sg5
(lp4169
Vcisatracurium (Nimbex)
p4170
aVtubocurarine
p4171
aVmivacurium (Mivacron)
p4172
aVvecuronium (Norcuron)
p4173
asg11
S'Isoquinoline derivative; shortest duration of action'
p4174
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4175
sg15
S'Q78#5'
p4176
sg17
S'5'
sg18
I2
sg19
S'78'
p4177
sa(dp4178
g3
I7
sg4
I16
sg5
(lp4179
Vvecuronium (Norcuron)
p4180
aVpancuronium (Pavulon)
p4181
aVpipecuronium (Arduan)
p4182
aVroncuronium (Zemuron)
p4183
asg11
S'Most rapid onset among nondepolarizing blockers --'
p4184
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4185
sg15
S'Q78#9'
p4186
sg17
S'9'
sg18
I3
sg19
S'78'
p4187
sa(dp4188
g3
I9
sg4
I13
sg5
(lp4189
Vpancuronium (Pavulon)
p4190
aVpipecuronium (Arduan)
p4191
aVtubocurarine
p4192
aVmivacurium (Mivacron)
p4193
asg11
S'Shortest duration of action among nondepolarizing neuromuscular blocking drugs:'
p4194
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4195
sg15
S'Q78#10'
p4196
sg17
S'10'
p4197
sg18
I3
sg19
S'78'
p4198
sa(dp4199
g3
I11
sg4
I13
sg5
(lp4200
Vreuptake into presynaptic vesicles
p4201
aVdiffusion away from postsynaptic receptors
p4202
aVmetabolism by postsynaptic acetylcholinesterase
p4203
asg11
S'Mechanism of termination of action of succinylcholine (Anectine):'
p4204
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4205
sg15
S'Q78#11'
p4206
sg17
S'11'
p4207
sg18
I1
sg19
S'78'
p4208
sa(dp4209
g3
I8
sg4
I7
sg5
(lp4210
V5-10 minutes
p4211
aV15-30 minutes
p4212
aV> 30 minutes
p4213
asg11
S'Succinylcholine (Anectine): duration of action'
p4214
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4215
sg15
S'Q78#12'
p4216
sg17
S'12'
p4217
sg18
I0
sg19
S'78'
p4218
sa(dp4219
g3
I22
sg4
I41
sg5
(lp4220
Vdysphagia, diplopia, ptosis,difficulty in focusing, mandibular muscle weakness
p4221
aVmandibular muscle weakness, ptosis, dysphagia, difficulty in focusing
p4222
aVdifficulty in focusing, mandibular muscle weakness, ptosis, diplopia, dysphagia
p4223
aVall symptoms occur simultaneously
p4224
asg11
S'Sequence of events following IV neuromuscular-blocking injection (nondepolarizing drug) to an awake patient:{first presentations to last}'
p4225
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions2/questionset2.htm'
p4226
sg15
S'Q78#16'
p4227
sg17
S'16'
p4228
sg18
I2
sg19
S'78'
p4229
sa(dp4230
g3
I5
sg4
I24
sg5
(lp4231
Vrapid onset; long duration of action
p4232
aVmechanism for neuromuscular-blocking action: interacts with muscarinic, cholinergic receptors.
p4233
aVcauses postsynaptic membrane depolarization
p4234
aVquality above
p4235
asg11
S'Succinylcholine (Anectine) pharmacology:'
p4236
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions3/questionset3.htm'
p4237
sg15
S'Q79#3'
p4238
sg17
S'3'
sg18
I2
sg19
S'79'
p4239
sa(dp4240
g3
I14
sg4
I29
sg5
(lp4241
Vreduced  duration of neuromuscular blockade (< one-minute)
p4242
aVincreased duration of neuromuscular-blockade (to 30 minutes)
p4243
aVabsence of neuromuscular-blockade
p4244
aVincreased duration of neuromuscular-blockade (1-3 hours)
p4245
asg11
S'Consequence of normal succinylcholine (Anectine) dosage in a patient with atypical pseudocholinesterase'
p4246
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions3/questionset3.htm'
p4247
sg15
S'Q79#10'
p4248
sg17
S'10'
p4249
sg18
I3
sg19
S'79'
p4250
sa(dp4251
g3
I11
sg4
I10
sg5
(lp4252
Vventricular tachycardia
p4253
aVparoxysmal atrial tachycardia
p4254
aVTorsades de Pointes
p4255
aVsinus bradycardia
p4256
asg11
S'Most common cardiac arrhythmias associated with succinylcholine (Anectine):'
p4257
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions3/questionset3.htm'
p4258
sg15
S'Q79#14'
p4259
sg17
S'14'
p4260
sg18
I3
sg19
S'79'
p4261
sa(dp4262
g3
I4
sg4
I6
sg5
(lp4263
VDuchenne\u005c
p4264
aVBecker muscular dystrophy
p4265
aVequally probable
p4266
asg11
S'More common muscular dystrophy:'
p4267
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions3/questionset3.htm'
p4268
sg15
S'Q79#17'
p4269
sg17
S'17'
p4270
sg18
I0
sg19
S'79'
p4271
sa(dp4272
g3
I15
sg4
I14
sg5
(lp4273
V< 5%
p4274
aVabout 20%
p4275
aVabout 50%
p4276
aV> 80%-90%
p4277
asg11
S'Extent of nicotinic receptor blockade required for neuromuscular transmission failure due to nondepolarizing neuromuscular blockers:'
p4278
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4279
sg15
S'Q80#0'
p4280
sg17
S'0'
sg18
I3
sg19
S'80'
p4281
sa(dp4282
g3
I16
sg4
I21
sg5
(lp4283
Vhalothane (Fluothane)
p4284
aVisoflurane (Forane)
p4285
aVnitrous oxide-opioid combinations
p4286
aVdesflurane (Suprane)
p4287
aVsevoflurane (Sevorane, Ultane)
p4288
asg11
S'Least likely to influence magnitude or duration of neuromuscular-blockade (caused by nondepolarizing agents):'
p4289
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4290
sg15
S'Q80#7'
p4291
sg17
S'7'
sg18
I2
sg19
S'80'
p4292
sa(dp4293
g3
I16
sg4
I20
sg5
(lp4294
Vatracurium (Tracrium)
p4295
aVroncuronium (Zemuron)
p4296
aVdoxacurium (Nuromax)
p4297
aVcisatracurium (Nimbex)
p4298
aVvecuronium (Norcuron)
p4299
asg11
S'Most likely to require greater reduction in blocker dosage as a result of volatile anesthetic use:'
p4300
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4301
sg15
S'Q80#9'
p4302
sg17
S'9'
sg18
I2
sg19
S'80'
p4303
sa(dp4304
g3
I10
sg4
I20
sg5
(lp4305
Vpancuronium (Pavulon)
p4306
aVpipecuronium (Arduan)
p4307
aVcisatracurium (Nimbex)
p4308
aVdoxacurium (Nuromax)
p4309
aVsuccinylcholine (Anectine)
p4310
asg11
S'Intermediate-duration agent (category of nondepolarizing neuromuscular-blocking drug):'
p4311
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4312
sg15
S'Q80#10'
p4313
sg17
S'10'
p4314
sg18
I2
sg19
S'80'
p4315
sa(dp4316
g3
I13
sg4
I24
sg5
(lp4317
Vchloramphenicol (Chloromycetin)
p4318
aVclarithromycin (Biaxin)
p4319
aVazithromycin (Zythromax)
p4320
aVtobramycin (Nebcin)
p4321
aVpenicillin V (Pen-Vee K, Veetids)
p4322
asg11
S'Antibiotic most likely to have an effect on neuromuscular-blockade due to nondepolarizing agents:'
p4323
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4324
sg15
S'Q80#11'
p4325
sg17
S'11'
p4326
sg18
I3
sg19
S'80'
p4327
sa(dp4328
g3
I4
sg4
I19
sg5
(lp4329
Vmanagement of plague
p4330
aVmanagement of tularemia
p4331
aVmanagement of brucellosis
p4332
aVsecond line treatment for tuberculosis
p4333
aVtreatment for viridans streptococcal endocarditis
p4334
asg11
S'Main use for streptomycin:'
p4335
sg13
S'http://www.pharmacology2000.com/Central/NMJ/questions4/questionset4.htm'
p4336
sg15
S'Q80#16'
p4337
sg17
S'16'
p4338
sg18
I3
sg19
S'80'
p4339
sa(dp4340
g3
I4
sg4
I9
sg5
(lp4341
Vexercise
p4342
aVaspirin
p4343
aVrespiratory infection
p4344
aVA, B, C
p4345
asg11
S'May precipitate acute asthma:'
p4346
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4347
sg15
S'Q81#0'
p4348
sg17
S'0'
sg18
I3
sg19
S'81'
p4349
sa(dp4350
g3
I31
sg4
I6
sg5
(lp4351
Vthe placebo effect
p4352
aVcross-tolerance
p4353
aVefficacy
p4354
aVpotency
p4355
asg11
S'Some asthmatic patients exhibit aspirin sensitivity (and sensitivity to other NSAIDS). Daily administration of aspirin causes desensitization not only to aspirin also to other NSAIDS. This phenomenon is:'
p4356
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4357
sg15
S'Q81#1'
p4358
sg17
S'1'
sg18
I1
sg19
S'81'
p4359
sa(dp4360
g3
I39
sg4
I38
sg5
(lp4361
VThe cardioselective beta-blocker, metoprolol, alleviated the arrhythmia and did not affect the patient\u005c
p4362
aVSince metoprolol is a beta agonist, the patient\u005c
p4363
aVThe expiratory component of the patient\u005c
p4364
aVMetoprolol increased airway obstruction, worsening the patient\u005c
p4365
asg11
S'A thirty-eight year old asthmatic who has been using beta adrenergic agonists for several years began to experience arrhythmias, premature atrial contractions. In order to suppress the arrhythmias, high-dose metoprolol therapy was started. Suggest a likely consequence:'
p4366
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4367
sg15
S'Q81#2'
p4368
sg17
S'2'
sg18
I3
sg19
S'81'
p4369
sa(dp4370
g3
I13
sg4
I4
sg5
(lp4371
Vipratropium
p4372
aVterbutaline
p4373
aVcromolyn
p4374
aVmethoxamine
p4375
asg11
S'Anti-asthma agent that acts in part by activating pulmonary beta-receptors thus increasing cAMP'
p4376
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4377
sg15
S'Q81#3'
p4378
sg17
S'3'
sg18
I1
sg19
S'81'
p4379
sa(dp4380
g3
I21
sg4
I36
sg5
(lp4381
VIncreased cardiac output increases pulmonary artery perfusion pressure in the lung
p4382
aVPulmonary vasodilation improves V/Q mismatching
p4383
aVBronchiolar relaxation improves ventilation.
p4384
aVActually, it is the use of supplimental oxygen that is more important than terbutaline.
p4385
asg11
S'V/Q (ventilation/perfusion) mismatching which occurs in severe asthma results in hypoxemia. Terbutaline inhalation inproves the V/Q ratio. Why?'
p4386
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4387
sg15
S'Q81#5'
p4388
sg17
S'5'
sg18
I2
sg19
S'81'
p4389
sa(dp4390
g3
I5
sg4
I39
sg5
(lp4391
Vtheophylline: hepatic oxidation and demethylation
p4392
aValbuterol: beta2 adrenergic blocker
p4393
aVipratropium bromide: well-absorbed quaternary anticholinergic; associated with dry mouth
p4394
aVBeclomethasone: enhances release of chemical mediators of bronchospasm which diminishes effectiveness of beta-2 adrenergic agonists.
p4395
asg11
S'Correct drug:property combination'
p4396
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4397
sg15
S'Q81#6'
p4398
sg17
S'6'
sg18
I3
sg19
S'81'
p4399
sa(dp4400
g3
I6
sg4
I35
sg5
(lp4401
VCorticosteroids relax smooth muscle
p4402
aVCorticosteroids inhibit the inflammatory response.
p4403
aVCorticosteroids reduce patient responsiveness to beta agonists
p4404
aVIn acute asthma, corticosteroids increase airway obstruction; therefore corticosteroids should only be used for chronic treatment.
p4405
asg11
S'Corticosteroids and the treatment of asthma:'
p4406
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4407
sg15
S'Q81#7'
p4408
sg17
S'7'
sg18
I1
sg19
S'81'
p4409
sa(dp4410
g3
I5
sg4
I5
sg5
(lp4411
Vipratropium bromide
p4412
aVaminophylline
p4413
aVmetaproterenol
p4414
aVcyclosporine
p4415
asg11
S'Phosphodiesterase-inhibitor used in asthma therapy:'
p4416
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4417
sg15
S'Q81#8'
p4418
sg17
S'8'
sg18
I1
sg19
S'81'
p4419
sa(dp4420
g3
I14
sg4
I4
sg5
(lp4421
Vbeclomethasone
p4422
aVcromolyn
p4423
aVmetaproterenol
p4424
aValbuterol
p4425
asg11
S'Prophylactic antiasthmatic drug probably acts by preventing release of bronchoconstrictive mediators from mast cells:'
p4426
sg13
S'http://www.pharmacology2000.com/Pulmonary/questions2/pul1.htm'
p4427
sg15
S'Q81#9'
p4428
sg17
S'9'
sg18
I1
sg19
S'81'
p4429
sa(dp4430
g3
I3
sg4
I69
sg5
(lp4431
Vbumetanide (Bumex) > acetazolamide (Diamox) > hydrochlorothiazide (HCTZ, Esidrix, HydroDIURIL)
p4432
aVhydrochlorothiazide (HCTZ, Esidrix, HydroDIURIL) >  furosemide (Lasix) > acetazolamide (Diamox)
p4433
aV acetazolamide (Diamox) > chlorthalidone (Hygroton) > ethacrynic acid (Edecrin)
p4434
aV furosemide (Lasix) >hydrochlorothiazide (HCTZ, Esidrix, HydroDIURIL) > acetazolamide (Diamox)
p4435
asg11
S'DECREASING diuretic efficiency'
p4436
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4437
sg15
S'Q83#2'
p4438
sg17
S'2'
sg18
I3
sg19
S'83'
p4439
sa(dp4440
g3
I6
sg4
I13
sg5
(lp4441
Vethacrynic acid (Edecrin)
p4442
aVfurosemide (Lasix)
p4443
aVtriamterene (Dyrenium)
p4444
asg11
S'Diuretic least likely to produce hypokalemia:'
p4445
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4446
sg15
S'Q83#3'
p4447
sg17
S'3'
sg18
I2
sg19
S'83'
p4448
sa(dp4449
g3
I66
sg4
I16
sg5
(lp4450
Vfurosemide (Lasix)
p4451
aVtriamterene (Dyrenium)
p4452
aVchlorothiazide (Diuril)
p4453
aVbumetanide (Bumex)
p4454
asg11
S'A patient with Type I diabetes presents with significant water retention and pulmonary congestion. Serum creatinine, BUN and potassium were significantly elevated. The diagnosis was advanced renal failure. A diuretic was given to treat water retention, but shortly thereafter the patient exhibited cardiac conduction changes which progressed to heart block and cardiac arrest. The diuretic which was determined to cause this event was probably:'
p4455
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4456
sg15
S'Q83#4'
p4457
sg17
S'4'
sg18
I1
sg19
S'83'
p4458
sa(dp4459
g3
I2
sg4
I13
sg5
(lp4460
Vfurosemide (Lasix)
p4461
aVbumetanide (Bumex)
p4462
aVmannitol (Osmitrol)
p4463
aVthiazides
p4464
asg11
S'Osmotic diuretic'
p4465
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4466
sg15
S'Q83#5'
p4467
sg17
S'5'
sg18
I2
sg19
S'83'
p4468
sa(dp4469
g3
I13
sg4
I16
sg5
(lp4470
Vchlorothiazide (Diuril)
p4471
aVbumetanide (Bumex)
p4472
aVmannitol (Osmitrol)
p4473
aVtriamterene (Dyrenium)
p4474
asg11
S'Diuretic acting primarily on the thick ascending limb of the loop of Henle:'
p4475
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4476
sg15
S'Q83#6'
p4477
sg17
S'6'
sg18
I1
sg19
S'83'
p4478
sa(dp4479
g3
I15
sg4
I18
sg5
(lp4480
Vchlorothiazide (Diuril)
p4481
aVacetazolamide (Diamox)
p4482
aVmetolazone (Zaroxolyn, Mykrox)
p4483
aVbumetanide (Bumex)
p4484
asg11
S'Diuretic that may be used to treat epilepsy, acute mountain sickness and open-angle glaucoma'
p4485
sg13
S'http://www.pharmacology2000.com/Renal/questions1/ren1.htm'
p4486
sg15
S'Q83#7'
p4487
sg17
S'7'
sg18
I1
sg19
S'83'
p4488
sa(dp4489
g3
I4
sg4
I52
sg5
(lp4490
Vincreases bicarbonate reabsorption in the proximal tubule
p4491
aVincreases secretion of bicarbonate by the ciliary body of the eye into aqueous humor
p4492
aVmay be effective in treatment metabolic alkalosis
p4493
aVmajor clincial application is the kidney--to produce a bicarbonate-driven diuresis
p4494
aVmain renal site of action is the thick ascending loop of Henle
p4495
asg11
S'Acetazolamide (Diamox)'
p4496
sg13
S'http://www.pharmacology2000.com/Renal/questions2/renal2.htm'
p4497
sg15
S'Q84#0'
p4498
sg17
S'0'
sg18
I2
sg19
S'84'
p4499
sa(dp4500
g3
I5
sg4
I20
sg5
(lp4501
Vnot secreted
p4502
aVexcreted by the S2 segment of the proximal tubule
p4503
aVcollecting duct
p4504
aVdistal convoluted tubule
p4505
aVascending Loop of Henle
p4506
asg11
S'Acetazolamide (Diamox) secretion:'
p4507
sg13
S'http://www.pharmacology2000.com/Renal/questions2/renal2.htm'
p4508
sg15
S'Q84#2'
p4509
sg17
S'2'
sg18
I1
sg19
S'84'
p4510
sa(dp4511
g3
I7
sg4
I20
sg5
(lp4512
Vacetazolamide (Diamox)
p4513
aVfurosemide (Lasix)
p4514
aVchlorothiazide (Diuril)
p4515
aVdorzolamide (Trusopf)
p4516
aVbumetanide (Bumex)
p4517
asg11
S'Topically-active carbonic anhydrase inhibitor for ocular use:'
p4518
sg13
S'http://www.pharmacology2000.com/Renal/questions2/renal2.htm'
p4519
sg15
S'Q84#3'
p4520
sg17
S'3'
sg18
I3
sg19
S'84'
p4521
sa(dp4522
g3
I7
sg4
I26
sg5
(lp4523
Vdistal tubule
p4524
aVcollecting duct
p4525
aVthin descending limb of the loop of Henle
p4526
aVthick ascending limb of the loop of Henle
p4527
aVat the site of glomerular filtration
p4528
asg11
S'Primary site of action of loop diuretics:'
p4529
sg13
S'http://www.pharmacology2000.com/Renal/questions3/renal3.htm'
p4530
sg15
S'Q85#0'
p4531
sg17
S'0'
sg18
I3
sg19
S'85'
p4532
sa(dp4533
g3
I4
sg4
I31
sg5
(lp4534
Vrapidly absorbed
p4535
aVeliminated by renal secretion only
p4536
aVeliminated by glomerular filtration only
p4537
aVloop diuretics act on the interstitial side of the principal cell
p4538
aVindomethacin (Indocin) increases loop diuretic clearance
p4539
asg11
S'Loop diuretics: Pharmacokinetics'
p4540
sg13
S'http://www.pharmacology2000.com/Renal/questions3/renal3.htm'
p4541
sg15
S'Q85#2'
p4542
sg17
S'2'
sg18
I0
sg19
S'85'
p4543
sa(dp4544
g3
I15
sg4
I19
sg5
(lp4545
Vchlorothiazide (Diuril)
p4546
aVmannitol (Osmitrol)
p4547
aVbumetanide (Bumex)
p4548
aVcarbonic anhydrase inhibitor
p4549
aVspironolactone (Aldactone)
p4550
asg11
S'Most efficacious diuretic in management of acute pulmonary edema secondary to congestive heart failure.'
p4551
sg13
S'http://www.pharmacology2000.com/Renal/questions3/renal3.htm'
p4552
sg15
S'Q85#5'
p4553
sg17
S'5'
sg18
I2
sg19
S'85'
p4554
sa(dp4555
g3
I5
sg4
I7
sg5
(lp4556
Vototoxicity
p4557
aVhypouricemia
p4558
aVhypermagnesemia
p4559
aVsevere fluid overload
p4560
aVhypernatremia
p4561
asg11
S'Furosemide (Lasix) toxicity:'
p4562
sg13
S'http://www.pharmacology2000.com/Renal/questions3/renal3.htm'
p4563
sg15
S'Q85#7'
p4564
sg17
S'7'
sg18
I0
sg19
S'85'
p4565
sa(dp4566
g3
I4
sg4
I17
sg5
(lp4567
Vfurosemide (Lasix)
p4568
aVbumetanide (Bumex)
p4569
aVacetazolamide (Diamox)
p4570
aVtriamterene (Dyrenium)
p4571
aVmannitol
p4572
asg11
S'Prototype carbonic anhydrase inhibitor:'
p4573
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4574
sg15
S'Q86#0'
p4575
sg17
S'0'
sg18
I2
sg19
S'86'
p4576
sa(dp4577
g3
I5
sg4
I13
sg5
(lp4578
Vfurosemide (Lasix)
p4579
aVtriamterene (Dyrenium)
p4580
aVspironolactone (Aldactone)
p4581
aVmannitol
p4582
asg11
S'Pharmacologic antagonism that mineralocorticoid receptors:'
p4583
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4584
sg15
S'Q86#5'
p4585
sg17
S'5'
sg18
I2
sg19
S'86'
p4586
sa(dp4587
g3
I7
sg4
I20
sg5
(lp4588
Vchlorothiazide (Diuril)
p4589
aVtorsemide (Demadex)
p4590
aVtriamterene (Dyrenium)
p4591
aVbumetanide (Bumex)
p4592
aVacetazolamide (Diamox)
p4593
asg11
S'Example(s) of potassium-sparing diuretics:'
p4594
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4595
sg15
S'Q86#6'
p4596
sg17
S'6'
sg18
I2
sg19
S'86'
p4597
sa(dp4598
g3
I6
sg4
I17
sg5
(lp4599
Vtorsemide (Demadex)
p4600
aVbumetanide (Bumex)
p4601
aVethacrynic acid (Edecrin)
p4602
aVtorsemide (Demadex)
p4603
asg11
S'Least likelyto be used clinically today:'
p4604
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4605
sg15
S'Q86#11'
p4606
sg17
S'11'
p4607
sg18
I2
sg19
S'86'
p4608
sa(dp4609
g3
I10
sg4
I14
sg5
(lp4610
Vdistal  tubule
p4611
aVcollecting duct
p4612
aVdescending loop of Henle
p4613
aVascending loop of Henle
p4614
aVproximal tubule
p4615
asg11
S'Primary site of action of bumetanide (Bumex):'
p4616
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4617
sg15
S'Q86#12'
p4618
sg17
S'12'
p4619
sg18
I3
sg19
S'86'
p4620
sa(dp4621
g3
I21
sg4
I13
sg5
(lp4622
Vmannitol
p4623
aVtriamterene (Dyrenium)
p4624
aVbumetanide (Bumex)
p4625
aVacetazolamide (Diamox)
p4626
asg11
S'Most effective diuretic in treatment of acute congestive heart failure -- in terms of magnitude of induced diuresis following IV administration:'
p4627
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4628
sg15
S'Q86#13'
p4629
sg17
S'13'
p4630
sg18
I2
sg19
S'86'
p4631
sa(dp4632
g3
I5
sg4
I6
sg5
(lp4633
Vhyperkalemic metabolic acidosis
p4634
aVototoxicity
p4635
aVhypouricemia
p4636
aVhypermagnesemia
p4637
asg11
S'Toxicities/toxicity associated with loop diuretics:'
p4638
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4639
sg15
S'Q86#16'
p4640
sg17
S'16'
p4641
sg18
I1
sg19
S'86'
p4642
sa(dp4643
g3
I14
sg4
I17
sg5
(lp4644
Vthin descending loop of Henle
p4645
aVthick ascending loop of Henle
p4646
aVdistal convoluted tubule
p4647
aVproximal tubule
p4648
aVcollecting duct
p4649
asg11
S'Primary site of action of hydrochlorothiazide (HCTZ, Esidrix, HydroDIURIL):'
p4650
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4651
sg15
S'Q86#17'
p4652
sg17
S'17'
p4653
sg18
I2
sg19
S'86'
p4654
sa(dp4655
g3
I5
sg4
I5
sg5
(lp4656
Vhyperkalemic states
p4657
aVhypouricemia
p4658
aVhypolipidemia
p4659
aVhyponatremia
p4660
asg11
S'Toxicities/toxicity associated with thiazide diuretics:'
p4661
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4662
sg15
S'Q86#20'
p4663
sg17
S'20'
p4664
sg18
I3
sg19
S'86'
p4665
sa(dp4666
g3
I13
sg4
I8
sg5
(lp4667
VACE inhibitor
p4668
aVcalcium channel blocker
p4669
aVbeta-blocker
p4670
aVthiazide
p4671
aVvasodilator
p4672
asg11
S'Least likely to be used initially in the pharmacological treatment of mild hypertension:'
p4673
sg13
S'http://www.pharmacology2000.com/Renal/questions4/questionset4.htm'
p4674
sg15
S'Q86#22'
p4675
sg17
S'22'
p4676
sg18
I4
sg19
S'86'
p4677
sa(dp4678
g3
I15
sg4
I10
sg5
(lp4679
Vatropine
p4680
aVscopolamine
p4681
aVpirenzepine
p4682
aVall produce about equal side effects.
p4683
asg11
S'Used in management of acid-peptic ulcer disease: Least likely to produce side effects.'
p4684
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4685
sg15
S'Q87#2'
p4686
sg17
S'2'
sg18
I2
sg19
S'87'
p4687
sa(dp4688
g3
I8
sg4
I27
sg5
(lp4689
Vinterferes with the gastric acid pump
p4690
aVblocks cAMP action by preventing protein phosphorylation
p4691
aVcompetes with histamine for H-2 receptor sites
p4692
aVcompetes with gastrin for H-2 receptor sites
p4693
asg11
S'Mechanism by which cimetidine decrease gastric acid secretion:'
p4694
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4695
sg15
S'Q87#3'
p4696
sg17
S'3'
sg18
I2
sg19
S'87'
p4697
sa(dp4698
g3
I18
sg4
I14
sg5
(lp4699
Vranitidine (Zantac)
p4700
aVthe cimetidine (Tagamet)
p4701
aVatropine
p4702
aVomeprazole (Prilosec)
p4703
asg11
S'Antiulcer medication that has an antiadrogenic effect--may cause gynecomastia (breast enlargement) in some patients:'
p4704
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4705
sg15
S'Q87#4'
p4706
sg17
S'4'
sg18
I1
sg19
S'87'
p4707
sa(dp4708
g3
I19
sg4
I12
sg5
(lp4709
Vbismuth compounds
p4710
aVmisoprostol (Cytotec)
p4711
aVsucralfate (Carafate)
p4712
aVviscous lidocaine
p4713
asg11
S'Anti-gastric ulcer drug that binds to mucosal protein substrate and then forms a gel that coats the ulcer.'
p4714
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4715
sg15
S'Q87#6'
p4716
sg17
S'6'
sg18
I2
sg19
S'87'
p4717
sa(dp4718
g3
I9
sg4
I11
sg5
(lp4719
Vsucralfate
p4720
aVomeprazole (Prilosec)
p4721
aVranitidine (Zantac)
p4722
aVbismuth compounds
p4723
asg11
S'Anti-ulcer agent that blocks proton gnerations by parietal cells:'
p4724
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4725
sg15
S'Q87#7'
p4726
sg17
S'7'
sg18
I1
sg19
S'87'
p4727
sa(dp4728
g3
I6
sg4
I13
sg5
(lp4729
Vranitidine (Zantac)
p4730
aVomeprazole (Prilosec)
p4731
aVcimetidine (Tagamet)
p4732
aVsucralfate
p4733
asg11
S'may produce hyperplasia of enterochromaffin-like cells:'
p4734
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4735
sg15
S'Q87#8'
p4736
sg17
S'8'
sg18
I1
sg19
S'87'
p4737
sa(dp4738
g3
I7
sg4
I16
sg5
(lp4739
Vfamotidine (Pepcid)
p4740
aVterfenadine (Seldane)
p4741
aVnizatidine (Axid)
p4742
aVcimetidine (Tagamet)
p4743
asg11
S'NOT classified as an H-2 receptor blocker:'
p4744
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4745
sg15
S'Q87#9'
p4746
sg17
S'9'
sg18
I1
sg19
S'87'
p4747
sa(dp4748
g3
I13
sg4
I16
sg5
(lp4749
Vsucralfate (Carafate)
p4750
aVomeprazole (Prilosec)
p4751
aVfamotidine (Pepcid)
p4752
aVmisoprostol (Cytotec)
p4753
asg11
S'Most effective in treating Zollinger-Ellison syndrome (caused by gastrin secreting tumors)'
p4754
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4755
sg15
S'Q87#11'
p4756
sg17
S'11'
p4757
sg18
I1
sg19
S'87'
p4758
sa(dp4759
g3
I2
sg4
I15
sg5
(lp4760
Vviscous lidocaine
p4761
aVchlorpromazine (Thorazine)
p4762
aVbismuth subsalicylate
p4763
aVcholestyramine (Questran, Questran Light)
p4764
asg11
S'Centrally-acting anti-emetic:'
p4765
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4766
sg15
S'Q87#12'
p4767
sg17
S'12'
p4768
sg18
I1
sg19
S'87'
p4769
sa(dp4770
g3
I5
sg4
I16
sg5
(lp4771
Vfamotidine (Pepcid)
p4772
aVcimetidine (Tagamet)
p4773
aVomeprazole (Prilosec)
p4774
aVsucralfate (Carafate)
p4775
asg11
S'Reflux esophagitis responds best to:'
p4776
sg13
S'http://www.pharmacology2000.com/Gastrointestinal/questions2/GI1.htm'
p4777
sg15
S'Q87#14'
p4778
sg17
S'14'
p4779
sg18
I2
sg19
S'87'
p4780
sa(dp4781
g3
I8
sg4
I14
sg5
(lp4782
Vdiagnosis of adrenal function disorders
p4783
aVtreatment of adrenal function disorders
p4784
aVtreatment of inflammatory/immunologic disorders
p4785
asg11
S'Natural and synthetic corticosteroids are mainly used for:'
p4786
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question1/questionset1.htm'
p4787
sg15
S'Q88#1'
p4788
sg17
S'1'
sg18
I2
sg19
S'88'
p4789
sa(dp4790
g3
I7
sg4
I6
sg5
(lp4791
Vangiotensin release
p4792
aVrenin
p4793
aVcalcitonin
p4794
aVcorticotropin
p4795
aVvasopressin
p4796
asg11
S'Adrenocortical steroid secretion is mainly controlled by:'
p4797
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question1/questionset1.htm'
p4798
sg15
S'Q88#2'
p4799
sg17
S'2'
sg18
I3
sg19
S'88'
p4800
sa(dp4801
g3
I3
sg4
I29
sg5
(lp4802
Vgluconeogenesis in diabetics
p4803
aVdecreased amino acid uptake in the liver
p4804
aVdecreased amino acid uptake in the kidney
p4805
aVdecreased glycogen synthase activity in the liver
p4806
aVdecreased glucose production for protein
p4807
asg11
S'Glucocorticoid metabolic effects:'
p4808
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question1/questionset1.htm'
p4809
sg15
S'Q88#9'
p4810
sg17
S'9'
sg18
I0
sg19
S'88'
p4811
sa(dp4812
g3
I5
sg4
I17
sg5
(lp4813
Vtriamcinolone (Aristocort)
p4814
aVfluprednisolone
p4815
aVprednisolone (Prelone)
p4816
aVfludrocortisone (Florinef)
p4817
aVdexamethasone (Decadron)
p4818
asg11
S'Example of short-to medium-acting glucocorticoid'
p4819
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question1/questionset1.htm'
p4820
sg15
S'Q88#14'
p4821
sg17
S'14'
p4822
sg18
I2
sg19
S'88'
p4823
sa(dp4824
g3
I2
sg4
I12
sg5
(lp4825
Vcortisone
p4826
aVfluprednisolone
p4827
aVtriamcinolone (Aristocort)
p4828
aVbetamethasone (Celestone)
p4829
aVdesoxycorticosterone acetate
p4830
asg11
S'Long-acting glucocorticoid'
p4831
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question1/questionset1.htm'
p4832
sg15
S'Q88#15'
p4833
sg17
S'15'
p4834
sg18
I3
sg19
S'88'
p4835
sa(dp4836
g3
I9
sg4
I9
sg5
(lp4837
Vdexamethasone
p4838
aVtriamcinolone
p4839
aVdesoxycorticosterone acetate
p4840
aVhydrocortisone (cortisol)
p4841
aVfludrocortisone
p4842
asg11
S'Most appropriate mineralocorticoids following management of acute adrenocortical insufficiency:'
p4843
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question2/questionset2.htm'
p4844
sg15
S'Q89#2'
p4845
sg17
S'2'
sg18
I4
sg19
S'89'
p4846
sa(dp4847
g3
I3
sg4
I23
sg5
(lp4848
Vinfection -- especially in AIDS patients
p4849
aVidiopathic atrophy
p4850
aVcongenital adrenal hyperplasia
p4851
aVsuppression of hypothalamic-pituitary axis by endogenous steroid
p4852
aVmutation in ACTH receptor gene
p4853
asg11
S'Secondary adrenal insufficiency:'
p4854
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question2/questionset2.htm'
p4855
sg15
S'Q89#5'
p4856
sg17
S'5'
sg18
I3
sg19
S'89'
p4857
sa(dp4858
g3
I6
sg4
I8
sg5
(lp4859
Vhyperpigmentation
p4860
aVarteriole hypotension
p4861
aVasthenia
p4862
aVabnormal Gi function
p4863
aVhypoglycemia
p4864
asg11
S"Cardinal symptom of Addison's disease:"
p4865
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question2/questionset2.htm'
p4866
sg15
S'Q89#7'
p4867
sg17
S'7'
sg18
I2
sg19
S'89'
p4868
sa(dp4869
g3
I16
sg4
I5
sg5
(lp4870
Vcortisol
p4871
aVspironolactone
p4872
aVmitotane
p4873
aVmitoxantrone
p4874
aVaminoglutethimide
p4875
asg11
S"In Cushing's syndrome due to adrenal neoplasm:most common drug for treating adrenocortical carcinoma:"
p4876
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question2/questionset2.htm'
p4877
sg15
S'Q89#15'
p4878
sg17
S'15'
p4879
sg18
I2
sg19
S'89'
p4880
sa(dp4881
g3
I6
sg4
I3
sg5
(lp4882
VAddison\u005c
p4883
aVCushing\u005c
p4884
aVConn\u005c
p4885
asg11
S'Primary aldosteronism -- aldosterone-producing adrenal adenoma'
p4886
sg13
S'http://www.pharmacology2000.com/Adrenocorticosteroids/question2/questionset2.htm'
p4887
sg15
S'Q89#17'
p4888
sg17
S'17'
p4889
sg18
I2
sg19
S'89'
p4890
sa(dp4891
g3
I3
sg4
I21
sg5
(lp4892
Vmost often presents in adults
p4893
aVanabolic metabolic disorder
p4894
aVcirculating insulin is virtually absent
p4895
aVglucagon levels are low
p4896
aVketoacidosis is rarely seen
p4897
asg11
S'Type I diabetes:'
p4898
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4899
sg15
S'Q91#2'
p4900
sg17
S'2'
sg18
I2
sg19
S'91'
p4901
sa(dp4902
g3
I8
sg4
I20
sg5
(lp4903
Vabsence of endogenous insulin
p4904
aVtissue supersensitivity to insulin
p4905
aVmost patients are obese
p4906
aVhyper-responsiveness of pancreatic B cell-response to insulin
p4907
aVketoacidosis
p4908
asg11
S'Characteristic(s) of Type II diabetes'
p4909
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4910
sg15
S'Q91#6'
p4911
sg17
S'6'
sg18
I2
sg19
S'91'
p4912
sa(dp4913
g3
I9
sg4
I8
sg5
(lp4914
Valpha cells
p4915
aVbeta cells
p4916
aVdelta cells
p4917
aVF cells
p4918
asg11
S'Somatostatin -- secreted from this pancreatic islets cell type:'
p4919
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4920
sg15
S'Q91#7'
p4921
sg17
S'7'
sg18
I2
sg19
S'91'
p4922
sa(dp4923
g3
I8
sg4
I5
sg5
(lp4924
Vpotassium
p4925
aVsodium
p4926
aVcalcium
p4927
aVmagnesium
p4928
aVchloride
p4929
asg11
S'Ion influx mow strictly associated with insulin secretion:'
p4930
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4931
sg15
S'Q91#10'
p4932
sg17
S'10'
p4933
sg18
I2
sg19
S'91'
p4934
sa(dp4935
g3
I9
sg4
I17
sg5
(lp4936
Vliver and GI tract
p4937
aVkidney and pancreas
p4938
aVpancreas and liver
p4939
aVliver and kidney
p4940
aVGI tract and kidney
p4941
asg11
S'The two main organs that remove insulin from circulation:'
p4942
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4943
sg15
S'Q91#11'
p4944
sg17
S'11'
p4945
sg18
I3
sg19
S'91'
p4946
sa(dp4947
g3
I11
sg4
I6
sg5
(lp4948
Vliver
p4949
aVkidney
p4950
aVpancreas
p4951
aVGI tract
p4952
aVlung
p4953
asg11
S'Most of ENDOGENOUSLY secreted insulin is cleared from the blood by:'
p4954
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4955
sg15
S'Q91#12'
p4956
sg17
S'12'
p4957
sg18
I0
sg19
S'91'
p4958
sa(dp4959
g3
I11
sg4
I6
sg5
(lp4960
Vliver
p4961
aVkidney
p4962
aVGI tract
p4963
aVpancreas
p4964
aVlung
p4965
asg11
S'Most of EXOGENOUSLY administered insulin is cleared from the blood by:'
p4966
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4967
sg15
S'Q91#13'
p4968
sg17
S'13'
p4969
sg18
I1
sg19
S'91'
p4970
sa(dp4971
g3
I12
sg4
I6
sg5
(lp4972
VGLUT-1
p4973
aVGLUT-2
p4974
aVGLUT-3
p4975
aVGLUT 4
p4976
aVGLUT-5
p4977
asg11
S'Glucose transporter is most important to in terms of lowering blood glucose:'
p4978
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4979
sg15
S'Q91#14'
p4980
sg17
S'14'
p4981
sg18
I3
sg19
S'91'
p4982
sa(dp4983
g3
I7
sg4
I9
sg5
(lp4984
Vpyruvate carboxylase
p4985
aVglucose 6-phosphatase
p4986
aVglucokinase
p4987
aVfructose bisphosphatase
p4988
aVphosphoenolpyruvate carboxykinase
p4989
asg11
S'Postprandial insulin release induces phosphorylations which activate:'
p4990
sg13
S'http://www.pharmacology2000.com/Diabetes/question1/questionset1.htm'
p4991
sg15
S'Q91#15'
p4992
sg17
S'15'
p4993
sg18
I2
sg19
S'91'
p4994
sa(dp4995
g3
I5
sg4
I5
sg5
(lp4996
Vlipodystrophies
p4997
aVhypotension
p4998
aVgallstones
p4999
aVhypoglycemia
p5000
aVretinopathy
p5001
asg11
S'Most common complication insulin therapy:'
p5002
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5003
sg15
S'Q93#0'
p5004
sg17
S'0'
sg18
I3
sg19
S'93'
p5005
sa(dp5006
g3
I6
sg4
I12
sg5
(lp5007
Vmuscarinic receptor
p5008
aVcalcium channel
p5009
aVpotassium channel
p5010
aVbeta adrenergic receptor
p5011
aValpha adrenergic receptor
p5012
asg11
S'Sulfonylurea hypoglycemic drug:receptor sites'
p5013
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5014
sg15
S'Q93#8'
p5015
sg17
S'8'
sg18
I2
sg19
S'93'
p5016
sa(dp5017
g3
I3
sg4
I17
sg5
(lp5018
Vchlorpropamide (Diabinese)
p5019
aVtolazamide (Tolinase)
p5020
aVacetohexamide
p5021
aVglipizide (Glucotrol)
p5022
aVTolbutamide (Orinase)
p5023
asg11
S'Second generation sulfonylurea:'
p5024
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5025
sg15
S'Q93#10'
p5026
sg17
S'10'
p5027
sg18
I3
sg19
S'93'
p5028
sa(dp5029
g3
I14
sg4
I22
sg5
(lp5030
Vchlorpropamide (Diabinese)
p5031
aVglyburide (Micronase, DiaBeta)
p5032
aVglipizide (Glucotrol)
p5033
aVglimepiride (Amaryl)
p5034
aVmetformin (Glucophage)
p5035
asg11
S'Second-generation sulfonylurea approved for once-daily use as monotherapy in management of Type II diabetes:'
p5036
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5037
sg15
S'Q93#11'
p5038
sg17
S'11'
p5039
sg18
I3
sg19
S'93'
p5040
sa(dp5041
g3
I21
sg4
I19
sg5
(lp5042
Vacetohexamide
p5043
aVchlorpropamide (Diabinese)
p5044
aVglyburide (Micronase, DiaBeta)
p5045
aVmetformin (Glucophage)
p5046
aVTolbutamide (Orinase)
p5047
asg11
S'Oral hypoglycemic agent most likely to be prescribed for patients with refractory obesity and who exhibit insulin resistance syndrome: in'
p5048
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5049
sg15
S'Q93#12'
p5050
sg17
S'12'
p5051
sg18
I3
sg19
S'93'
p5052
sa(dp5053
g3
I3
sg4
I20
sg5
(lp5054
Vmetformin (Glucophage)
p5055
aVacetazolamide (Diamox)
p5056
aVTolbutamide (Orinase)
p5057
aVacarbose (Precose)
p5058
aVtroglitazone (Rezulin)
p5059
asg11
S'Aldose reductase inhibitor:'
p5060
sg13
S'http://www.pharmacology2000.com/Diabetes/question3/questionset3.htm'
p5061
sg15
S'Q93#13'
p5062
sg17
S'13'
p5063
sg18
I3
sg19
S'93'
p5064
sa(dp5065
g3
I5
sg4
I17
sg5
(lp5066
Vtypically adult onset
p5067
aVlow plasma glucagon
p5068
aVinsulin nearly absent
p5069
aVpancreatic B cell is responsive to insulinogenic stimuli
p5070
asg11
S'Characteristics of Type I diabetes:'
p5071
sg13
S'http://www.pharmacology2000.com/Diabetes/question4/questionset4.htm'
p5072
sg15
S'Q94#4'
p5073
sg17
S'4'
sg18
I2
sg19
S'94'
p5074
sa(dp5075
g3
I4
sg4
I10
sg5
(lp5076
Vusually developed ketoacidosis
p5077
aVexhibits volume excess
p5078
aVCNS symptoms
p5079
aVexhibits hypo-osmolality
p5080
asg11
S'Clinical presentation: NIDDM'
p5081
sg13
S'http://www.pharmacology2000.com/Diabetes/question4/questionset4.htm'
p5082
sg15
S'Q94#13'
p5083
sg17
S'13'
p5084
sg18
I2
sg19
S'94'
p5085
sa(dp5086
g3
I5
sg4
I9
sg5
(lp5087
Vweight reduction
p5088
aVdiet
p5089
aVinsulin
p5090
aVsulfonylurea drugs
p5091
aVall the both
p5092
asg11
S'Type II diabetes treatment --'
p5093
sg13
S'http://www.pharmacology2000.com/Diabetes/question4/questionset4.htm'
p5094
sg15
S'Q94#16'
p5095
sg17
S'16'
p5096
sg18
I4
sg19
S'94'
p5097
sa(dp5098
g3
I6
sg4
I9
sg5
(lp5099
Vexcessive appetite
p5100
aVtachycardia, palpitations -- sympathetic overactivity
p5101
aVhypoglycemia
p5102
asg11
S'Most common complication of insulin treatment'
p5103
sg13
S'http://www.pharmacology2000.com/Diabetes/question4/questionset4.htm'
p5104
sg15
S'Q94#19'
p5105
sg17
S'19'
p5106
sg18
I2
sg19
S'94'
p5107
sa(dp5108
g3
I11
sg4
I12
sg5
(lp5109
Vthyroxine
p5110
aVtriiodothyronine
p5111
aVboth equally absorbed
p5112
aVneither absorbed orally, requires parenteral administration
p5113
asg11
S'Thyroid hormone more likely to be completely absorbed following oral administration:'
p5114
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5115
sg15
S'Q95#0'
p5116
sg17
S'0'
sg18
I1
sg19
S'95'
p5117
sa(dp5118
g3
I9
sg4
I4
sg5
(lp5119
Vincreased
p5120
aVdecreased
p5121
aVno change
p5122
asg11
S'Effective hyperthyroidism on thyroxine (T4) metabolic clearance:'
p5123
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5124
sg15
S'Q95#1'
p5125
sg17
S'1'
sg18
I0
sg19
S'95'
p5126
sa(dp5127
g3
I4
sg4
I6
sg5
(lp5128
Vrifampin
p5129
aViopanoic acid
p5130
aVdopamine
p5131
aVcholestyramine
p5132
aVsalicylates
p5133
asg11
S"Associated with 5'-deiodinase inhibition:"
p5134
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5135
sg15
S'Q95#5'
p5136
sg17
S'5'
sg18
I1
sg19
S'95'
p5137
sa(dp5138
g3
I9
sg4
I6
sg5
(lp5139
Vandrogens
p5140
aVcolestipol
p5141
aVinterleukin 2
p5142
aVamiodarone
p5143
aVestrogens
p5144
asg11
S'Associated with increased TBG (thyroxine-binding globulin):'
p5145
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5146
sg15
S'Q95#6'
p5147
sg17
S'6'
sg18
I4
sg19
S'95'
p5148
sa(dp5149
g3
I4
sg4
I4
sg5
(lp5150
VT4
p5151
aVT3
p5152
aVequal potent
p5153
asg11
S'More potent thyroid hormone:'
p5154
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5155
sg15
S'Q95#14'
p5156
sg17
S'14'
p5157
sg18
I1
sg19
S'95'
p5158
sa(dp5159
g3
I7
sg4
I6
sg5
(lp5160
Vdessicated thyroid
p5161
aVliothyronine
p5162
aVlevothyroxine
p5163
aVpropylthiouracil
p5164
aVmethimazole
p5165
asg11
S'Preparation of choice for thyroid replacement.'
p5166
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5167
sg15
S'Q95#16'
p5168
sg17
S'16'
p5169
sg18
I2
sg19
S'95'
p5170
sa(dp5171
g3
I30
sg4
I6
sg5
(lp5172
Vmethimazole
p5173
aVpropylthiouracil
p5174
aViopanoic acid
p5175
aVperchlorate
p5176
aVliothyronine
p5177
asg11
S'Inhibits conversion T4 to T3 in the liver, kidney, pituitary gland, brain;may be useful in treating hyperthyroidism; routinely used as a radiographic contrast agent'
p5178
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5179
sg15
S'Q95#17'
p5180
sg17
S'17'
p5181
sg18
I2
sg19
S'95'
p5182
sa(dp5183
g3
I8
sg4
I6
sg5
(lp5184
Vmethimazole
p5185
aVpropylthiouracil
p5186
aVboth are equally likely
p5187
asg11
S'Thioamide less likely to cross the placental barrier:'
p5188
sg13
S'http://www.pharmacology2000.com/Thyroid/question3/questionset3.htm'
p5189
sg15
S'Q95#18'
p5190
sg17
S'18'
p5191
sg18
I1
sg19
S'95'
p5192
sa(dp5193
g3
I12
sg4
I21
sg5
(lp5194
Vmaturation of neural centers (e.g.,amygdala)
p5195
aVmaturation of the gonad
p5196
aVresponsiveness of the pituitary to hypothalamic gonadotropin-releasing hormones
p5197
asg11
S'Mechanism responsible for onset of ovarian function of the time of puberty:'
p5198
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5199
sg15
S'Q96#0'
p5200
sg17
S'0'
sg18
I0
sg19
S'96'
p5201
sa(dp5202
g3
I14
sg4
I27
sg5
(lp5203
Vhuman menopausal gonadotropin (hMG)
p5204
aVfollicle-stimulating hormone (FSH)
p5205
aVadrenocorticotropic hormone (ACTH)
p5206
aVsex hormone-binding globulin (SHBG)
p5207
aVdehydroepiandrosterone (DAG a)
p5208
asg11
S'At the beginning of each cycle, some vesicular follicles enlarge in response to:'
p5209
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5210
sg15
S'Q96#2'
p5211
sg17
S'2'
sg18
I1
sg19
S'96'
p5212
sa(dp5213
g3
I24
sg4
I14
sg5
(lp5214
Vsex hormone-binding globulin
p5215
aVluteinizing hormone
p5216
aVfollicle-stimulating hormone
p5217
aVcorticosteroid-binding globulin (transcortin)
p5218
aVaspartate aminotransferase
p5219
asg11
S'Granulosa cells in the one of several vesicular follicles that begins to develop more rapidly than the others do so under the influence of:'
p5220
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5221
sg15
S'Q96#3'
p5222
sg17
S'3'
sg18
I1
sg19
S'96'
p5223
sa(dp5224
g3
I5
sg4
I8
sg5
(lp5225
Vearly cycle
p5226
aVjust before midcycle
p5227
aVlate in cycle
p5228
asg11
S'Peak time of estrogen secretion:'
p5229
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5230
sg15
S'Q96#6'
p5231
sg17
S'6'
sg18
I1
sg19
S'96'
p5232
sa(dp5233
g3
I7
sg4
I5
sg5
(lp5234
Vpregnant mare
p5235
aVstallion
p5236
aVpregnant woman
p5237
asg11
S'Most prolific natural source of estrogenic substances:'
p5238
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5239
sg15
S'Q96#11'
p5240
sg17
S'11'
p5241
sg18
I1
sg19
S'96'
p5242
sa(dp5243
g3
I5
sg4
I5
sg5
(lp5244
Vestriol
p5245
aVandrostenedione
p5246
aVprogesterone
p5247
aVdehydroepiandrosterone
p5248
aVpregnenolone
p5249
asg11
S'Immediate estrone and testosterone precursor:'
p5250
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5251
sg15
S'Q96#13'
p5252
sg17
S'13'
p5253
sg18
I1
sg19
S'96'
p5254
sa(dp5255
g3
I10
sg4
I6
sg5
(lp5256
Vdiethylstilbestrol
p5257
aVestrone
p5258
aVestradiol
p5259
aVethinyl estradiol
p5260
aVmethallenestril
p5261
asg11
S'Example of a steroidal, synthetic compound with estrogenic activity'
p5262
sg13
S'http://www.pharmacology2000.com/Gonadal/question1/questionset1.htm'
p5263
sg15
S'Q96#14'
p5264
sg17
S'14'
p5265
sg18
I3
sg19
S'96'
p5266
sa(dp5267
g3
I8
sg4
I6
sg5
(lp5268
Vprogesterone
p5269
aVandrostenedione
p5270
aVethinyl estradiol
p5271
aVestriol
p5272
aVestrone
p5273
asg11
S'Useful for initiation of treatment of primary hypogonadism:'
p5274
sg13
S'http://www.pharmacology2000.com/Gonadal/question2/questionset2.htm'
p5275
sg15
S'Q97#0'
p5276
sg17
S'0'
sg18
I2
sg19
S'97'
p5277
sa(dp5278
g3
I6
sg4
I22
sg5
(lp5279
Vdecrease in plasma cholesterol
p5280
aVdecrease in LDL receptors
p5281
aVincrease in LDL serum levels
p5282
aVsignificant increase in HDL
p5283
aVsignificant increase in triglyceride levels
p5284
asg11
S'Lipid profile/receptor changes associated with oophorectomy:'
p5285
sg13
S'http://www.pharmacology2000.com/Gonadal/question2/questionset2.htm'
p5286
sg15
S'Q97#2'
p5287
sg17
S'2'
sg18
I2
sg19
S'97'
p5288
sa(dp5289
g3
I7
sg4
I6
sg5
(lp5290
Vestradiol
p5291
aVethinyl estradiol
p5292
aVdiethylstilbestrol
p5293
aVquinestrol
p5294
aVestriol
p5295
asg11
S'Nonsteroidal, synthetic agent with estrogenic activity:'
p5296
sg13
S'http://www.pharmacology2000.com/Gonadal/question2/questionset2.htm'
p5297
sg15
S'Q97#5'
p5298
sg17
S'5'
sg18
I2
sg19
S'97'
p5299
sa(dp5300
g3
I6
sg4
I17
sg5
(lp5301
Vdramatically increases protein metabolism
p5302
aVinhibits lipoproteins lipase
p5303
aVfavor fat deposition
p5304
aVblunts insulin response to glucose
p5305
aVinhibits ketogenesis
p5306
asg11
S'Progesterone effect(s):'
p5307
sg13
S'http://www.pharmacology2000.com/Gonadal/question2/questionset2.htm'
p5308
sg15
S'Q97#10'
p5309
sg17
S'10'
p5310
sg18
I2
sg19
S'97'
p5311
sa(dp5312
g3
I4
sg4
I6
sg5
(lp5313
Vdesogestrel
p5314
aVdimethisterone
p5315
aVprogesterone
p5316
aVmegestrol acetate
p5317
aVhydroxyprogesterone
p5318
asg11
S'Most important human progestin:'
p5319
sg13
S'http://www.pharmacology2000.com/Gonadal/question2/questionset2.htm'
p5320
sg15
S'Q97#13'
p5321
sg17
S'13'
p5322
sg18
I2
sg19
S'97'
p5323
sa(dp5324
g3
I11
sg4
I15
sg5
(lp5325
Vdanazol (Donocrine)
p5326
aVMedroxyprogesterone acetate
p5327
aVclomiphene (Clomid)
p5328
aVL-Norgestrel
p5329
aVtamoxifen (Nolvadex)
p5330
asg11
S'Primarily used to promote ovulation in patients wishing to become pregnant:'
p5331
sg13
S'http://www.pharmacology2000.com/Gonadal/question3/questionset3.htm'
p5332
sg15
S'Q98#0'
p5333
sg17
S'0'
sg18
I2
sg19
S'98'
p5334
sa(dp5335
g3
I9
sg4
I8
sg5
(lp5336
Vbreakthrough bleeding
p5337
aVchanges in serum  proteins
p5338
aVgastrointestinal disorders
p5339
asg11
S'Considered a severe adverse effect associated with contraceptive agents:'
p5340
sg13
S'http://www.pharmacology2000.com/Gonadal/question3/questionset3.htm'
p5341
sg15
S'Q98#1'
p5342
sg17
S'1'
sg18
I2
sg19
S'98'
p5343
sa(dp5344
g3
I19
sg4
I8
sg5
(lp5345
Vketoconazole (Nizoral)
p5346
aVmethyltestosterone
p5347
aVleuprolide acetate
p5348
aVstanozolol
p5349
asg11
S'Used for treating advanced prostatic carcinoma; works by producing continuous gonadal suppression; is a gonadotropin-releasing hormone analog'
p5350
sg13
S'http://www.pharmacology2000.com/Gonadal/question5/questionset5.htm'
p5351
sg15
S'Q100#1'
p5352
sg17
S'1'
sg18
I2
sg19
S'100'
p5353
sa(dp5354
g3
I3
sg4
I9
sg5
(lp5355
Vtestosterone propionate
p5356
aVtestosterone
p5357
aVtestosterone enanthate
p5358
aVtestosterone undecanoate
p5359
aVtestosterone cypionate
p5360
asg11
S'Most rapidly absorbed:'
p5361
sg13
S'http://www.pharmacology2000.com/Gonadal/question5/questionset5.htm'
p5362
sg15
S'Q100#2'
p5363
sg17
S'2'
sg18
I1
sg19
S'100'
p5364
sa(dp5365
g3
I6
sg4
I16
sg5
(lp5366
Vdanazol (Donocrine)
p5367
aVclomiphene (Clomid)
p5368
aVanastrozole (Arimidex)
p5369
aVnorethindrone (Aygestin)
p5370
asg11
S'Aromatase inhibitor -- selective nonsteroidal form'
p5371
sg13
S'http://www.pharmacology2000.com/Gonadal/question5/questionset5.htm'
p5372
sg15
S'Q100#5'
p5373
sg17
S'5'
sg18
I2
sg19
S'100'
p5374
sa(dp5375
g3
I7
sg4
I18
sg5
(lp5376
Vincreases corticosteroid-binding globulin
p5377
aVincreases plasma renin activity
p5378
aVincreases aldosterone secretion
p5379
aVincreases ACTH response to metyrapone
p5380
aVincreases thyroxine levels
p5381
asg11
S'Oral contraceptive effects on endocrine function except:'
p5382
sg13
S'http://www.pharmacology2000.com/Gonadal/question5/questionset5.htm'
p5383
sg15
S'Q100#7'
p5384
sg17
S'7'
sg18
I3
sg19
S'100'
p5385
sa(dp5386
g3
I10
sg4
I5
sg5
(lp5387
Vandrostenedione
p5388
aVdehydroepiandrosterone
p5389
aVdehydroepiandrosterone sulfate
p5390
aVtestosterone
p5391
asg11
S'Most likely to be produced in quantity in the testes:'
p5392
sg13
S'http://www.pharmacology2000.com/Gonadal/question5/questionset5.htm'
p5393
sg15
S'Q100#8'
p5394
sg17
S'8'
sg18
I3
sg19
S'100'
p5395
sa(dp5396
g3
I9
sg4
I6
sg5
(lp5397
Vliver
p5398
aVadrenal cortex
p5399
aVthyroid
p5400
aVgonads
p5401
aVbreast
p5402
asg11
S'Primary target organ for adrenocorticotropin (ACTH):'
p5403
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question1/questionset1.htm'
p5404
sg15
S'Q101#1'
p5405
sg17
S'1'
sg18
I1
sg19
S'101'
p5406
sa(dp5407
g3
I6
sg4
I6
sg5
(lp5408
Vliver
p5409
aVadrenal cortex
p5410
aVthyroid
p5411
aVgonads
p5412
aVbreast
p5413
asg11
S'Primary target organ for leutinizing hormone:'
p5414
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question1/questionset1.htm'
p5415
sg15
S'Q101#2'
p5416
sg17
S'2'
sg18
I3
sg19
S'101'
p5417
sa(dp5418
g3
I8
sg4
I17
sg5
(lp5419
Vgrowth hormone releasing hormone
p5420
aVcorticotropin-releasing hormone
p5421
aVdopamine
p5422
aVgonadotropin-releasing hormone
p5423
aVsomatotropin release-inhibiting hormone (somatostatin, SRIH)
p5424
asg11
S'Hypothalamic hormone linked to the pituitary hormone prolactin'
p5425
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question1/questionset1.htm'
p5426
sg15
S'Q101#3'
p5427
sg17
S'3'
sg18
I2
sg19
S'101'
p5428
sa(dp5429
g3
I8
sg4
I18
sg5
(lp5430
Vcraniopharyngiomas and other hypophyseal-pituitary region disease
p5431
aVlack of hypothalamic growth hormone-releasing factors
p5432
aVhigh-level of serum growth hormone antibodies
p5433
asg11
S'Most common cause of congenital growth hormone deficiency:'
p5434
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question1/questionset1.htm'
p5435
sg15
S'Q101#8'
p5436
sg17
S'8'
sg18
I1
sg19
S'101'
p5437
sa(dp5438
g3
I12
sg4
I26
sg5
(lp5439
Vactivation of thyroid cell  IP3 system
p5440
aVactivation of guanylyl cyclase system
p5441
aVactivation of adenylyl cyclase system
p5442
aVblockade of beta adrenergic receptors
p5443
aVthrough alpha adrenergic receptor antagonism
p5444
asg11
S'Mechanism of thyrotropin action -- results in ultimately increased thyroid hormone production:'
p5445
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question2/questionset2.htm'
p5446
sg15
S'Q102#6'
p5447
sg17
S'6'
sg18
I2
sg19
S'102'
p5448
sa(dp5449
g3
I7
sg4
I7
sg5
(lp5450
Vliver
p5451
aVkidney
p5452
aVexcreted unchanged; no degradation
p5453
asg11
S'Primary thyrotropin (TSH) degradation site:'
p5454
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question2/questionset2.htm'
p5455
sg15
S'Q102#7'
p5456
sg17
S'7'
sg18
I1
sg19
S'102'
p5457
sa(dp5458
g3
I9
sg4
I4
sg5
(lp5459
VTRH
p5460
aVTSH
p5461
aVCRH
p5462
aVadrenocorticotropin
p5463
asg11
S'Hypothalamic hormone causing pituitary release of beta-endorphins and ACTH:'
p5464
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question2/questionset2.htm'
p5465
sg15
S'Q102#8'
p5466
sg17
S'8'
sg18
I2
sg19
S'102'
p5467
sa(dp5468
g3
I5
sg4
I10
sg5
(lp5469
Vcholesterol esterases activity
p5470
aVreduced mineralocorticoid production
p5471
aVadrenal atrophy
p5472
aVskin depigmentation
p5473
asg11
S'ACTH adrenocortical stimulation results in:'
p5474
sg13
S'http://www.pharmacology2000.com/Hypothalamic/question2/questionset2.htm'
p5475
sg15
S'Q102#9'
p5476
sg17
S'9'
sg18
I0
sg19
S'102'
p5477
sa(dp5478
g3
I9
sg4
I16
sg5
(lp5479
Vcyclophosphamide (Cytoxan)
p5480
aVbusulfan (Myleran)
p5481
aVthiopeta (Thioplex)
p5482
aVdacarbazine (DTIC)
p5483
asg11
S'Polyfunctional alkylating agent used specifically for chronic myeloid leukemia:'
p5484
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5485
sg15
S'Q104#2'
p5486
sg17
S'2'
sg18
I1
sg19
S'104'
p5487
sa(dp5488
g3
I5
sg4
I6
sg5
(lp5489
Valopecia
p5490
aVmyelosuppression
p5491
aVrenal damage
p5492
aVhepatic failure
p5493
asg11
S'Major toxicity of alkylating drugs:'
p5494
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5495
sg15
S'Q104#3'
p5496
sg17
S'3'
sg18
I1
sg19
S'104'
p5497
sa(dp5498
g3
I6
sg4
I18
sg5
(lp5499
Vmelphalan (Alkeran)
p5500
aVcyclophosphamide (Cytoxan)
p5501
aVlomustine (CCNU,CeeNU)
p5502
aVthiopeta (Thioplex)
p5503
asg11
S'Most useful alkylating drug currently available:'
p5504
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5505
sg15
S'Q104#4'
p5506
sg17
S'4'
sg18
I1
sg19
S'104'
p5507
sa(dp5508
g3
I15
sg4
I20
sg5
(lp5509
Vlomustine (CCNU,CeeNU)
p5510
aVcarmustine (BNCU,BiCNU)
p5511
aVstreptozocin (Zanosar)
p5512
aVprocarbazine (Matulane)
p5513
asg11
S'Nitrosourea with minimal bone-marrow suppression and effective in treating pancreatic, islet cell carcinoma.'
p5514
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5515
sg15
S'Q104#7'
p5516
sg17
S'7'
sg18
I2
sg19
S'104'
p5517
sa(dp5518
g3
I16
sg4
I13
sg5
(lp5519
Valtretamine (Hexalen)
p5520
aVcisplatin (Platinol)
p5521
aVprocarbazine (Matulane)
p5522
aVmethotrexate
p5523
asg11
S'Used in combination with vinblastine and bleomycin: a major advance in treating nonseminomatous testicular cancer:'
p5524
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5525
sg15
S'Q104#8'
p5526
sg17
S'8'
sg18
I1
sg19
S'104'
p5527
sa(dp5528
g3
I12
sg4
I15
sg5
(lp5529
Vmercaptomurine (6-MP)
p5530
aVmethotrexate
p5531
aVprocarbazine (Matulane)
p5532
aVallopurinol (Zyloprim, Purinol)
p5533
asg11
S'Anticancer drug that is also used to treat psoriasis and rheumatoid arthritis:'
p5534
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5535
sg15
S'Q104#10'
p5536
sg17
S'10'
p5537
sg18
I1
sg19
S'104'
p5538
sa(dp5539
g3
I13
sg4
I10
sg5
(lp5540
V6-thioguanine
p5541
aVflurouracil (5-FU)
p5542
aV6-mercaptopurine
p5543
aVazatadine (Optimine)
p5544
asg11
S'Combination of allopurinol with this anticancer drug can cause an increase in toxicity:'
p5545
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5546
sg15
S'Q104#11'
p5547
sg17
S'11'
p5548
sg18
I2
sg19
S'104'
p5549
sa(dp5550
g3
I6
sg4
I13
sg5
(lp5551
Vmethotrexate
p5552
aVcladribine (Leustatin)
p5553
aVvinblastine (Velban) 
p5554
aVcytarabine (ara-C)
p5555
asg11
S'Recommended for treating hairy cell leukemia'
p5556
sg13
S'http://www.pharmacology2000.com/Anticancer/questions1/antic1.htm'
p5557
sg15
S'Q104#12'
p5558
sg17
S'12'
p5559
sg18
I1
sg19
S'104'
p5560
sa(dp5561
g3
I11
sg4
I13
sg5
(lp5562
Valtretamine (Hexalen)
p5563
aVcisplatin (Platinol)
p5564
aVmethotrexate
p5565
aVfludarabine (Fludara)
p5566
asg11
S'Folic acid antagonist: binds to catalytic site of dihydrofolate reductase-'
p5567
sg13
S'http://www.pharmacology2000.com/Anticancer/questions2/antic2.htm'
p5568
sg15
S'Q105#0'
p5569
sg17
S'0'
sg18
I2
sg19
S'105'
p5570
sa(dp5571
g3
I17
sg4
I24
sg5
(lp5572
Vincreased levels of dihydrofolate reductase (DHFR)
p5573
aVincreased drug efflux from the cells by increased active transport
p5574
aVdecreased HGPRT activity
p5575
aVdecreased polyglutamate formation
p5576
asg11
S'Most common mechanism of resistance to both 6-MP (6-mercaptopurine) and 6-TG (6-thioguanine):'
p5577
sg13
S'http://www.pharmacology2000.com/Anticancer/questions2/antic2.htm'
p5578
sg15
S'Q105#2'
p5579
sg17
S'2'
sg18
I2
sg19
S'105'
p5580
sa(dp5581
g3
I22
sg4
I16
sg5
(lp5582
Vcytarabine (ARA-C)
p5583
aVvinblastine (Velban)
p5584
aVfluorouracil (5-FU)
p5585
aVcladribine (Leustatin)
p5586
asg11
S'This pyrimidine analog is used systemically to treat adenocarcinomas, topically for skin cancer and works through inhibition of DNA synthesis.'
p5587
sg13
S'http://www.pharmacology2000.com/Anticancer/questions2/antic2.htm'
p5588
sg15
S'Q105#3'
p5589
sg17
S'3'
sg18
I2
sg19
S'105'
p5590
sa(dp5591
g3
I4
sg4
I13
sg5
(lp5592
Vbusulfan (Myleran)
p5593
aVmercaptopurine (Purinethol)
p5594
aVmethotrexate
p5595
aVdaunorubicin (DaunoXome)
p5596
asg11
S' Leucovorin "rescue"'
p5597
sg13
S'http://www.pharmacology2000.com/Anticancer/questions2/antic2.htm'
p5598
sg15
S'Q105#4'
p5599
sg17
S'4'
sg18
I2
sg19
S'105'
p5600
sa(dp5601
g3
I13
sg4
I13
sg5
(lp5602
Vthioguanine
p5603
aVmercaptopurine (Purinethol)
p5604
aVcytarabine (ARA-C)
p5605
aVfludarabine (Fludara)
p5606
asg11
S'Administrate of this drug concurrently with allopurinol can result in excessive toxicity;'
p5607
sg13
S'http://www.pharmacology2000.com/Anticancer/questions2/antic2.htm'
p5608
sg15
S'Q105#5'
p5609
sg17
S'5'
sg18
I1
sg19
S'105'
p5610
sa(dp5611
g3
I8
sg4
I13
sg5
(lp5612
Vazatadine (Optimine)
p5613
aVvinblastine (Velban)
p5614
aVcladribine (Leustatin)
p5615
aVmethotrexate
p5616
asg11
S'Anticancer agent that works by depolymerization of microtubules:'
p5617
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5618
sg15
S'Q106#0'
p5619
sg17
S'0'
sg18
I1
sg19
S'106'
p5620
sa(dp5621
g3
I15
sg4
I16
sg5
(lp5622
Vtopotecan (Hycamtin)
p5623
aVvincristine (Oncovin)
p5624
aVvinblastine (Velban)
p5625
aVprednisone (Deltasone)
p5626
asg11
S'Administration of this plant alkaloid anticancer agent is associated with significant incidence of neurotoxicity.'
p5627
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5628
sg15
S'Q106#1'
p5629
sg17
S'1'
sg18
I1
sg19
S'106'
p5630
sa(dp5631
g3
I19
sg4
I18
sg5
(lp5632
Vvincristine (Oncovin) 
p5633
aVpaclitaxel (Taxol)
p5634
aVirinotecan (Camptosar)
p5635
aVetoposide (VP-16,VePe-sid)
p5636
asg11
S'Derivative from the Western Yew and European Yew tree, this anticancer drug acts by enhacing tubulin polymerization.'
p5637
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5638
sg15
S'Q106#2'
p5639
sg17
S'2'
sg18
I1
sg19
S'106'
p5640
sa(dp5641
g3
I26
sg4
I16
sg5
(lp5642
Vvincristine (Oncovin)
p5643
aVtopotecan (Hycamtin)
p5644
aVdoxorubicin (Adriamycin)
p5645
aVmitomycin (Mutamycin)
p5646
asg11
S"May be useful in control of metastatic ovarian cancer, this topoisomerase I inhibitor's dose-limiting adverse effects include: neutropenia, thromobcytopenia and anemia."
p5647
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5648
sg15
S'Q106#3'
p5649
sg17
S'3'
sg18
I1
sg19
S'106'
p5650
sa(dp5651
g3
I27
sg4
I18
sg5
(lp5652
Vvincristine (Oncovin)
p5653
aVpaclitaxel (Taxol)
p5654
aVtopotecan (Hycamtin)
p5655
aVetoposide (VP-16,VePe-sid)
p5656
asg11
S'Active in late S-G2 phase of the cell cycle, the mechanism of this semisynthetic derivative of podophyllotoxin anticancer drug is through inhibition of topoisomerase II.'
p5657
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5658
sg15
S'Q106#4'
p5659
sg17
S'4'
sg18
I3
sg19
S'106'
p5660
sa(dp5661
g3
I34
sg4
I16
sg5
(lp5662
Vvincristine (Oncovin)
p5663
aVirinotecan (Camptosar)
p5664
aVpaclitaxel (Taxol)
p5665
aVdocetaxel (Taxotere)
p5666
asg11
S'A patient with fluorouracil-nonresponsive colon cancer is given this prodrug which following activation is a topoisomerase I inhibitor. Following administration, the patient experiences very severe diarrhea which causes hypovolemia. This drug probably was:'
p5667
sg13
S'http://www.pharmacology2000.com/Anticancer/questions3/antic3.htm'
p5668
sg15
S'Q106#5'
p5669
sg17
S'5'
sg18
I1
sg19
S'106'
p5670
sa(dp5671
g3
I16
sg4
I16
sg5
(lp5672
Vdactinomycin  (Cosmegen)
p5673
aVbleomycin (Blenoxane)
p5674
aVdaunorubicin (DaunoXome)
p5675
aVdoxorubicin (Adriamycin)
p5676
asg11
S'Major clinical use of this antracycline anticancer, antibiotic is in treatment of acute leukemia.'
p5677
sg13
S'http://www.pharmacology2000.com/Anticancer/questions4/antic4.htm'
p5678
sg15
S'Q107#1'
p5679
sg17
S'1'
sg18
I2
sg19
S'107'
p5680
sa(dp5681
g3
I7
sg4
I16
sg5
(lp5682
Vplicamycin (Mithramycin)
p5683
aVdactinomycin  (Cosmegen)
p5684
aVdoxorubicin (Adriamycin)
p5685
aVbleomycin (Blenoxane)
p5686
asg11
S'Among anticancer antibiotics: most toxic--'
p5687
sg13
S'http://www.pharmacology2000.com/Anticancer/questions4/antic4.htm'
p5688
sg15
S'Q107#2'
p5689
sg17
S'2'
sg18
I2
sg19
S'107'
p5690
sa(dp5691
g3
I20
sg4
I16
sg5
(lp5692
Vdoxorubicin (Adriamycin)
p5693
aVmitomycin (Mutamycin)
p5694
aVvincristine (Oncovin)
p5695
aVplicamycin (Mithramycin)
p5696
asg11
S'Antibiotic anticancer drug that is bioactivated to an alkylating agent. Hypoxic solid tumor stem cells may be most susceptible.'
p5697
sg13
S'http://www.pharmacology2000.com/Anticancer/questions4/antic4.htm'
p5698
sg15
S'Q107#3'
p5699
sg17
S'3'
sg18
I1
sg19
S'107'
p5700
sa(dp5701
g3
I29
sg4
I16
sg5
(lp5702
Vplicamycin (Mithramycin)
p5703
aVidarubicin (Idamycin)
p5704
aVbleomycin (Blenoxane)
p5705
aVpaclitaxel (Taxol)
p5706
asg11
S'Anthracycline analog useful in treating acute myeloid leukemia; In combination with cytarabine (ARA-C), it can produce complete remissions in patients with acute myelogenous leukemia.'
p5707
sg13
S'http://www.pharmacology2000.com/Anticancer/questions4/antic4.htm'
p5708
sg15
S'Q107#4'
p5709
sg17
S'4'
sg18
I1
sg19
S'107'
p5710
sa(dp5711
g3
I18
sg4
I16
sg5
(lp5712
Vdactinomycin  (Cosmegen)
p5713
aVdoxorubicin (Adriamycin)
p5714
aVbleomycin (Blenoxane)
p5715
aVplicamycin (Mithramycin)
p5716
asg11
S'Anticancer drug: acts on osteoclasts to decrease serum calcium levels (independent of its antitumor action)'
p5717
sg13
S'http://www.pharmacology2000.com/Anticancer/questions4/antic4.htm'
p5718
sg15
S'Q107#5'
p5719
sg17
S'5'
sg18
I3
sg19
S'107'
p5720
sa(dp5721
g3
I8
sg4
I10
sg5
(lp5722
V5%
p5723
aV15%
p5724
aV25%
p5725
aV50%
p5726
aV75%
p5727
asg11
S'Cure rate for cancer (1998):'
p5728
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5729
sg15
S'Q108#2'
p5730
sg17
S'2'
sg18
I3
sg19
S'108'
p5731
sa(dp5732
g3
I6
sg4
I10
sg5
(lp5733
Vdiffuse large cell lymphoma
p5734
aVWilm\u005c
p5735
aVchoriocarcinoma
p5736
aVcolon cancer
p5737
aVtesticular cancer
p5738
asg11
S'Cancer type relatively resistant to treatment:'
p5739
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5740
sg15
S'Q108#3'
p5741
sg17
S'3'
sg18
I3
sg19
S'108'
p5742
sa(dp5743
g3
I7
sg4
I10
sg5
(lp5744
V10^4 cells
p5745
aV10^6 cells
p5746
aV10^8 cells
p5747
aV10^10 cells
p5748
aV10^12 cells
p5749
asg11
S' Cancer cell burden associated with widespread disease'
p5750
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5751
sg15
S'Q108#4'
p5752
sg17
S'4'
sg18
I4
sg19
S'108'
p5753
sa(dp5754
g3
I6
sg4
I36
sg5
(lp5755
Vdrug should be administered at law or the maximum doses but with increased frequency
p5756
aVdrug should be administered infrequently to minimize side effects
p5757
aVdrugs more beneficial if major toxicities are nonoverlapping
p5758
aVdrugs rarely effective in combination
p5759
asg11
S'Chemotherapeutic (anticancer) dosing principles:'
p5760
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5761
sg15
S'Q108#8'
p5762
sg17
S'8'
sg18
I2
sg19
S'108'
p5763
sa(dp5764
g3
I5
sg4
I20
sg5
(lp5765
Vchlorambucil (Leukeran)
p5766
aVmechlorethamine (Mustargen)
p5767
aVthiopeta (Thioplex)
p5768
aVmelphalan (Alkeran)
p5769
aVcyclophosphamide (Cytoxan)
p5770
asg11
S'"Secondary" alkylating agent:'
p5771
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5772
sg15
S'Q108#10'
p5773
sg17
S'10'
p5774
sg18
I2
sg19
S'108'
p5775
sa(dp5776
g3
I2
sg4
I22
sg5
(lp5777
Vmelphalan (Alkeran)
p5778
aVchlorambucil (Leukeran)
p5779
aVlomustine (CCNU,CeeNU)
p5780
aVcyclophosphamide (Cytoxan)
p5781
aVifofamide (Ifex)
p5782
asg11
S'Nitrosourea-alkylating agent'
p5783
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5784
sg15
S'Q108#12'
p5785
sg17
S'12'
p5786
sg18
I2
sg19
S'108'
p5787
sa(dp5788
g3
I6
sg4
I21
sg5
(lp5789
Vchlorambucil (Leukeran)
p5790
aVsemustine (methyl CCNU)
p5791
aV thiopeta (Thioplex)
p5792
aVcyclophosphamide (Cytoxan)
p5793
aVmechlorethamine (Mustargen)
p5794
asg11
S'Prodrug-requires activation by microsomal enzyme system:'
p5795
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5796
sg15
S'Q108#15'
p5797
sg17
S'15'
p5798
sg18
I3
sg19
S'108'
p5799
sa(dp5800
g3
I6
sg4
I20
sg5
(lp5801
Vbusulfan (Myleran)
p5802
aVmelphalan (Alkeran)
p5803
aVmechlorethamine (Mustargen)
p5804
aVcyclophosphamide (Cytoxan)
p5805
aVthiopeta (Thioplex)
p5806
asg11
S' Most useful alkylating agent at present'
p5807
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5808
sg15
S'Q108#18'
p5809
sg17
S'18'
p5810
sg18
I3
sg19
S'108'
p5811
sa(dp5812
g3
I6
sg4
I3
sg5
(lp5813
Vhepatic
p5814
aVpulmonary
p5815
aVrenal
p5816
asg11
S'Major route of elimination for nitrosoureas:'
p5817
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5818
sg15
S'Q108#21'
p5819
sg17
S'21'
p5820
sg18
I2
sg19
S'108'
p5821
sa(dp5822
g3
I17
sg4
I20
sg5
(lp5823
Vbusulfan (Myleran)
p5824
aVmechlorethamine (Mustargen)
p5825
aVcyclophosphamide (Cytoxan)
p5826
aVstreptozocin (Zanosar)
p5827
aVthiopeta (Thioplex)
p5828
asg11
S"Most likely to be effective in insulin-secreting islet cell pancreatic carcinoma and sometimes in non-Hodgkin's lymphoma:"
p5829
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5830
sg15
S'Q108#23'
p5831
sg17
S'23'
p5832
sg18
I3
sg19
S'108'
p5833
sa(dp5834
g3
I17
sg4
I16
sg5
(lp5835
Vdacarbazine (DTIC)
p5836
aVprocarbazine (Matulane)
p5837
aVcisplatin (Platinol)
p5838
aValtretamine (Hexalen)
p5839
asg11
S'In combination with bleomycin (Blenoxane) and vinblastine (Velban)-curative for nonseminomatous testicular cancer:'
p5840
sg13
S'http://www.pharmacology2000.com/Anticancer/questions7/questionset7.htm'
p5841
sg15
S'Q108#24'
p5842
sg17
S'24'
p5843
sg18
I2
sg19
S'108'
p5844
sa(dp5845
g3
I9
sg4
I11
sg5
(lp5846
Vbone marrow depression
p5847
aVrenal dysfunction
p5848
aVnausea and vomiting
p5849
aVacoustic nerve dysfunction
p5850
asg11
S'major acute side effect of cisplatin (Platinol)'
p5851
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5852
sg15
S'Q109#2'
p5853
sg17
S'2'
sg18
I2
sg19
S'109'
p5854
sa(dp5855
g3
I8
sg4
I9
sg5
(lp5856
Vrenal dysfunction
p5857
aVhepatic failure
p5858
aVneurotoxicity
p5859
aVbone marrow suppression
p5860
aValopecia
p5861
asg11
S'Most important toxic effect associated with alkylating agents:'
p5862
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5863
sg15
S'Q109#3'
p5864
sg17
S'3'
sg18
I3
sg19
S'109'
p5865
sa(dp5866
g3
I7
sg4
I12
sg5
(lp5867
VIV cyclophosphamide (Cytoxan)
p5868
aVoral cyclophosphamide (Cytoxan)
p5869
aVequally likely
p5870
asg11
S'More likely to cause nausea and vomiting:'
p5871
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5872
sg15
S'Q109#5'
p5873
sg17
S'5'
sg18
I0
sg19
S'109'
p5874
sa(dp5875
g3
I19
sg4
I11
sg5
(lp5876
Vcardiotoxicity
p5877
aVretroperitoneal fibrosis
p5878
aVnephrotoxicity and gout
p5879
aVhepatotoxicity
p5880
aVdepletion of bone calcium
p5881
asg11
S' In hematologic cancer chemotherapy with purine antagonists, allopurinol (Zyloprim, Purinol) coadministration is used to prevent:'
p5882
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5883
sg15
S'Q109#12'
p5884
sg17
S'12'
p5885
sg18
I2
sg19
S'109'
p5886
sa(dp5887
g3
I6
sg4
I8
sg5
(lp5888
Vmonocytic leukemia
p5889
aVlymphoma
p5890
aV testicular cancer
p5891
aVoat cell carcinoma
p5892
asg11
S'Clinical use teniposide (Vumon)'
p5893
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5894
sg15
S'Q109#16'
p5895
sg17
S'16'
p5896
sg18
I1
sg19
S'109'
p5897
sa(dp5898
g3
I9
sg4
I6
sg5
(lp5899
Vbone marrow depression
p5900
aVneurotoxicity
p5901
aVequal frequency
p5902
asg11
S'Significant frequency-adverse effect associated with vincristine (Oncovin)'
p5903
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5904
sg15
S'Q109#18'
p5905
sg17
S'18'
p5906
sg18
I1
sg19
S'109'
p5907
sa(dp5908
g3
I9
sg4
I4
sg5
(lp5909
Vdiarrhea
p5910
aVnausea
p5911
aVvomiting
p5912
aVmyelosuppression
p5913
asg11
S'Dose-limiting adverse effect for irinotecan (Camptosar):'
p5914
sg13
S'http://www.pharmacology2000.com/Anticancer/questions8/questionset8.htm'
p5915
sg15
S'Q109#21'
p5916
sg17
S'21'
p5917
sg18
I3
sg19
S'109'
p5918
sa(dp5919
g3
I2
sg4
I7
sg5
(lp5920
Vneomycin
p5921
aVpenicillin
p5922
aVkanamycin (Kantrex)
p5923
aVstreptomycin
p5924
asg11
S'Topical use:'
p5925
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5926
sg15
S'Q110#0'
p5927
sg17
S'0'
sg18
I0
sg19
S'110'
p5928
sa(dp5929
g3
I2
sg4
I7
sg5
(lp5930
Vaspirin
p5931
aVcephalothin (Keflin)
p5932
aVpenicillin
p5933
aVstreptomycin
p5934
asg11
S'Glomerular filtration:'
p5935
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5936
sg15
S'Q110#2'
p5937
sg17
S'2'
sg18
I3
sg19
S'110'
p5938
sa(dp5939
g3
I9
sg4
I15
sg5
(lp5940
Vblocks cell wall synthesis
p5941
aVinhibits protein synthesis
p5942
aVfolic acid synthesis inhibitor
p5943
aVnucleic acid synthesis inhibitor
p5944
asg11
S'Mechanism of bacteriocidal action: kanamycin (Kantrex)'
p5945
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5946
sg15
S'Q110#4'
p5947
sg17
S'4'
sg18
I1
sg19
S'110'
p5948
sa(dp5949
g3
I5
sg4
I18
sg5
(lp5950
Vamikacin (Amikin)
p5951
aVpenicillin G
p5952
aVamphotericin B (Fungizone, Amphotec) been
p5953
aVcefotaxime (Claforan)
p5954
asg11
S'Neuromuscular blockade at high dosages:'
p5955
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5956
sg15
S'Q110#5'
p5957
sg17
S'5'
sg18
I0
sg19
S'110'
p5958
sa(dp5959
g3
I9
sg4
I14
sg5
(lp5960
Vpenicillin G
p5961
aVkanamycin (Kantrex)
p5962
aVtobramycin (Nebcin)
p5963
aVclindamycin (Cleocin)
p5964
asg11
S'Pseudomonas strains resistant to carbenicillin may be sensitive to:'
p5965
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5966
sg15
S'Q110#7'
p5967
sg17
S'7'
sg18
I2
sg19
S'110'
p5968
sa(dp5969
g3
I8
sg4
I37
sg5
(lp5970
Vto treat sepsis caused by gram-negative bacteria such as Pseudomonas.
p5971
aVin combination with Penicillin G for endocarditis due to viridans streptococci
p5972
aVas a single agent to treat staphylococcal infections.
p5973
aVin combination with cephalosporin in immunocompromised patients.
p5974
asg11
S'Gentamicin (Garamycin) should NOT be used:'
p5975
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5976
sg15
S'Q110#9'
p5977
sg17
S'9'
sg18
I2
sg19
S'110'
p5978
sa(dp5979
g3
I21
sg4
I12
sg5
(lp5980
Vstreptomycin
p5981
aVamikacin (Amikin)
p5982
aVneomycin
p5983
aVdoxycycline (Vibramycin, Doryx)
p5984
asg11
S'Semisynthetic derivative of kanamycin: less toxin than kanamycin; may be effective against organisms resistant to gentamicin and tobramycin.'
p5985
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5986
sg15
S'Q110#10'
p5987
sg17
S'10'
p5988
sg18
I1
sg19
S'110'
p5989
sa(dp5990
g3
I7
sg4
I10
sg5
(lp5991
Vpenicillin
p5992
aVstreptomycin
p5993
aVgentamicin (Garamycin)
p5994
aVtobramycin (Nebcin)
p5995
asg11
S'Main use: second-line treatment of tuberculosis'
p5996
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions3/amino1.htm'
p5997
sg15
S'Q110#11'
p5998
sg17
S'11'
p5999
sg18
I1
sg19
S'110'
p6000
sa(dp6001
g3
I25
sg4
I13
sg5
(lp6002
Vlow cost
p6003
aVinfection by beta-lactamase-producing staphylococci
p6004
aVbiliary secretion for patients with renal disease
p6005
asg11
S'Primary, possibly sole-indication for use of methicillin (Staphcillin), nafcillin (Nafcil, Unipen), and cloxacillin (Cloxapen):'
p6006
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions4/ques4.htm'
p6007
sg15
S'Q111#6'
p6008
sg17
S'6'
sg18
I1
sg19
S'111'
p6009
sa(dp6010
g3
I2
sg4
I23
sg5
(lp6011
Vticarcillin (Ticar)
p6012
aVpiperacillin (Pipracil)
p6013
aVantipseudomonal penicillin in combination with an aminoglycoside
p6014
aVA and B
p6015
aVA,  B and C
p6016
asg11
S'Pseudomonal infections:'
p6017
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions4/ques4.htm'
p6018
sg15
S'Q111#8'
p6019
sg17
S'8'
sg18
I4
sg19
S'111'
p6020
sa(dp6021
g3
I7
sg4
I8
sg5
(lp6022
Vrenal failure
p6023
aVcardiotoxicity
p6024
aVhypersensitivity reactions
p6025
aVhepatic failure
p6026
aVneutropenia
p6027
asg11
S'Most serious adverse effect associated with penicillins:'
p6028
sg13
S'http://www.pharmacology2000.com/Antibacterial/questions4/ques4.htm'
p6029
sg15
S'Q111#9'
p6030
sg17
S'9'
sg18
I2
sg19
S'111'
p6031
sa(dp6032
g3
I9
sg4
I17
sg5
(lp6033
Vribavirin (Virazole,Rebetron)
p6034
aVinterferon
p6035
aVganciclovir (DHPG, Cytovene)
p6036
aVvidarabine (Vira-A)
p6037
asg11
S'Group of endogenous proteins that exhibit antiviral activities;'
p6038
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6039
sg15
S'Q119#0'
p6040
sg17
S'0'
sg18
I1
sg19
S'119'
p6041
sa(dp6042
g3
I13
sg4
I20
sg5
(lp6043
Vfoscarnet (Foscavir)
p6044
aVzidovudine (Retrovir, AZT, azidothymidine)
p6045
aVamantidine (Symmetrel)
p6046
aVindinavir (Crixivan)
p6047
asg11
S'First available reverse transcriptase drug for treatment of HIV-1; a deoxythymidine analogue'
p6048
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6049
sg15
S'Q119#1'
p6050
sg17
S'1'
sg18
I1
sg19
S'119'
p6051
sa(dp6052
g3
I41
sg4
I20
sg5
(lp6053
Vzalcitabine (Hivid, ddc)
p6054
aVtrifluridine (Viroptic)
p6055
aVdidanosine (Videx, ddI)
p6056
aVfoscarnet (Foscavir)
p6057
asg11
S'Synthetic analog of deoxyadenosine; active triphosphate form inhibits viral replication by competitively inhibiting HIV reverse transcriptase and by chain termination;may be prescribed concurrently with zidovudine or given as monotherapy; major clinical toxicity is a dose-dependent pancreatitis.'
p6058
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6059
sg15
S'Q119#2'
p6060
sg17
S'2'
sg18
I2
sg19
S'119'
p6061
sa(dp6062
g3
I3
sg4
I20
sg5
(lp6063
Vrimantadine (Flumadine)
p6064
aVribavirin (Virazole,Rebetron)
p6065
aVsaquinavir (Invirase)
p6066
aVstavudine (Zerit, d4T)
p6067
asg11
S'HIV protease inhibitor'
p6068
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6069
sg15
S'Q119#4'
p6070
sg17
S'4'
sg18
I2
sg19
S'119'
p6071
sa(dp6072
g3
I16
sg4
I24
sg5
(lp6073
Vdidanosine (Videx, ddI)
p6074
aVzidovudine (Retrovir, AZT, azidothymidine)
p6075
aVzalcitabine (Hivid, ddc)
p6076
aVsaquinavir (Invirase)
p6077
asg11
S'Most likely to cause additive myelosuppresion in an HIV patient also receiving ganciclovir for CMV retinitis:'
p6078
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6079
sg15
S'Q119#6'
p6080
sg17
S'6'
sg18
I1
sg19
S'119'
p6081
sa(dp6082
g3
I15
sg4
I20
sg5
(lp6083
Vamantidine (Symmetrel)
p6084
aVritonavir (Norvir)
p6085
aVdidanosine (Videx, ddI)
p6086
aVlamivudine (Epivir, 3TC)
p6087
asg11
S'HIV drug treatment most likely to chang serum concentrations of fluoxetine (Prozac). '
p6088
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6089
sg15
S'Q119#7'
p6090
sg17
S'7'
sg18
I1
sg19
S'119'
p6091
sa(dp6092
g3
I4
sg4
I19
sg5
(lp6093
Vzidovudine (Retrovir, AZT, azidothymidine)
p6094
aVacyclovir (Zovirax)
p6095
aVinterferon
p6096
aVribavirin (Virazole,Rebetron)
p6097
asg11
S'Used to treat HSV:'
p6098
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6099
sg15
S'Q119#8'
p6100
sg17
S'8'
sg18
I1
sg19
S'119'
p6101
sa(dp6102
g3
I4
sg4
I18
sg5
(lp6103
Vritonavir (Norvir)
p6104
aVdidanosine (Videx, ddI)
p6105
aVindinavir (Crixivan)
p6106
aVsaquinavir (Invirase)
p6107
asg11
S'HIV reverse transcriptase inhibitor'
p6108
sg13
S'http://www.pharmacology2000.com/Antiviral/questions4/virus2.htm'
p6109
sg15
S'Q119#9'
p6110
sg17
S'9'
sg18
I1
sg19
S'119'
p6111
sa(dp6112
g3
I7
sg4
I22
sg5
(lp6113
Vstavudine (Zerit, d4T)
p6114
aVefavirenz (EFV; Sustiva)
p6115
aVzalcitabine (Hivid, ddc)
p6116
aVindinavir (Crixivan)
p6117
asg11
S'Once daily anti-HIV/AIDS non-nucleoside reverse transcriptase inhibitor'
p6118
sg13
S'http://www.pharmacology2000.com/Antiviral/questions5/virq5.htm'
p6119
sg15
S'Q120#0'
p6120
sg17
S'0'
sg18
I1
sg19
S'120'
p6121
sa(dp6122
g3
I5
sg4
I28
sg5
(lp6123
Vindinavir (Crixivan) + AZT (zidovudine) + ddI
p6124
aVAZT (zidovudine) + ddI
p6125
aVzidovudine (Retrovir, AZT, azidothymidine)
p6126
aVddC + 3TC
p6127
asg11
S'Reasonable initial HIV treatment protocols'
p6128
sg13
S'http://www.pharmacology2000.com/Antiviral/questions5/virq5.htm'
p6129
sg15
S'Q120#3'
p6130
sg17
S'3'
sg18
I0
sg19
S'120'
p6131
sa(dp6132
g3
I8
sg4
I25
sg5
(lp6133
Vclindamycin (Cleocin)
p6134
aVtrimethoprim-sulfamethoxazole (Bactrim)
p6135
aVamphotericin B (Fungizone, Amphotec) + flucytosine (Ancobon)
p6136
aVoral itraconazole (Sporanox)
p6137
asg11
S'Acute treatment of cryptococcal infections in HIV patients'
p6138
sg13
S'http://www.pharmacology2000.com/Antiviral/questions5/virq5.htm'
p6139
sg15
S'Q120#6'
p6140
sg17
S'6'
sg18
I2
sg19
S'120'
p6141
sa(dp6142
g3
I4
sg4
I18
sg5
(lp6143
Vzalcitabine (Hivid, ddc)
p6144
aVamantidine (Symmetrel)
p6145
aVacyclovir (Zovirax)
p6146
aVidoxuridine (Herplex)
p6147
asg11
S'Prophylaxis against influenze A:'
p6148
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6149
sg15
S'Q121#0'
p6150
sg17
S'0'
sg18
I1
sg19
S'121'
p6151
sa(dp6152
g3
I16
sg4
I16
sg5
(lp6153
Vacyclovir (Zovirax)
p6154
aVfamciclovir (Famvir)
p6155
aVvalacyclovir (Valtrex)
p6156
aVcidofovir (Vistide)
p6157
asg11
S'First-pass metabolism of this drug results in the active form, penciclovir (Denavir):'
p6158
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6159
sg15
S'Q121#2'
p6160
sg17
S'2'
sg18
I1
sg19
S'121'
p6161
sa(dp6162
g3
I24
sg4
I18
sg5
(lp6163
Vganciclovir (DHPG, Cytovene)
p6164
aVfoscarnet (Foscavir)
p6165
aVcidofovir (Vistide)
p6166
aVvalacyclovir (Valtrex)
p6167
asg11
S'Monophosphorylation of this antiviral drug is catalyzed by virus-specified protein kinase phophotransferase in CMV-infected cells and by viral thymidine kinase in HSV-infected cells.'
p6168
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6169
sg15
S'Q121#3'
p6170
sg17
S'3'
sg18
I0
sg19
S'121'
p6171
sa(dp6172
g3
I28
sg4
I16
sg5
(lp6173
Vfoscarnet (Foscavir)
p6174
aVfamciclovir (Famvir)
p6175
aVcidofovir (Vistide)
p6176
aVvidarabine (Vira-A)
p6177
asg11
S' Nephrotoxicity, the major dose-limiting toxicity associated with i.v. use of this drug can be prevented by probenecid (Benemid) (a blocker of tubular secretion)'
p6178
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6179
sg15
S'Q121#4'
p6180
sg17
S'4'
sg18
I2
sg19
S'121'
p6181
sa(dp6182
g3
I29
sg4
I22
sg5
(lp6183
Vvidarabine (Vira-A)
p6184
aVganciclovir (DHPG, Cytovene)
p6185
aVfoscarnet (Foscavir)
p6186
aVzidovudine (Retrovir, AZT, azidothymidine)
p6187
asg11
S'Mainly eliminated by renal mechanisms as the hypoxanthine metabolite, this antiviral agent is effective for treating acute keratoconjunctivitis (ointment) and HSV encephalitis (i.v.)'
p6188
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6189
sg15
S'Q121#5'
p6190
sg17
S'5'
sg18
I0
sg19
S'121'
p6191
sa(dp6192
g3
I23
sg4
I15
sg5
(lp6193
Vinterferon
p6194
aVamantidine (Symmetrel)
p6195
aVdidanosine (Videx, ddI)
p6196
aVsaquinavir (Invirase)
p6197
asg11
S'Inhibition of viral replication by: (1) Competitive inhibition of HIV reverse transcriptase and (2) by chain termination.'
p6198
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6199
sg15
S'Q121#6'
p6200
sg17
S'6'
sg18
I2
sg19
S'121'
p6201
sa(dp6202
g3
I3
sg4
I17
sg5
(lp6203
Vzidovudine (Retrovir, AZT, azidothymidine)
p6204
aVinterferon
p6205
aVamantidine (Symmetrel)
p6206
aVritonavir (Norvir)
p6207
asg11
S'HIV protease inhibitor'
p6208
sg13
S'http://www.pharmacology2000.com/Antiviral/questions6/antiv6.htm'
p6209
sg15
S'Q121#9'
p6210
sg17
S'9'
sg18
I3
sg19
S'121'
p6211
sa(dp6212
g3
I14
sg4
I6
sg5
(lp6213
Vketoconazole
p6214
aVamphotericin B
p6215
aVflucytosine
p6216
aVgrisefulvin
p6217
aVclotrimazole
p6218
asg11
S'Antifungal polyene macrolide that preferentially binds to fungal ergosterol which alters cellular permeability.'
p6219
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6220
sg15
S'Q122#0'
p6221
sg17
S'0'
sg18
I1
sg19
S'122'
p6222
sa(dp6223
g3
I27
sg4
I5
sg5
(lp6224
Vmiconazole
p6225
aVterbinafine
p6226
aVnystatin
p6227
aVfluconazole
p6228
aVflucytosine
p6229
asg11
S'Polyene macrolide only used topically, due to systemic toxicity; active against most Candida species--most commonly used for suppression of local candidal infection.'
p6230
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6231
sg15
S'Q122#2'
p6232
sg17
S'2'
sg18
I2
sg19
S'122'
p6233
sa(dp6234
g3
I19
sg4
I3
sg5
(lp6235
Vketoconazole
p6236
aVitraconazole
p6237
aVfluconazole
p6238
asg11
S'Of ketoconazole, itraconazole, and fluconazole--most likely to cause increased arrhythmogenic effects of astemizole or terphidine'
p6239
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6240
sg15
S'Q122#3'
p6241
sg17
S'3'
sg18
I0
sg19
S'122'
p6242
sa(dp6243
g3
I8
sg4
I3
sg5
(lp6244
Vfluconazole
p6245
aVitraconazole
p6246
aVketoconazole
p6247
asg11
S'Most potent of the presently available anti-fungal azoles:'
p6248
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6249
sg15
S'Q122#6'
p6250
sg17
S'6'
sg18
I1
sg19
S'122'
p6251
sa(dp6252
g3
I14
sg4
I3
sg5
(lp6253
Vketoconazole
p6254
aVitraconazole
p6255
aVfluconazole
p6256
asg11
S'Azole most likely to get into the cerebral spinal fluid (CSF):'
p6257
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6258
sg15
S'Q122#7'
p6259
sg17
S'7'
sg18
I2
sg19
S'122'
p6260
sa(dp6261
g3
I23
sg4
I6
sg5
(lp6262
Vketoconazole
p6263
aVitraconazole
p6264
aVflucytosine
p6265
aVamphotericin B
p6266
aVnystatin
p6267
asg11
S'Given by i.v. administration, the drug of choice for nearly all life-threatening mycotic infections--usually used as the initial induction regimen'
p6268
sg13
S'http://www.pharmacology2000.com/Antifungal/questions1/fung1.htm'
p6269
sg15
S'Q122#8'
p6270
sg17
S'8'
sg18
I3
sg19
S'122'
p6271
sa(dp6272
g3
I14
sg4
I23
sg5
(lp6273
Vincreased platelet count
p6274
aVreduced blood flow
p6275
aVstickiness of falciparum parasites to the vascular epithelium
p6276
aVfalciparum parasite-induced thrombocytopenic purpura
p6277
aVfalciparum parasite induced polycythemia vera
p6278
asg11
S'Microhemorrhages in the brain and other organs associated with Falciparum parasites mainly due to:'
p6279
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6280
sg15
S'Q126#0'
p6281
sg17
S'0'
sg18
I2
sg19
S'126'
p6282
sa(dp6283
g3
I8
sg4
I6
sg5
(lp6284
Vtransfusion recipients
p6285
aVtravelers
p6286
aVIV drug users
p6287
asg11
S'Most U.S. cases of malaria are found in:'
p6288
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6289
sg15
S'Q126#2'
p6290
sg17
S'2'
sg18
I1
sg19
S'126'
p6291
sa(dp6292
g3
I23
sg4
I8
sg5
(lp6293
VPlasmodium malariae
p6294
aVPlasmodium falciparum
p6295
aVPlasmodium vivax
p6296
aVPlasmodium ovale
p6297
asg11
S'Of about 156 species of plasmodium,this species, causative of human malaria, produces the most serious complications, including death:'
p6298
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6299
sg15
S'Q126#4'
p6300
sg17
S'4'
sg18
I1
sg19
S'126'
p6301
sa(dp6302
g3
I4
sg4
I40
sg5
(lp6303
Vpresence of both cold phase & hot phase
p6304
aVmild, "viral"-like prodrome preceding by  24-48 hours major symptoms
p6305
aVdirect observation of intraerythrocytic parasites in thick/thin smears
p6306
aVthe patient has or has not taken prophylactic drugs during travel
p6307
asg11
S'Definitive diagnosis of malaria:'
p6308
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6309
sg15
S'Q126#7'
p6310
sg17
S'7'
sg18
I2
sg19
S'126'
p6311
sa(dp6312
g3
I2
sg4
I8
sg5
(lp6313
V1-2 days
p6314
aV8-10 days
p6315
aVthree weeks
p6316
aVsix weeks
p6317
asg11
S'Malaria-incubation period'
p6318
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6319
sg15
S'Q126#8'
p6320
sg17
S'8'
sg18
I1
sg19
S'126'
p6321
sa(dp6322
g3
I8
sg4
I13
sg5
(lp6323
VP vivax &  P ovale
p6324
aVP falciparum & P.  malariae
p6325
aVall four species
p6326
asg11
S'Treatment must eliminate parasites from both liver erythrocytes:'
p6327
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6328
sg15
S'Q126#16'
p6329
sg17
S'16'
p6330
sg18
I0
sg19
S'126'
p6331
sa(dp6332
g3
I3
sg4
I9
sg5
(lp6333
Vmitotic spindle inhibitors
p6334
aVDNA gyrase inhibitors
p6335
aVdihydrofolate reductase inhibitors
p6336
asg11
S'Antimalarial drug classification:'
p6337
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6338
sg15
S'Q126#17'
p6339
sg17
S'17'
p6340
sg18
I2
sg19
S'126'
p6341
sa(dp6342
g3
I7
sg4
I15
sg5
(lp6343
Vpyrimethamine (Daraprim)
p6344
aVsulfadiazine
p6345
aVdoxycycline (Vibramycin, Doryx)
p6346
aVmefloquine (Lariam)
p6347
asg11
S'An example of a 4-aminoquinoline antimalarial drug:'
p6348
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions2/questionset2.htm'
p6349
sg15
S'Q126#18'
p6350
sg17
S'18'
p6351
sg18
I3
sg19
S'126'
p6352
sa(dp6353
g3
I19
sg4
I5
sg5
(lp6354
Vdogs
p6355
aVrodents
p6356
aVbirds
p6357
aVcats
p6358
aVmosquitoes
p6359
asg11
S'Only known definitive host for the sexual stages of T. gondii (Toxoplasmosis gondii)-main resource of infection'
p6360
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions4/questionset4.htm'
p6361
sg15
S'Q127#5'
p6362
sg17
S'5'
sg18
I3
sg19
S'127'
p6363
sa(dp6364
g3
I9
sg4
I36
sg5
(lp6365
VBlood schizonticidal activity against P falciparum (some species)
p6366
aVSignificant effects against blood schizonts of P vivax
p6367
aVActive against immunocytes or liver stages of P falciparumor P vivax
p6368
aVrapid onset of action
p6369
aVminimal side effects
p6370
asg11
S'Concerning sulfonamides & sulfones and antimalarial activity: the'
p6371
sg13
S'http://www.pharmacology2000.com/Antiparasitic/questions4/questionset4.htm'
p6372
sg15
S'Q127#9'
p6373
sg17
S'9'
sg18
I0
sg19
S'127'
p6374
sa(dp6375
g3
I7
sg4
I6
sg5
(lp6376
Vvasospasm
p6377
aVviscous metamorphosis
p6378
aVhemostasis
p6379
aVfibrinolysis
p6380
aVcoagulation
p6381
asg11
S'Spontaneous arresting of bleeding from blood vessel:'
p6382
sg13
S'http://www.pharmacology2000.com/Coagulation/question1/questionset1.htm'
p6383
sg15
S'Q129#0'
p6384
sg17
S'0'
sg18
I2
sg19
S'129'
p6385
sa(dp6386
g3
I8
sg4
I6
sg5
(lp6387
Vvasospasm
p6388
aVplatelet aggregation
p6389
aVfibrinolysis
p6390
aVplatelet adhesion
p6391
asg11
S'Platelet sticking to exposed damage blood vessel collagen:'
p6392
sg13
S'http://www.pharmacology2000.com/Coagulation/question1/questionset1.htm'
p6393
sg15
S'Q129#1'
p6394
sg17
S'1'
sg18
I3
sg19
S'129'
p6395
sa(dp6396
g3
I10
sg4
I9
sg5
(lp6397
VCrohn\u005c
p6398
aVmyocardial infarction
p6399
aVabruptio placentae
p6400
aVWilson\u005c
p6401
aVChristmas factor deficiency
p6402
asg11
S'Expectable cause of disseminated intravascular coagulation (DIC):'
p6403
sg13
S'http://www.pharmacology2000.com/Coagulation/question1/questionset1.htm'
p6404
sg15
S'Q129#7'
p6405
sg17
S'7'
sg18
I2
sg19
S'129'
p6406
sa(dp6407
g3
I3
sg4
I5
sg5
(lp6408
Vt-PA
p6409
aVurokinase
p6410
aVstreptokinase
p6411
aVaminocaproic acid
p6412
asg11
S'Inhibitor of fibrinolysis'
p6413
sg13
S'http://www.pharmacology2000.com/Coagulation/question1/questionset1.htm'
p6414
sg15
S'Q129#8'
p6415
sg17
S'8'
sg18
I3
sg19
S'129'
p6416
sa(dp6417
g3
I7
sg4
I7
sg5
(lp6418
Vplasminogen
p6419
aVproaccelerin
p6420
aVplasmin
p6421
aVChristmas factor
p6422
aVStuart-Prower factor
p6423
asg11
S'Limits thrombosis extension by proteolytic fibrin digestion:'
p6424
sg13
S'http://www.pharmacology2000.com/Coagulation/question1/questionset1.htm'
p6425
sg15
S'Q129#9'
p6426
sg17
S'9'
sg18
I2
sg19
S'129'
p6427
sa(dp6428
g3
I1
sg4
I18
sg5
(lp6429
Vhigh-molecular-weight heparin fraction
p6430
aVacts by preventing platelet degranulation
p6431
aVprimary prevention of deep venous thrombosis after hip replacement surgery
p6432
asg11
S'Enoxaparin:'
p6433
sg13
S'http://www.pharmacology2000.com/Coagulation/question2/questionset2.htm'
p6434
sg15
S'Q130#0'
p6435
sg17
S'0'
sg18
I2
sg19
S'130'
p6436
sa(dp6437
g3
I5
sg4
I8
sg5
(lp6438
Vosteoporosis
p6439
aValopecia
p6440
aVbleeding
p6441
aVspontaneous fractures
p6442
aVreduced glomerular filtration
p6443
asg11
S'Major adverse effect of heparin:'
p6444
sg13
S'http://www.pharmacology2000.com/Coagulation/question2/questionset2.htm'
p6445
sg15
S'Q130#1'
p6446
sg17
S'1'
sg18
I2
sg19
S'130'
p6447
sa(dp6448
g3
I5
sg4
I5
sg5
(lp6449
Vheparin
p6450
aVenoxaparin
p6451
aVdalteparin and danaproid
p6452
asg11
S'Specified in anti-factor Xa units:'
p6453
sg13
S'http://www.pharmacology2000.com/Coagulation/question2/questionset2.htm'
p6454
sg15
S'Q130#4'
p6455
sg17
S'4'
sg18
I2
sg19
S'130'
p6456
sa(dp6457
g3
I7
sg4
I9
sg5
(lp6458
Vfibrinogen
p6459
aVplatelets
p6460
aVantithrombin III
p6461
aVaminocaproic acid
p6462
aVtissue plasminogen activator
p6463
asg11
S'Heparin biological activity depends most directly on:'
p6464
sg13
S'http://www.pharmacology2000.com/Coagulation/question2/questionset2.htm'
p6465
sg15
S'Q130#5'
p6466
sg17
S'5'
sg18
I2
sg19
S'130'
p6467
sa(dp6468
g3
I5
sg4
I26
sg5
(lp6469
Vnone-Warfarin does not cross the placental barrier
p6470
aVcauses abnormal bone formation
p6471
aVdespite limited Warfarin effects on the fetus, it may be used at low dosages
p6472
asg11
S'Warfarin effects on the fetus:'
p6473
sg13
S'http://www.pharmacology2000.com/Coagulation/question2/questionset2.htm'
p6474
sg15
S'Q130#9'
p6475
sg17
S'9'
sg18
I1
sg19
S'130'
p6476
sa(dp6477
g3
I1
sg4
I18
sg5
(lp6478
Vhigh-molecular-weight heparin fraction
p6479
aVacts by preventing platelet degranulation
p6480
aVprimary prevention of deep venous thrombosis after hip replacement surgery
p6481
asg11
S'Enoxaparin:'
p6482
sg13
S'http://www.pharmacology2000.com/Coagulation/question3/questionset3.htm'
p6483
sg15
S'Q131#0'
p6484
sg17
S'0'
sg18
I2
sg19
S'131'
p6485
sa(dp6486
g3
I5
sg4
I8
sg5
(lp6487
Vosteoporosis
p6488
aValopecia
p6489
aVbleeding
p6490
aVspontaneous fractures
p6491
aVreduced glomerular filtration
p6492
asg11
S'Major adverse effect of heparin:'
p6493
sg13
S'http://www.pharmacology2000.com/Coagulation/question3/questionset3.htm'
p6494
sg15
S'Q131#1'
p6495
sg17
S'1'
sg18
I2
sg19
S'131'
p6496
sa(dp6497
g3
I5
sg4
I5
sg5
(lp6498
Vheparin
p6499
aVenoxaparin
p6500
aVdalteparin and danaproid
p6501
asg11
S'Specified in anti-factor Xa units:'
p6502
sg13
S'http://www.pharmacology2000.com/Coagulation/question3/questionset3.htm'
p6503
sg15
S'Q131#4'
p6504
sg17
S'4'
sg18
I2
sg19
S'131'
p6505
sa(dp6506
g3
I7
sg4
I9
sg5
(lp6507
Vfibrinogen
p6508
aVplatelets
p6509
aVantithrombin III
p6510
aVaminocaproic acid
p6511
aVtissue plasminogen activator
p6512
asg11
S'Heparin biological activity depends most directly on:'
p6513
sg13
S'http://www.pharmacology2000.com/Coagulation/question3/questionset3.htm'
p6514
sg15
S'Q131#5'
p6515
sg17
S'5'
sg18
I2
sg19
S'131'
p6516
sa(dp6517
g3
I5
sg4
I26
sg5
(lp6518
Vnone-Warfarin does not cross the placental barrier
p6519
aVcauses abnormal bone formation
p6520
aVdespite limited Warfarin effects on the fetus, it may be used at low dosages
p6521
asg11
S'Warfarin effects on the fetus:'
p6522
sg13
S'http://www.pharmacology2000.com/Coagulation/question3/questionset3.htm'
p6523
sg15
S'Q131#9'
p6524
sg17
S'9'
sg18
I1
sg19
S'131'
p6525
sa(dp6526
g3
I15
sg4
I7
sg5
(lp6527
Vcryoprecipitate
p6528
aVtranexamic acid
p6529
aVdesmopressin acetate
p6530
aVurokinase
p6531
aVaspirin
p6532
asg11
S'Not factor VIII, but increases factor VIII activity in patients with mild hemophilia A:'
p6533
sg13
S'http://www.pharmacology2000.com/Coagulation/question4/questionset4.htm'
p6534
sg15
S'Q132#0'
p6535
sg17
S'0'
sg18
I2
sg19
S'132'
p6536
sa(dp6537
g3
I8
sg4
I6
sg5
(lp6538
Valteplase
p6539
aVreteplase
p6540
aVanistreplase
p6541
aVdicumarol
p6542
aVprotamine sulfate
p6543
asg11
S'Complex of purified human plasminogen and bacterial streptokinase'
p6544
sg13
S'http://www.pharmacology2000.com/Coagulation/question4/questionset4.htm'
p6545
sg15
S'Q132#1'
p6546
sg17
S'1'
sg18
I2
sg19
S'132'
p6547
sa(dp6548
g3
I11
sg4
I8
sg5
(lp6549
Vadenylyl cyclase
p6550
aVguanylyl cyclase
p6551
aVadenosine deaminase
p6552
aVcyclooxygenase
p6553
aVstreptokinase
p6554
asg11
S'Aspirin irreversibly inhibits this enzyme, preventing thromboxane A2 synthesis.'
p6555
sg13
S'http://www.pharmacology2000.com/Coagulation/question4/questionset4.htm'
p6556
sg15
S'Q132#6'
p6557
sg17
S'6'
sg18
I3
sg19
S'132'
p6558
sa(dp6559
g3
I4
sg4
I6
sg5
(lp6560
Vthromboxane A2
p6561
aVaspirin
p6562
aVabciximab
p6563
aVADP
p6564
aVstreptokinase
p6565
asg11
S'Blocks GPIIb/IIIa platelet receptors:'
p6566
sg13
S'http://www.pharmacology2000.com/Coagulation/question4/questionset4.htm'
p6567
sg15
S'Q132#9'
p6568
sg17
S'9'
sg18
I2
sg19
S'132'
p6569
sa(dp6570
g3
I17
sg4
I8
sg5
(lp6571
Vinterleukin-2
p6572
aVtumor necrosis factor beta
p6573
aVinterferon-gamma
p6574
aVIL-4
p6575
aVIL-6
p6576
asg11
S'T helper lymphocytes -- regulate each other; this substance produced by TH1cells inhibits TH2 cellular proliferation:'
p6577
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6578
sg15
S'Q133#5'
p6579
sg17
S'5'
sg18
I2
sg19
S'133'
p6580
sa(dp6581
g3
I15
sg4
I6
sg5
(lp6582
VType I
p6583
aVType II
p6584
aVType III
p6585
asg11
S'Hypersensitivity: cross-linking of membrane-bound IgE on blood basophils or tissue mast cells by antigen'
p6586
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6587
sg15
S'Q133#9'
p6588
sg17
S'9'
sg18
I0
sg19
S'133'
p6589
sa(dp6590
g3
I5
sg4
I14
sg5
(lp6591
VImmediate Hypersensitivity Type  I
p6592
aVDelayed Hypersensitivity
p6593
aVImmediate Hypersensitivity Type II
p6594
aVImmediate Hypersensitivity Type III
p6595
asg11
S'Hemolytic disease of the newborn:'
p6596
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6597
sg15
S'Q133#10'
p6598
sg17
S'10'
p6599
sg18
I2
sg19
S'133'
p6600
sa(dp6601
g3
I21
sg4
I14
sg5
(lp6602
VImmediate Hypersensitivity Type III
p6603
aVImmediate Hypersensitivity Type II
p6604
aVDelayed Hypersensitivity
p6605
aVImmediate Hypersensitivity Type I
p6606
asg11
S'Associated with elevated levels of antigen-antibody complexes, which cause tissue damage; complement activation results in anaphylatoxic and chemotactic activities:'
p6607
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6608
sg15
S'Q133#11'
p6609
sg17
S'11'
p6610
sg18
I0
sg19
S'133'
p6611
sa(dp6612
g3
I6
sg4
I12
sg5
(lp6613
VImmediate Hypersensitivity Type I
p6614
aVImmediate Hypersensitivity Type II
p6615
aVImmediate Hypersensitivity Type III
p6616
asg11
S'Administration of penicillin to allergic patients:'
p6617
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6618
sg15
S'Q133#12'
p6619
sg17
S'12'
p6620
sg18
I1
sg19
S'133'
p6621
sa(dp6622
g3
I12
sg4
I14
sg5
(lp6623
VImmediate Hypersensitivity Type I
p6624
aVImmediate Hypersensitivity Type II
p6625
aVImmediate Hypersensitivity Type III
p6626
aVDelayed Hypersensitivity
p6627
asg11
S'Effective in eliminating infections caused by intracellular pathogens such as Leishmania species:'
p6628
sg13
S'http://www.pharmacology2000.com/Immunosupression/question1/questionset1.htm'
p6629
sg15
S'Q133#13'
p6630
sg17
S'13'
p6631
sg18
I3
sg19
S'133'
p6632
sa(dp6633
g3
I15
sg4
I16
sg5
(lp6634
Vtacrolimus
p6635
aVcyclosporine (Sandimmune, Neoral)
p6636
aVprednisone (Deltasone)
p6637
aVdactinomycin  (Cosmegen)
p6638
aVmethotrexate
p6639
asg11
S'Agent acts directly at site 6 to diminish tissue injury: (see figure)'
p6640
sg13
S'http://www.pharmacology2000.com/Immunosupression/question2/questionset2.htm'
p6641
sg15
S'Q134#0'
p6642
sg17
S'0'
sg18
I2
sg19
S'134'
p6643
sa(dp6644
g3
I12
sg4
I17
sg5
(lp6645
Vprednisone (Deltasone)
p6646
aVcyclophosphamide (Cytoxan)
p6647
aVdactinomycin  (Cosmegen)
p6648
aVmethotrexate
p6649
aVazathioprine (Imuran)
p6650
asg11
S'Inhibit(s) at differentiation/synthesis step (see figure):'
p6651
sg13
S'http://www.pharmacology2000.com/Immunosupression/question2/questionset2.htm'
p6652
sg15
S'Q134#2'
p6653
sg17
S'2'
sg18
I2
sg19
S'134'
p6654
sa(dp6655
g3
I10
sg4
I19
sg5
(lp6656
Vprednisone (Deltasone)
p6657
aVtacrolimus
p6658
aVazathioprine (Imuran)
p6659
aVRHo(D) immune globulin
p6660
aVcyclophosphamide (Cytoxan)
p6661
asg11
S'Acts at antigen recognition site: (see figure)'
p6662
sg13
S'http://www.pharmacology2000.com/Immunosupression/question2/questionset2.htm'
p6663
sg15
S'Q134#5'
p6664
sg17
S'5'
sg18
I3
sg19
S'134'
p6665
sa(dp6666
g3
I11
sg4
I8
sg5
(lp6667
Vcyclosporine
p6668
aVprednisone (Deltasone)
p6669
aVtacrolimus
p6670
aVIFN-alpha
p6671
aVthalidomide
p6672
asg11
S'Example of first-class of hormonal agents noted to have lipolytic properties:'
p6673
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6674
sg15
S'Q135#0'
p6675
sg17
S'0'
sg18
I1
sg19
S'135'
p6676
sa(dp6677
g3
I24
sg4
I14
sg5
(lp6678
Vtacrolimus
p6679
aVinterferon
p6680
aVcyclosporine (Sandimmune, Neoral)
p6681
aVprednisone (Deltasone) and
p6682
aVthalidomide
p6683
asg11
S'About two-thirds of children with early diabetic symptoms can discontinue or reduce insulin treatment within about six weeks after starting treatment with this drug:'
p6684
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6685
sg15
S'Q135#4'
p6686
sg17
S'4'
sg18
I2
sg19
S'135'
p6687
sa(dp6688
g3
I7
sg4
I11
sg5
(lp6689
Vpenicillin
p6690
aVsulfonamides
p6691
aViodides
p6692
aVphenytoin (Dilantin)
p6693
aVhydralazine (Apresoline)
p6694
asg11
S'Autoimmune (Type II) drug reaction:'
p6695
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6696
sg15
S'Q135#6'
p6697
sg17
S'6'
sg18
I4
sg19
S'135'
p6698
sa(dp6699
g3
I27
sg4
I5
sg5
(lp6700
Vinosiplex
p6701
aVthymopoietin
p6702
aVlevamisole
p6703
aVBCG
p6704
aVIGIV
p6705
asg11
S'For synthesized for treating parasitic infections, this drug is now FDA approved for clinical use in the treatment of Dukes class C colorectal cancer after surgery:'
p6706
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6707
sg15
S'Q135#10'
p6708
sg17
S'10'
p6709
sg18
I2
sg19
S'135'
p6710
sa(dp6711
g3
I4
sg4
I51
sg5
(lp6712
Vdue to elevated levels of antigen-antibody complexes
p6713
aVstems from cross-linking of membrane-bound IgE on blood basophils or tissue mast cells by antigen
p6714
aVfollows from formation of antigen- antibody complexes between foreign antigen and IgM or IgG immunoglobulins
p6715
aVtissue damage due to influx of antigen-nonspecific inflammatory cells (macrophages and neutrophils)
p6716
asg11
S'Type 1 immediate hypersensitivity:'
p6717
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6718
sg15
S'Q135#13'
p6719
sg17
S'13'
p6720
sg18
I1
sg19
S'135'
p6721
sa(dp6722
g3
I18
sg4
I8
sg5
(lp6723
Vrheumatoid arthritis
p6724
aVsystemic lupus erythematosus
p6725
aVinsulin dependent diabetes
p6726
asg11
S'Autoimmune disorder: associated with antibodies made against self DNA, red blood cells, histones, platelets'
p6727
sg13
S'http://www.pharmacology2000.com/Immunosupression/question3/questionset3.htm'
p6728
sg15
S'Q135#14'
p6729
sg17
S'14'
p6730
sg18
I1
sg19
S'135'
p6731
sa(dp6732
g3
I10
sg4
I6
sg5
(lp6733
Vhistamine
p6734
aVinterleukin 1
p6735
aVbradykinin
p6736
aVneuropeptides
p6737
aVserotonin
p6738
asg11
S'Mediator of chronic inflammation (for example rheumatoid arthritis)'
p6739
sg13
S'http://www.pharmacology2000.com/Inflammation/question1/questionset1.htm'
p6740
sg15
S'Q137#6'
p6741
sg17
S'6'
sg18
I1
sg19
S'137'
p6742
sa(dp6743
g3
I21
sg4
I5
sg5
(lp6744
Vglucocorticoids
p6745
aVaspirin
p6746
aVdiclofenac
p6747
aVindomethacin
p6748
aVphenylbutazone
p6749
asg11
S'Initial drug of choice for treating most articular and musculoskeletal disorders (because of low-cost, safety, and efficacy)'
p6750
sg13
S'http://www.pharmacology2000.com/Inflammation/question1/questionset1.htm'
p6751
sg15
S'Q137#8'
p6752
sg17
S'8'
sg18
I1
sg19
S'137'
p6753
sa(dp6754
g3
I24
sg4
I21
sg5
(lp6755
Vallopurinol (Zyloprim, Purinol)
p6756
aVcolchicine
p6757
aVprobenecid (Benemid)
p6758
aVsulfinpyrazone (Anturane)
p6759
aVacetaminophen (Tylenol, Panadol)
p6760
asg11
S'Previously most popular drug for treating inflammation of acute gouty arthritis -- NSAIDs now more commonly used because of diarrhea associated with earlier medication:'
p6761
sg13
S'http://www.pharmacology2000.com/Inflammation/question3/questionset3.htm'
p6762
sg15
S'Q139#3'
p6763
sg17
S'3'
sg18
I1
sg19
S'139'
p6764
sa(dp6765
g3
I15
sg4
I22
sg5
(lp6766
Vpenicillamine (Cuprimine)
p6767
aVsulfasalazine (Azulfidine)
p6768
aVacetaminophen (Tylenol, Panadol)
p6769
aVetodolac (Lodine)
p6770
aVpiroxicam (Feldene)
p6771
asg11
S'effective in management of mild to moderate pain, when anti-inflammatory action is not necessary'
p6772
sg13
S'http://www.pharmacology2000.com/Inflammation/question3/questionset3.htm'
p6773
sg15
S'Q139#4'
p6774
sg17
S'4'
sg18
I2
sg19
S'139'
p6775
sa(dp6776
g3
I9
sg4
I27
sg5
(lp6777
Vpolymorphonuclear leukocytes migration into the joint
p6778
aVincreased numbers of mononuclear phagocytes (macrophages)
p6779
aVurate crystals phagocytosis by synoviocytes
p6780
aVprostaglandin, lysosomal &, interleukin 1 release
p6781
asg11
S'Probably the initial step in acute gouty arthritis attack:'
p6782
sg13
S'http://www.pharmacology2000.com/Inflammation/question3/questionset3.htm'
p6783
sg15
S'Q139#5'
p6784
sg17
S'5'
sg18
I2
sg19
S'139'
p6785
sa(dp6786
g3
I10
sg4
I19
sg5
(lp6787
Vcolchicine
p6788
aVprobenecid (Benemid)
p6789
aVsulfinpyrazone (Anturane)
p6790
aVallopurinol (Zyloprim, Purinol)
p6791
aVoxaprozin (Daypro)
p6792
asg11
S'Reduces uric acid synthesis: for management of gout--'
p6793
sg13
S'http://www.pharmacology2000.com/Inflammation/question3/questionset3.htm'
p6794
sg15
S'Q139#8'
p6795
sg17
S'8'
sg18
I3
sg19
S'139'
p6796
sa.